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A B S T R A C T
Background
Vitamins and minerals play multiple functions within the central nervous system which may help to maintain brain health and optimal
cognitive functioning. Supplementation of the diet with various vitamins and minerals has been suggested as a means of maintaining
cognitive function, or even of preventing dementia, in later life.
Objectives
To evaluate the eIects of vitamin and mineral supplementation on cognitive function in cognitively healthy people aged 40 years or more.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group’s (CDCIG) specialised register, as well as MEDLINE, Embase,
PsycINFO, CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP from inception to 26th January 2018.
Selection criteria
We included randomised controlled trials that evaluated the cognitive eIects on people aged 40 years or more of any vitamin or mineral
supplements taken by mouth for at least three months.
Data collection and analysis
Study selection, data extraction, and quality assessments were done in duplicate. Vitamins were considered broadly in the categories of
B vitamins, antioxidant vitamins, and combinations of both. Minerals were considered separately, where possible. If interventions and
outcomes were considered suIiciently similar, then data were pooled. In order to separate short-term cognitive eIects from possible
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longer-term eIects on the trajectory of cognitive decline, data were pooled for various treatment durations from 3 months to 12 months
and up to 10 years or more.
Main results
In total, we included 28 studies with more than 83,000 participants. There were some general limitations of the evidence. Most participants
were enrolled in studies which were not designed primarily to assess cognition. These studies oPen had no baseline cognitive assessment
and used only brief cognitive assessments at follow-up. Very few studies assessed the incidence of dementia. Most study reports did not
mention adverse events or made only very general statements about them. Only 10 studies had a mean follow-up > 5 years. Only two
studies had participants whose mean age was < 60 years at baseline. The risk of bias in the included studies was generally low, other than a
risk of attrition bias for longer-term outcomes. We considered the certainty of the evidence behind almost all results to be moderate or low.
We included 14 studies with 27,882 participants which compared folic acid, vitamin B12, vitamin B6, or a combination of these to placebo.
The majority of participants were aged over 60 years and had a history of cardio- or cerebrovascular disease. We found that giving B vitamin
supplements to cognitively healthy adults, mainly in their 60s and 70s, probably has little or no eIect on global cognitive function at any
time point up to 5 years (SMD values from -0.03 to 0.06) and may also have no eIect at 5-10 years (SMD -0.01). There were very sparse data
on adverse eIects or on incidence of cognitive impairment or dementia.
We included 8 studies with 47,840 participants in which the active intervention was one or more of the antioxidant vitamins: ß-carotene,
vitamin C or vitamin E. Results were mixed. For overall cognitive function, there was low-certainty evidence of benefit associated with ß-
carotene aPer a mean of 18 years of treatment (MD 0.18 TICS points, 95% CI 0.01 to 0.35) and of vitamin C aPer 5 years to 10 years (MD 0.46
TICS points, 95% CI 0.14 to 0.78), but not at earlier time points. From two studies which reported on dementia incidence, there was low-
certainty evidence of no eIect of an antioxidant vitamin combination or of vitamin E, either alone or combined with selenium. One of the
included studies had been designed to look for eIects on the incidence of prostate cancer; it found a statistically significant increase in
prostate cancer diagnoses among men taking vitamin E.
One trial with 4143 participants compared vitamin D3 (400 IU/day) and calcium supplements to placebo. We found low- to moderate-
certainty evidence of no eIect of vitamin D3 and calcium supplements at any time-point up to 10 years on overall cognitive function (MD
aPer a mean of 7.8 years -0.1 MMSE points, 95% CI -0.81 to 0.61) or the incidence of dementia (HR 0.94, 95% CI 0.72 to 1.24). A pilot study
with 60 participants used a higher dose of vitamin D3 (4000 IU on alternate days) and found preliminary evidence that this dose probably
has no eIect on cognitive function over six months.
We included data from one trial of zinc and copper supplementation with 1072 participants. There was moderate-certainty evidence of
little or no eIect on overall cognitive function (MD 0.6 MMSE points, 95% CI -0.19 to 1.39) or on the incidence of cognitive impairment aPer
5 years to 10 years. A second smaller trial provided no usable data, but reported no cognitive eIects of six months of supplementation
with zinc gluconate.
From one study with 3711 participants, there was low-certainty evidence of no eIect of approximately five years of selenium
supplementation on the incidence of dementia (HR 0.83, 95% CI 0.61 to 1.13).
Finally, we included three trials of complex supplements (combinations of B vitamins, antioxidant vitamins, and minerals) with 6306
participants. From the one trial which assessed overall cognitive function, there was low-certainty evidence of little or no eIect on the TICS
(MD aPer a mean of 8.5 years 0.12, 95% CI -0.14 to 0.38).
Authors' conclusions
We did not find evidence that any vitamin or mineral supplementation strategy for cognitively healthy adults in mid or late life has a
meaningful eIect on cognitive decline or dementia, although the evidence does not permit definitive conclusions. There were very few
data on supplementation starting in midlife (< 60 years); studies designed to assess cognitive outcomes tended to be too short to assess
maintenance of cognitive function; longer studies oPen had other primary outcomes and used cognitive measures which may have lacked
sensitivity. The only positive signals of eIect came from studies of long-term supplementation with antioxidant vitamins. These may be
the most promising for further research.
P L A I N   L A N G U A G E   S U M M A R Y
Vitamin and mineral supplementation for preventing cognitive deterioration in cognitively healthy people in mid and late life
Review question
This review aimed to find out whether people aged 40 years or older could maintain their mental abilities or reduce their risk of dementia
by taking vitamin or mineral supplements.
Background
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There is great interest in anything people might do to keep themselves mentally healthy as they age and, especially, to reduce their risk of
developing dementia. Various vitamin and mineral supplements have been suggested as ways to do this. Vitamins and minerals have many
functions in the body and the ways they might aIect brain health are not well understood. Therefore, we were interested in the eIects of
any vitamins or minerals, either alone or in combination.
What we did
We searched up to January 2018 for all trials which had studied the eIect on cognition (thinking and remembering) of any vitamin or
mineral supplements in people aged 40 years or more who had no cognitive problems at the beginning of the study. The studies had to
include a comparison group which had not taken the supplement being studied and, to be sure the comparison was fair, it should have
been decided at random whether people got the supplement or not.
What we found
We grouped the 28 included trials according to the kind of supplement they used and how it might work.
Most of the trials were not originally designed to study cognition or dementia and used only simple measures of cognition. Very few studies
investigated whether participants developed dementia. Long-term studies are probably needed to find eIects on the risk of dementia or
cognitive decline but only 10 studies had an average length of follow-up longer than five years. The studies were generally well-conducted
although the longer trials had diIiculty following up all of the participants and this could have biased some of the longer-term results.
There were 14 trials of B vitamins (folic acid, vitamin B6, vitamin B12) with nearly 28,000 participants, mainly in their 60s and 70s. Most of
these trials were quite short (less than two years). We found no evidence that B vitamins had any eIect on cognition.
There were 8 trials of antioxidant vitamins (beta-carotene/vitamin A, vitamin C, vitamin E) with approximately 47,000 participants. These
trials tended to be longer than the B vitamin trials so may have had more chance of detecting eIects on dementia and cognitive decline. The
results were mixed. We found low-certainty evidence of better overall cognitive function aPer an average of 18 years taking beta-carotene
and aPer five years to 10 years taking vitamin C, but no eIects aPer shorter periods of treatment. There were also small benefits of beta-
carotene, vitamin C, and antioxidant combinations on memory at some time points but not others. There was no evidence of any benefits
from vitamin E alone. Two studies examined the risk of developing dementia. One found no eIect of a combination of antioxidant vitamins
and the other found no eIect of vitamin E, either alone or combined with the mineral selenium. Most of the studies did not report any
information about harmful eIects. One included trial was designed to look for an eIect on the risk of prostate cancer; it found a higher
risk among the men taking vitamin E.
There was a small trial of vitamin D supplements which found they probably had no eIect on cognition over six months. There were longer
trials of vitamin D with calcium (one trial), zinc and copper (one trial), and complex multivitamins (three trials). All lasted between five
and 10 years, but none of them found any evidence of beneficial eIects on cognition. One trial found no eIect of selenium taken for
approximately five years on the risk of developing dementia.
Conclusions
We found no good evidence to suggest that middle-aged or older people can preserve cognitive function or prevent dementia by taking
vitamin or mineral supplements. There were a few positive results associated with long-term use of antioxidant vitamins, particularly beta-
carotene and vitamin C, although the eIects were small. Further research into the eIects of these vitamins may be worthwhile.
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Summary of findings for the main comparison.   B vitamins compared to placebo for maintaining cognitive function in cognitively healthy people in
mid and late life
B Vitamins compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognitively healthy people in mid and late life
Setting: community
Intervention: B Vitamins (folic acid, vitamins B6 and vitamin B12, alone or in combination)
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with
placebo
Risk with B Vitamins
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Overall cognitive functioning 3 to 12 months of
supplementation (final measurement data)
assessed with: MMSE or TICSm
- SMD 0
(0.08 lower to 0.08 higher)
- 2556
(3 RCTs)
⊕⊕⊕⊝
MODERATE 1
 
Overall cognitive functioning 3 to 12 months of
supplementation (change from baseline data)
assessed with: MMSE or TICSm
- SMD 0.03 lower
(0.26 lower to 0.19 higher)
- 317
(2 RCTs)
⊕⊕⊝⊝
LOW 1 2
 
Overall cognitive functioning > 1 to 2 years of
supplementation (final measurement data)
assessed with: MMSE, TICS, or TICSm
- SMD 0.15 higher
(0.17 lower to 0.47 higher)
- 6956
(5 RCTs)
⊕⊕⊕⊝
MODERATE 1
 
Overall cognitive functioning > 1 to 2 years of
supplementation (change from baseline data)
assessed with MMSE
- SMD 0.06 higher
(0.2 lower to 0.31 higher)
- 241
(1 RCT)
⊕⊕⊝⊝
LOW 1 2
 
Overall cognitive functioning > 2 to 5 years of
supplementation (final measurement data)
assessed with MMSE, TICS, F-TICSm or a compos-
ite score
- SMD 0.01 lower
(0.11 lower to 0.09 higher)
- 3985
(4 RCTs)
⊕⊕⊕⊝
MODERATE 1
 
Overall cognitive functioning - > 5-10 years of
supplementation (final measurement data)
- SMD 0.01 lower
(0.09 lower to 0.07 higher)
- 10249
(3 RCTs)
⊕⊕⊝⊝
LOW 1 3
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assessed with MMSE, TICS or TICSm
Study populationIncidence of MCI or dementia > 2 to 5 years of
supplementation
assessed with: MMSE < 24 on 2 or more occasions
follow-up: median 2.8 years
103 per 1.000 91 per 1.000
(69 to 121)
RR 0.89
(0.67 to 1.18)
1803
(1 RCT)
⊕⊕⊕⊝
MODERATE 1
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for indirectness due to restricted inclusion criteria for participants in included studies
2 Downgraded for imprecision due to small sample size and wide confidence intervals
3 Downgraded for study limitations due to missing data from 26% of participants in SEARCH 2010
MMSE: Mini Mental State Examination
TICS: Telephone Interview for Cognitive Status
TICSm: modified Telephone Interview for Cognitive Status
F-TICSm: modified Telephone Interveiw for Cognitive Status (French version)
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Antioxidants compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognitively healthy people in mid and late life
Setting: community
Intervention: antioxidant vitamins (vitamins C, E, and beta-carotene, alone or in combination)
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with
placebo
Risk with Antioxi-
dants
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
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Vitamin E supplementation
Overall cognitive functioning
assessed with: MMSE
Scale from: 0 to 30
follow-up: 3 months
The mean
MMSE score
was 26.6
MD 1.4 higher
(1.18 higher to 1.62
higher)
- 74
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2 3
Higher score indicates better cognitive
function.
Vitamin E supplementation
Overall cognitive functioning
assessed with: TICS
Scale from: 0 to 41
follow-up: range 6 years to 10
years
Two studies found no evidence of an ef-
fect of vitamin E
- (2 RCTs) ⊕⊕⊝⊝
LOW 4 5
Range of follow-up durations was ap-
proximate. Mean in one study was 9.6
years and in the other study was 8.9
years. There were 5226 participants
in one study. The number in the oth-
er study was not reported for this time
point (approximately 800).
Beta-carotene supplemen-
tation
Overall cognitive functioning
assessed with: TICS
Scale from: 0 to 41
follow-up: mean 12 months
The mean TICS
score was 34.29
MD 0.14 lower
(0.37 lower to 0.09
higher)
- 1904
(1 RCT)
⊕⊕⊕⊝
MODERATE 6
Higher score indicates better cognitive
function.
Beta-carotene supplemen-
tation
Overall cognitive functioning
assessed with: TICS
follow-up: mean 8.9 years
Not reported MD 0.13 lower
(0.46 lower to 0.19
higher)
- (1 RCT) ⊕⊕⊝⊝
LOW 4 7
Mean difference with 95% CI reported
in paper. Absolute values in each treat-
ment group not reported. Number in
each treatment group at final follow-up
not reported.
Beta-carotene supplemen-
tation
Overall cognitive functioning
assessed with: TICS
Scale from: 0 to 41
follow-up: mean 18 years
The mean TICS
score was 34.23
MD 0.18 higher
(0.01 higher to 0.35
higher)
- 4052
(1 RCT)
⊕⊕⊕⊝
MODERATE 6
 
Vitamin C supplementation
Overall cognitive functioning
assessed with: TICS
follow-up: mean 8.9 years
Not reported MD 0.46 higher
(0.14 higher to 0.78
higher)
- (1 RCT) ⊕⊕⊝⊝
LOW 4 7
Mean difference with 95% CI reported
in paper. Absolute values in each group
not reported. Number in each treatment
group at final follow-up not reported.
Supplementation with be-
ta-carotene + vit C + vit E
The mean
TICSm score
was 24.02
MD 0.09 higher
(0.05 lower to 0.23
higher)
- 20536
(1 RCT)
⊕⊕⊕⊝
MODERATE 8
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Overall cognitive functioning
assessed with: TICSm
Scale from: 0 to 39
follow-up: mean 5 years
Supplementation with be-
ta-carotene + vit C + vit E
Overall cognitive functioning
assessed with: 3MS (modified
MMSE)
Scale from: 0 to 100
follow-up: median 6.9 years
The mean 3MS
score was 92.1
MD 0.6 higher
(0.2 lower to 1.4 high-
er)
- 1100
(1 RCT)
⊕⊕⊕⊝
MODERATE 4
Higher score indicates better cognitive
function.
Incidence of all-cause demen-
tia
follow-up: mean approxi-
mately 5 years
Two studies, one using a combination of
beta-carotene, vit C and vit E and one us-
ing vit E ± selenium, found no significant
difference in the incidence of dementia.
- 25 993
(2 RCTs)
⊕⊕⊝⊝
LOW 8 9
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for risk of bias due to lack of blinding (open-label study)
2 Downgraded for indirectness (diabetic participants only)
3 Downgraded for imprecision due to small sample size
4 Downgraded for risk of bias due to incomplete outcome data
5 Downgraded for indirectness (both studies included only women and in one study all participants also had cardiovascular disease or 3 or more coronary risk factors)
6 Downgraded for indirectness (included men only)
7 Downgraded for indirectness (included only women with cardiovascular disease or ≥ 3 coronary risk factors)
8 Downgraded for indirectness (all participants had high risk of coronary heart disease death over the next 5 years)
9 Downgraded for imprecision due to wide confidence interval
MMSE: Mini Mental State Examination
TICS: Telephone Interview for Cognitive Status
TICSm: Modified Telephone Interview for Cognitive Status
3MS: The Modified Mini-Mental State Examination
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Summary of findings 3.   Vitamin D3 compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Vitamin D3 compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population: cognitively healthy people in mid and late life
Setting: community
Intervention: vitamin D3 +/- calcium carbonate
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo Risk with Vitamin D3
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Com-
ments
Overall cognitive functioning
assessed with: MoCA change from
baseline
Scale from: 0 to 30
follow-up: 6 months
There was no significant difference between groups in the change
in MoCA score (P=0.186).
  60
(1 RCT)
⊕⊕⊕⊝
MODERATE 1
Experi-
mental
interven-
tion was
vitamin
D3 4000
IU on al-
ternate
days.
Data not
fully re-
ported
(confer-
ence ab-
stract
only).
Overall cognitive functioning
assessed with: 3MS
Scale from: 0 to 100
follow-up: mean 7.8 years
The mean 3MS score was 96.6 MD 0.1 lower
(0.81 lower to 0.61 higher)
- 918
(1 RCT)
⊕⊕⊝⊝
LOW 2 3
Exper-
imen-
tal inter-
vention
was vit-
amin D3
400 IU/
day and
calcium
carbon-
ate 1000
mg/day.
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Incidence of probable dementia or
MCI
follow-up: mean 7.8 years
No significant difference in incidence between treatment groups.
In an intention-to-treat analysis, incidence was 62.2/10 000 per-
son-years in the vit D + Ca group and 65.9/10 000 person-years in
the placebo group (HR 0.94, 95% CI 0.72 to 1.24, P = 0.68).
- 4143
(1 RCT)
⊕⊕⊝⊝
LOW3 4
Exper-
imen-
tal inter-
vention
was vit-
amin D3
400 IU/
day and
calcium
carbon-
ate 1000
mg/day.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for imprecision (small sample size)
2 Downgraded for risk of bias due to incomplete outcome data
3 Downgraded for indirectness (study included women only)
4 Downgraded for imprecision due to wide confidence interval
MCI: Mild Cognitive Impairment
MOCA: Montreal cognitive assessment
3MS: The Modified Mini-Mental State Examination
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Zinc + copper compared to placebo for maintaining cognitive function in cognitively healthy people in mid and late life
Patient or population:cognitively healthy people in mid and late life
Setting: Community
Intervention: Zinc + copper oxides
Comparison: Placebo
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Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo Risk with Zinc + copper
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Overall cogni-
tive functioning
assessed with:
3MS
Scale from: 0 to
100
follow-up: me-
dian 6.9 years
The mean 3MS score was 92.1 MD 0.6 higher
(0.19 lower to 1.39 higher)
- 1072
(1 RCT)
⊕⊕⊕⊝
MODERATE 1 2
 
Incidence of de-
mentia or MCI
assessed with:
3MS score < 80
follow-up: me-
dian 6.9 years
4.5% of participants met the authors' definition of cognitive impairment (3MS <
80) and "there was no significant effect of treatment group on likelihood of having
cognitive impairment."
- 1072
(1 RCT)
⊕⊕⊝⊝
LOW 3
 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for risk of bias due to unclear selective reporting and high risk of bias due to incomplete outcome data
2 Downgraded for indirectness (YaIe 2004 included participants with age-related macular degeneration)
3 Downgraded two levels for study limitations due to incomplete outcome data and selective reporting
3MS: The Modified Mini-Mental State Examination
MCI: Mild cognitive impairment
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Patient or population: cognitively healthy people in mid and late life
Setting: community
Intervention: complex multivitamins (combinations of B vitamins and antioxidant vitamins +/- minerals)
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with control Risk with Complex multivit-
amin
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Overall cognitive functioning
assessed with: TICS
Scale from: 0 to 41
follow-up: mean 2.5 years
The mean TICS
score was 34.3
MD 0.04 higher
(0.09 lower to 0.18 higher)
- 5947
(1 RCT)
⊕⊕⊝⊝
LOW 1 2
Follow-up ranged
from 0.18 to 5.3
years.
Overall cognitive functioning
assessed with: TICS
Scale from: 0 to 41
follow-up: mean 8.5 years
The mean TICS
score was 33.1
MD 0.12 higher
(0.14 lower to 0.38 higher)
- 2324
(1 RCT)
⊕⊕⊝⊝
LOW 1 2
Follow-up ranged
from 0.3 to 14.2
years.
Incidence of MCI or all-cause dementia -
not measured
  - - -  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded for study limitations due to incomplete outcome data and wide range of follow-up durations
2 Downgraded for indirectness (study included only men)
TICS: Telephone Interview for Cognitive Status
MCI: mild cognitive impairment
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B A C K G R O U N D
Description of the condition
Cognitive health, mild cognitive impairment, and dementia
There is no consensus definition of cognitive health or successful
cognitive ageing, but it has been described as ‘‘not just the absence
of cognitive impairment, but the development and preservation
of the multidimensional cognitive structure that allows the older
adult to maintain social connectedness, an ongoing sense of
purpose, and the abilities to function independently, to permit
functional recovery from illness and injury, and to cope with
residual cognitive deficits” (Depp 2012; Hendrie 2006). Successful
cognitive ageing is distinct from mild cognitive impairment (MCI)
and dementia.
Dementia is a syndrome of cognitive and functional decline that is
usually progressive. It aIects multiple cognitive domains, among
which memory is usually prominent, but orientation, executive
function, language, perception, and social cognition are also oPen
aIected. In most cases, the onset of dementia is gradual. It is
usually preceded by a stage of mild cognitive impairment when
cognitive deficits beyond those of normal ageing are detectable,
but function is not significantly impaired. The term dementia is
used once the cognitive deficits begin to have a significant eIect on
daily activities. As the syndrome progresses, those aIected become
increasingly dependent on others for all activities of daily living.
Types of MCI and dementia
Subtypes of dementia are distinguished by the underlying
pathology. The four most common subtypes are Alzheimer's
disease dementia (AD) (accounting for an estimated 60% to 70%
of all dementia cases); vascular dementia (VaD); dementia with
Lewy Bodies (DLB); and frontotemporal dementia (FTD). Accurate
diagnosis of the subtypes may be diIicult. Mixed pathology is
common, with more than 80% of cases having some features
of Alzheimer’s disease (Jellinger 2006; WHO 2012). However, the
proportion of dementia attributable to Alzheimer’s disease reduces
with age (Savva 2009).
There are numerous diIerent operational definitions of MCI,
with diIerent scope (e.g. memory or non-memory impairments)
(Matthews 2007), prevalence (Stephan 2007), and risk of
progression to dementia (Matthews 2008). Currently, there is no
single, universally accepted definition of MCI (Stephan 2013),
but adaptations of the criteria suggested by Petersen 1999 are
commonly used in clinical trials. Categorisation of MCI may also be
based on the suspected underlying cause of the cognitive deficits,
e.g. MCI due to Alzheimer's disease and MCI due to vascular disease
(termed 'vascular cognitive impairment, no dementia': VCIND).
It is increasingly recognised that some dementia syndromes,
including AD, have a very long preclinical phase with pathological
changes beginning years, or even decades, before the onset of
symptoms (Sperling 2011). Attempts have been made to develop
criteria to capture preclinical states as early as possible. For
example, the label 'pre-MCI' has been applied to people with
impaired executive function and language, elevated apathy scores,
and reduced volumes of leP brain areas of the hippocampus,
an area involved in consolidation of information from short-term
memory to long-term memory but also spatial memory, enabling
orientation. (Duara 2011). It is likely that biomarker tests, tests that
measure some biological state, will be needed to identify people in
the earliest stages of dementing illnesses.
Prevalence of MCI and dementia
In the UK Medical Research Council's population-based Cognitive
Function and Ageing Study (CFAS), which mapped 18 diIerent
definitions of MCI, the range of prevalence estimates was found
to be variable (0.1% to 42.0%), and conversion rates to dementia
generally low (Stephan 2007). Prevalence rates and rates of
conversion to dementia have been reported to be higher in
specialist settings than in population-based studies (adjusted
conversion rate from MCI to dementia 9.6% versus 4.9%) (Mitchell
2009).
The risk of dementia increases with age. According to a World
Health Organization (WHO) report, only 2% to 10% of cases
start before the age of 65 years (WHO 2012). The same report
estimated that there were 35.6 million people with dementia in
the world in 2010, and that this figure would double every 20
years to reach 65.7 million in 2030 (WHO 2012). However, there is
a degree of uncertainty about the expected increase in prevalence
of dementia. Recent research by Matthews 2013 in the UK and by
Christensen 2013 in Denmark indicates that age-specific prevalence
of dementia may be falling in developed countries, suggesting the
possibility that dementia risk may be modifiable. Nevertheless,
because of population ageing, the overall prevalence continues to
rise.
Risk factors
Generally, risk factors for dementia can be divided into modifiable
and non-modifiable categories. Non-modifiable risk factors include
age, genetic factors, and gender (females are at higher risk). At a
population level, age is the most significant risk factor. In people
older than 65 years, the risk of AD (the commonest cause of
dementia) doubles every five years (Launer 1999; McCullagh 2001;
Van den Berg 2012; Van der Flier 2005). A pooled analysis of four
prospective studies in Europe found that the incidence of AD among
people aged 90 years and over was 63.5/1000 person-years (Launer
1999). Genetics plays a major role in early onset AD, but a lesser role
in the much commoner late onset disease.
Many potentially modifiable risk factors are common to AD
and vascular dementia. These include diabetes mellitus, midlife
obesity, midlife hypertension, smoking,,and physical inactivity
(Prince 2014; WHO 2012). The fact that risk factors are active in
midlife is consistent with what is known of the long preclinical
phase of dementia and implies that there is a long period in which
preventive eIorts could be eIective.
At present, there is no cure for any subtype of dementia,
but identifying and targeting modifiable risk factors might oIer
opportunities to modify its onset and course. Studies to test
this hypothesis have investigated cognitive stimulation, exercise,
diet, and other nutritional interventions, and the management
of vascular risk factors, such as hypertension, diabetes, obesity,
smoking, and physical inactivity (Lindsay 2002; Lourida 2013;
Norton 2014; Wilson 2002).
Description of the intervention
This review focusses on the eIect of vitamins or minerals (or both)
on cognitive functioning. Vitamins are organic compounds that
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are essential for the normal physiological process in the body and
play important roles in growth and development (Kennedy 2011).
MInerals are inorganic elements and as nutrients are also needed
by the body to grow and develop normally (Centers for Disease
Control and Prevention 2014). Most of these essential nutrients
are available naturally in the diet. Dietary supplements are any
consumed products that aim to provide nutrients additional to
those obtained in the regular diet.
How the intervention might work
Vitamins and minerals have numerous important roles in human
physiology. Recognised biological roles of all those considered for
this review are summarised briefly in Appendix 1.
The most commonly cited mechanisms by which vitamins and
minerals may influence cognitive function are (1) via eIects on
specific plasma amino-acids called homocysteine for B vitamins
(folic acid, vitamin B6, and vitamin B12) and (2) via antioxidant
eIects, reducing the concentration of free radicals that may
damage human cells, for vitamins C, E, and ß-carotene, possibly
vitamin D, and some minerals such as selenium. These hypotheses
about possible mechanisms are based largely on preclinical
studies and on observations of associations between elevated
homocysteine levels or elevated markers of oxidative stress and
cognitive decline or dementia (Clarke 2007a, Bennett 2009).
Detailed understanding of mechanisms is, however, lacking.
Why it is important to do this review
The prevalence and high societal costs of dementia are such that
even small reductions in its age-specific incidence would have
a large impact on healthcare costs and on the overall burden it
causes to patients, their families, and communities. In order to
decide where preventive eIorts should be concentrated, robust
assessments are needed of the eIects of interventions and of the
‘dose’ and duration of intervention necessary to achieve an eIect.
For individuals, fear of cognitive decline and dementia may be
powerful motivators to seek preventive interventions. Vitamin
and mineral supplementation and cognitive activities (e.g.
computerised ‘brain training’ games), in particular, are subject to
promotion by those with commercial interests. It is important for
people to know whether time, eIort, and money they might invest
to prevent cognitive decline is likely to be well spent. Information
about adverse eIects is also important. Although nutritional and
behavioural interventions are oPen perceived to be ‘low risk’,
they are not necessarily without the potential to cause harm. For
example, trials have found high doses of vitamin E to be associated
with higher rates of side eIects than placebo (Bjelakovic 2012;
Brigelius-Flohe 2007; Miller 2005).
O B J E C T I V E S
To evaluate the eIects of vitamin and mineral supplementation on
cognitive function in cognitively healthy people aged 40 years or
more.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised or quasi-randomised controlled trials,
published or unpublished, reported in any language. We included
trials with a duration of intervention of 12 weeks or more. Trials
in cognitively healthy people with a duration as short as 12
weeks typically investigate cognitive enhancement rather than
maintenance of cognitive function. We included these trials in order
to give a full picture of the data, although it is recognised that
the relationship between short-term cognitive enhancement and
maintenance of cognitive function over longer periods of time, or
incidence of dementia, is unclear.
Types of participants
We included trials in which the participants were cognitively
healthy people from midlife onwards, i.e. participants aged 40 years
and over without a dementia diagnosis or cognitive impairment
at baseline ('midlife' was defined for the purposes of disease
classification, in DSM-IV 1994, as between 40 years and 65
years).The cognitive status of participants was determined by the
trialists' own definitions of ‘cognitively healthy’. These definitions
were recorded. We contacted trialists if further clarification was
needed to determine health status. If trials included a cognitively
mixed population, we required at least 80% of participants to
be free of cognitive impairment (including subjective cognitive
impairment) at baseline.
Types of interventions
We included studies comparing the eIect of orally-administered
vitamin or mineral supplements (or vitamin and mineral
supplements) with control interventions which were not expected
to have an eIect on cognition (placebo or no intervention/usual
care). Eligible vitamins and minerals are listed in Appendix 1. These
vitamins and minerals could be given singly or in combination
and at any dose, for a minimum of 12 weeks. Trials of vitamins
or minerals (or vitamins and minerals) given in combination with
other nutrients (e.g. fatty acids, amino acids) or with drugs were
excluded unless the design allowed the eIects of vitamins or
minerals to be isolated. For example, a trial comparing vitamin X
to amino acid Y was ineligible, but a trial comparing vitamin X and
amino acid Y to amino acid Y only was eligible.
Types of outcome measures
Primary outcomes
Mean overall cognitive functioning measured with any
internationally accepted and validated measure: for example,
Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-
cog); Mini Mental State Examination (MMSE); Repeatable Battery for
the Assessment of Neuropsychological Status (RBANS); Cambridge
Cognition Examination (CAMCOG).
Secondary outcomes
Any internationally accepted and validated measures of:
• specific cognitive functioning subdomain: episodic memory;• specific cognitive functioning subdomain: executive
functioning;
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• specific cognitive functioning subdomain: speed of processing;• incidence of MCI or all-cause dementia;• quality of life, either generic or disease-specific;• clinical global impression (a scale measuring a clinician's
judgement on overall symptom severity);• functional performance;• number of participants experiencing one or more serious
adverse events (SAE);• mortality.
If a trial provided data on more than one cognitive scale for
a specific outcome, we applied a hierarchy of cognition-related
outcomes and used data on the cognitive scale that was highest
on this hierarchy. For example, if a trial reported results on both
the Mini Mental State Examination and the Clinical Dementia
Rating scale (CDR), we used the outcome data from MMSE in
our quantitative analyses. The rank of a scale in the hierarchy
was determined by the frequency of its use in a large set of 79
trials, evaluating vitamin and mineral supplementation, dietary
interventions, and physical exercise interventions.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane
Dementia and Cognitive Improvement Group’s (CDCIG) specialised
register.
ALOIS is maintained by the Information Specialist for the CDCIG,
and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy elderly populations. The studies are
identified through:
1. Monthly searches of a number of major healthcare databases:
MEDLINE, Embase, CINAHL, PsycINFO and LILACS;
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan's Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others);
3. Quarterly search of The Cochrane Library’s Central Register of
Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources: ISI
Web of Knowledge Conference Proceedings; Index to Theses;
Australasian Digital Theses.
To view a list of all sources searched for ALOIS see About ALOIS on
the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia,
cognitive improvement, and cognitive enhancement trials, can
be viewed in the ‘methods used in reviews’ section within the
editorial information about the Cochrane Dementia and Cognitive
Improvement Group.
We ran additional searches in MEDLINE, Embase, PsycINFO,
CINAHL, ClinicalTrials.gov and the WHO Portal/ICTRP to ensure that
the searches for each suite of reviews was as comprehensive and
as up-to-date as possible to identify published, unpublished, and
ongoing trials. The search strategies that we created and used can
be seen in Appendix 2.
Searching other resources
We screened reference lists of all included trials. In addition,
we screened reference lists of recent systematic reviews, health
technology assessment reports, and subject-specific guidelines
identified through www.guideline.gov. The search was restricted to
those guidelines meeting National Guideline Clearinghouse’s (NGC)
2013 inclusion criteria published in this year or later.
We contacted experts in the field and companies marketing
included interventions, in order to provide additional randomised
trial reports that were not identified by the database search.
Data collection and analysis
Selection of studies
We used crowdsourcing to screen the search results. Details of
this have been described here: http://www.medicine.ox.ac.uk/
alois/content/modifiable-risk-factors. In brief, teams of volunteers
performed a ‘first assessment’ on the search results. The volunteers
were recruited through the author team’s institutions. They
screened the results using an online tool developed for Cochrane
Embase project but tailored for this programme of work. The
crowd decided, based on a reading of title and abstract, whether
the citation was describing a randomised or quasi-randomised
trial, irrespective of the citations topic. It is estimated that this
removes 75% to 90% of results retrieved. The remaining titles
and abstracts were then screened by the author team, followed
by full text screening. Two clinicians in the author team screened
independently (AA, DD, RA). In the event of disagreement that
could not be resolved by discussion, a methodologist (LYC) and
additional clinician (NT or JA) arbitrated on eligibility and reasons
for exclusion. All consensus rulings and reasons for exclusion
were subsequently verified by methodologists (AR and MdN or
LYC). Citations and full text papers from the update searches
conducted in 2017 and 2018 were screened independently by two
clinicians (JM and GM), who reached consensus through discussion
if necessary.
Data extraction and management
Two review authors, working independently, extracted trial
information using a structured data extraction form. Discrepancies
were resolved by discussion, or by the involvement of a third
reviewer. Where possible, we extracted (as a minimum) the
following information related to characteristics of participants,
intervention, and study design:
Participant characteristics:
• gender;• baseline age (range, median, mean);• baseline cognitive function;• cognitive diagnostic status.
Intervention characteristics:
• nature of the intervention; generic and trade name of
intervention;
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• description of the control condition;• duration of treatment;• dosage and frequency;• any concomitant treatments;• treatment adherence.
Methodological characteristics:
• trial design (individual or cluster randomisation; parallel group,
factorial, or crossover design);• number of participants;• outcome measures used;• duration of follow-up as measured from randomisation;• duration of follow-up as measured from end of treatment;• source of financial support;• publication status.
If eligible cognitive outcome data were available at multiple time
points, we grouped outcomes into short-term (12 weeks/three
months to one year), medium-term (> one year to two years) and
longer-term results (> two to five years, > five to 10 years and
>10 years). For the secondary outcome all-cause dementia, only
outcome data aPer one or more years of follow-up were considered.
Within these time periods, the longest available data reported by
the study were extracted (for example, if study reported data at
six months, 9 months and one year, only the one-year data were
extracted and analysed for the short-term time point.
For dichotomous outcomes (such as incident dementia or
mortality), we extracted from each trial the number of participants
with each outcome.
For continuous outcomes, we extracted the number of participants
in whom the outcome was measured, and the mean and standard
deviation of the change from baseline or of the mean value at
each relevant time point. When necessary, means and measures of
dispersion were approximated from figures in the reports.
For crossover trials, we extracted data on the first treatment period
only.
Whenever possible, we extracted intention-to-treat data i.e.
analysing all patients according to the group randomisation. If
this was not available, then we extracted and reported data from
available case analyses. If these data were also not available, we
considered data from 'per protocol' analyses. We contacted the
trialists if we could not obtain the necessary data from the trial
report.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias in each of
the included trials using Cochrane's 'Risk of bias' tool (Higgins
2011). We resolved disagreements by consensus. We assessed
the risk of bias potentially introduced by suboptimal design or
conduct in the domains of sequence generation, concealment
of allocation, blinding of participants and caregivers, blinding of
outcome assessors, selective outcome reporting, and incomplete
outcome data, including the type of statistical analyses used (true
intention-to-treat versus other). The general definitions that were
used are reported in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011); the review-specific definitions
described in Appendix 3 are in part derived from a previously
published systematic review (Rutjes 2012).
Measures of treatment e:ect
The measure of treatment eIect for continuous outcomes was a
mean diIerence (MD) if all studies measuring that outcome used
the same scale and a standardised mean diIerence (SMD), defined
as the between-group diIerence in mean values divided by the
pooled standard deviation (SD), if an outcome was measured with
a variety of scales. The treatment eIect for dichotomous outcomes
was expressed as a relative risk (RR).
Unit of analysis issues
We included no cluster-randomised trials and identified no other
unit of analysis issues.
Dealing with missing data
Missing data in the individual trials may put the study estimates of
eIects at a high risk of bias, and may lower the overall certainty
of the evidence according to GRADE (Higgins 2011). We dealt
with missing data in our 'Risk of bias' assessments and planned
to evaluate attrition bias in stratified analyses of the primary
outcomes (Appendix 3). We thus analysed the available information
and did not contact authors with a request to provide missing
information. We did not impute missing data ourselves.
Assessment of heterogeneity
We considered diIerences in trial populations, interventions
(including duration of treatment), and outcomes when assessing
clinical heterogeneity and deciding which data to pool. We used
visual inspection of forest plots and the tau2 and I2 statistics when
considering whether to downgrade our confidence in results for
inconsistency between trials, see also Data synthesis.
Assessment of reporting biases
Due to the low number of studies included in meta-analyses, we did
not perform any funnel plot analyses to explore possible reporting
biases.
Data synthesis
We pooled interventions which have been postulated to share a
main mechanism of action in preventing development of dementia.
Specifically, we pooled data from trials of:
• the antioxidant vitamins C, E, and ß-carotene, and• B vitamins (thiamine (B1), pyridoxine (B6), folic acid (B9) and
cobalamin (B12)) on the grounds that these are cofactors for
key metabolic processes and are involved in reducing high
homocysteine levels.
Whenever possible, we used standard inverse-variance random-
eIects meta-analysis to combine outcome data across the trials
(DerSimonian 1986) (see Data extraction and management for
definitions of time points). When indicated, we converted scales
to a consistent direction of eIect across all trials, so that
negative estimates of eIect referred to those favouring active
supplementation, while positive estimates referred to those
favouring control. We visually inspected forest plots for the
presence of heterogeneity and calculated the variance estimate
tau2 as a measure of between-trial heterogeneity (DerSimonian
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1986). We prespecified a tau2 of 0.04 to represent low heterogeneity,
0.09 to represent moderate heterogeneity, and 0.16 to represent
high heterogeneity between trials (Spiegelhalter 2004). The I2
statistic and the corresponding Chi2 test were depicted in addition
(Higgins 2003) for the benefit of readers more familiar with this
statistic. I2 describes the percentage of variation across trials
attributable to heterogeneity rather than chance, with values of
25%, 50%, and 75% typically being interpreted as low, moderate,
and high between-trial heterogeneity. Tau2 was preferred over
I2 in the interpretation of between-trial heterogeneity, as the
interpretation of I2 can be aIected by the precision of trials included
in the meta-analysis (Rücker 2008). All P values were two-sided.
Statistical analysis was done in Review Manager 5 (Review Manager
2014); and in STATA, release 13 (StataCorp, College Station, Texas).
Subgroup analysis and investigation of heterogeneity
Where we identified substantial inconsistency between trials in a
meta-analysis, we inspected forest plots to look for obvious sources
of inconsistency and reviewed the trials for clinical heterogeneity.
Because of the small numbers of trials from which data could be
pooled, we conducted no subgroup analyses.
Sensitivity analysis
We did not conduct any sensitivity analyses.
GRADE and summary of findings table
We constructed 'Summary of Findings' (SoF) tables for comparisons
of B vitamins, antioxidant vitamins, Vitamin D + calcium, Zinc
+ Copper and complex multivitamins with placebo. For each
comparison, we included in the SoF tables results related to overall
cognitive function and the incidence of dementia at each time
point. If a study presented results for the same participants at
diIerent time points, and these could not be pooled with results
from other studies, then we presented in the SoF table only the
results from the longest period of follow-up.
We used GRADE to describe the certainty of the overall body of
evidence for each outcome in the 'Summary of findings' table
(Higgins 2011; Guyatt 2008).
Certainty refers to the degree of confidence which can be placed
in the estimates of treatment benefits and harms. There are four
possible ratings: 'high', 'moderate', 'low' and 'very low'. The GRADE
approach rates evidence from RCTs which do not have serious
limitations as 'high-certainty'. However, several factors can lead
to the downgrading of the evidence to 'moderate', 'low' or 'very
low'. The degree of downgrading is determined by the seriousness
of these factors: study limitations (risk of bias); inconsistency;
indirectness of evidence; imprecision; and publication bias (Higgins
2011; Guyatt 2008). Rating evidence 'high-certainty' implies that we
are confident in our estimate of the eIect, and further research is
very unlikely to change this. A rating of 'very low'-certainty indicates
that we are very uncertain about the obtained summary estimate
of the eIect.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
We conducted searches in December 2014, July 2015, March
2016, August 2016, March 2017, and January 2018. In total, we
retrieved 7,257 records from the six searches. APer de-duplication,
5211 records remained. A Crowd and the CDCIG information
specialist assessed these at title and abstract level. In total, 725
results remained aPer this assessment. The review team then
screened these records. Of these, we assessed 74 full-text articles
for eligibility and included 28 studies. One study was placed in
the section 'Awaiting classification'; although it was marked as
'completed' in the trial registry, we were unable to find any results
or to get any response from the authors. This process is depicted in
Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
We included 28 studies with a total of more than 83,000 participants
in the review.
Studies of B vitamins
We included 14 studies with 27,882 participants in which the
active intervention was folic acid, vitamin B12, vitamin B6, or a
combination of these (Andreeva 2011; Dangour 2015; Durga 2007;
Eussen 2006; Ford 2010; Hankey 2013; Kang 2008; Lewerin 2005;
McMahon 2006; SEARCH 2010; Stott 2005; Toole 2004; Van der
Zwaluw 2014; Walker 2012). Seven of the 14 studies had been
designed with cognition as a primary outcome.
• Study design. Nine studies compared the B vitamin or B vitamin
combination to placebo in a two-arm, parallel group design. In
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one two-arm, parallel group study (Toole 2004), the intervention
was a multivitamin containing the United States' Food and Drug
Administration (FDA) recommended daily allowances (RDA) of
vitamins supplemented with high doses of folic acid, vitamin B6,
and vitamin B12 while the comparator arm was a multivitamin
containing the RDAs only. One study (Eussen 2006) had a three-
arm, parallel group design with active intervention groups
receiving B12 and (folic acid + B12); we combined these to make
a single active intervention group. Four studies had factorial
designs with placebo controls. SEARCH 2010 had a 2 x 2 factorial
design including (folic acid + B12) and simvastatin. Andreeva
2011 had a 2 x 2 factorial design including (folic acid + B6 + B12)
and omega fatty acids. Stott 2005 had a 2 x 2 x 2 factorial design
including (folic acid + B12), B2, and B6 and reported results for
all eight groups separately; for comparability with other studies,
we included the (folic acid + B12) and the (folic acid + B12 + B6
groups), combining these to make a single active intervention
group. Kang 2008 had a 2 x 2 x 2 x 2 factorial design. It reported
on a cognitive substudy of the Women's Antioxidant and Folic
Acid Cardiovascular Study (WAFACS), which was established
by adding a fourth arm - (folic acid + B6 + B12) - to the
Women's Antioxidant Cardiovascular Study (WACS). The active
interventions in WAFACS were therefore (folic acid + B6 + B12),
vitamin E, vitamin C, and ß-carotene. Kang 2008 reported on the
eIects of the B vitamins.• Interventions. The active interventions varied in their
constituents and dose. In one trial, the active intervention of
interest was folic acid alone; in one trial, it was B12 alone. In
five trials, the active intervention was (folic acid + B12) and in six
trials (folic acid + B12 + B6), although in one of these trials the
B12 dose was minimal. Daily doses of folic acid ranged from 0.4
mg to 2.5 mg, of B6 from 3 mg to 50 mg and of B12 from 0.02 mg
to 1 mg. All studies had a placebo control, although for most of
the factorial studies the comparison was 'B vitamin' versus 'no B
vitamin' where the 'no B vitamin' group were taking a variety of
other interventions. In one trial, all participants were also given
600 IU of vitamin D3 daily.• Population. The study populations varied.* Six studies recruited participants with a history of cardio-
or cerebrovascular disease (Andreeva 2011, Hankey 2013;
MRC/BHF 2002, SEARCH 2010, Stott 2005, Toole 2004)
and one recruited men with hypertension (Ford 2010).
Three studies included only participants with elevated
serum homocysteine levels (> 12 or 13 μmol/L) at baseline
(Durga 2007, McMahon 2006, Van der Zwaluw 2014). Two
studies included only participants with mild to moderate
B12 deficiency (Dangour 2015; Eussen 2006). One study
included only diabetic participants (Anand 2011). In one
study, participants were selected on the basis of elevated
psychological distress (Walker 2012).* In all studies, there was evidence that most participants
were cognitively healthy at baseline, but inclusion of small
numbers of participants with cognitive impairment was
possible. The inclusion decision was marginal for two
studies. Stott 2005 reported median MMSE at baseline of 28
with an IQR of 26 to 29; hence 25% of participants in this UK
study had an MMSE < 26. In Toole 2004, all participants had
had a 'non-disabling' ischaemic stroke and baseline MMSE
was 26.9 (SD 3.4) so it is likely that some participants had a
degree of cognitive impairment at baseline. Only participants
with 'severe cognitive impairment' were excluded. We
decided to include both of these studies, but to consider the
population as a possible source of heterogeneity.* The age of participants also varied. In six studies, the mean
age at the onset of supplementation was between 60 years
and 70 years; in eight studies the mean age was between 70
years and 80 years.
Studies of antioxidant vitamins
We included eight studies with 47,840 participants in which the
active intervention was one or more of the antioxidant vitamins:
vitamin E, vitamin C, ß-carotene (Anand 2011; Grodstein 2007; Kang
2006; Kang 2009; Kesse-Guyot 2011; Kryscio 2017; MRC/BHF 2002;
YaIe 2004). Only one of these studies had been designed primarily
to assess cognition.
• Study design. One study (Anand 2011) compared vitamin E to
no vitamin E in a randomised, open-label design. The remaining
studies were placebo-controlled. One (Kang 2006) was a 2 x 2
factorial comparison of vitamin E and low dose aspirin. One
(Kryscio 2017) was a 2 x 2 factorial comparison of vitamin E
and selenium supplements (this trial was also included in a
comparison of selenium with placebo, below). Grodstein 2007
reported data on ß-carotene. It started as a two-arm parallel
group study (ß-carotene and placebo, the Physicians' Health
Study I (PHS-I)) which lasted for 13 years. APer a gap of up to
18 months in some cases, approximately half the participants
in PHS-I and some new recruits entered the Physicians' Health
Study II (PHS-II) and a cognitive assessment was added. The
original randomisation of participants in PHS-I to ß-carotene or
placebo was retained in PHS-II while vitamin C, vitamin E, and
a complex multivitamin were added in a factorial design. The
paper therefore reported data aPer both long-term (mean 18
years, range 15 to 20 years) and shorter-term (mean one year,
range three months to three years) treatment with ß-carotene.
Kang 2009 studied vitamin E, vitamin C, and ß-carotene in a
2 x 2 x 2 factorial design. In the remaining three studies, the
active intervention was a combination of antioxidant vitamins.
MRC/BHF 2002 had a 2 x 2 factorial design comparing (vitamin
E + vitamin C + ß-carotene) and simvastatin. YaIe 2004 was a
four-arm parallel group study; in this comparison, we included
the (vitamin E + vitamin C + ß-carotene) and placebo arms
(YaIe 2004 had two additional arms: one treated with zinc and
cupric oxide, which we included in another comparison, and one
treated with the antioxidant combination plus zinc and cupric
oxide, which we excluded). Finally, Kesse-Guyot 2011 compared
a combination of vitamin E, vitamin C, ß-carotene, zinc, and
selenium to placebo. In this case, it was not possible to separate
the antioxidant vitamins from the minerals. This study also
diIered in the timing of the cognitive assessment which took
place six years aPer the end of the eight-year supplementation
period.• Interventions. There were data on vitamin E from four trials, on
vitamin C from one trial, and on ß-carotene from two trials. Most
of these data were from factorial trials in which the comparison
group was receiving a variety of interventions. In two trials, the
active intervention was the antioxidant combination (vitamin
E + vitamin C + ß-carotene), in one trial, it was the same
combination with zinc and selenium and in one trial there were
both vitamin E and (vitamin E + selenium) arms. All vitamin E was
given as alpha-tocopherol. Doses of vitamin C ranged from 120
mg to 500 mg daily, of vitamin E from 600 IU on alternate days to
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660 IU daily (except in Kesse-Guyot 2011 in which the vitamin E
dose in the combined antioxidant was only 45 IU daily) and of ß-
carotene from 6 mg to 50 mg daily.• Population. The study populations varied.* Two studies included women only (Kang 2006, Kang 2009)
and two studies included men only (Grodstein 2007; Kryscio
2017). In Anand 2011, all participants had type 2 diabetes
and were taking oral hypoglycaemics. In Kang 2009, all
participants had cardiovascular disease or three or more
coronary risk factors. In MRC/BHF 2002, participants were
recruited on the basis of a high risk of coronary heart disease
death over the next five years. In YaIe 2004, all participants
had age-related macular degeneration.* Reflecting the fact that these studies were overwhelmingly
cognitive 'add-ons' to studies with other purposes, only one
study (Anand 2011) conducted any cognitive assessment
at baseline. In this study, which was conducted in an
economically-deprived population in India, a score of 24
or more on the Tamil version of the MMSE was considered
normal cognition. Although we could not be sure that
the other studies did not include some participants with
cognitive impairment, we considered it likely in all cases that
the study populations were very largely free of dementia
or significant cognitive impairment and that the data were
informative for our review question.* The age of participants included in this comparison was
generally lower than in the B vitamin comparison. In three
studies (Anand 2011, the long-term component of Grodstein
2007 and Kesse-Guyot 2011), the mean age at randomisation
was between 50 and 60 years. In four studies, the mean or
median age at randomisation was between 60 and 70 years.
For the shorter-term component of Grodstein 2007, the mean
age at randomisation was 71 years. MRC/BHF 2002 did not
report a mean age of participants; the range at baseline was
40 years to 80 years.
Studies of vitamin D
We included one trial with 4143 participants which compared
(vitamin D3 + calcium carbonate) with placebo (Rossom 2012, the
Women's Health Initiative Memory Study, or WHIMS) and a small
pilot study with 60 participants comparing vitamin D3 and placebo
(Aspell 2017). Cognition was a primary outcome in Aspell 2017.
Although Rossom 2012 was an ancillary study to a larger study with
diIerent primary aims, participants did have a detailed assessment
to exclude dementia or cognitive impairment prior to enrolment in
WHIMS.
• Study design. Both studies were two-arm parallel group studies.
The mean duration of treatment and follow-up in Rossom 2012
was 7.8 years; in Aspell 2017, it was six months.• Intervention. The doses diIered markedly in these two studies.
In Rossom 2012, the experimental intervention was 400 IU
vitamin D3 and 1000 mg calcium carbonate daily. Use of
personal supplemental vitamin D up to 600 IU (later 1000 IU) and
of calcium up to 1000 mg was also permitted. All participants
were also enrolled in WHI Hormone Therapy trials and may have
been taking estrogen with or without progestin under those
protocols. In Aspell 2017, the experimental intervention was
4000 IU of vitamin D3 on alternate days.• Population. The participants in Rossom 2012 were 4143 women
with a mean age of 71 years (range 65 to 80 years). The
participants in Aspell 2017 were 60 community-dwelling men
and women with a mean age of 68.5 years.
Studies of zinc and copper
We included two trials comparing zinc or zinc and copper
supplements with placebo (Maylor 2006, YaIe 2004), but only YaIe
2004 with 1072 participants reported usable data. Maylor 2006 was
designed to assess cognitive function, but YaIe 2004 was part of a
trial whose primary outcome was the eIect of supplementation on
age-related macular degeneration.
• Study design and interventions. Maylor 2006 was a three-arm,
parallel-group trial with 232 participants which compared two
doses of zinc gluconate (15 mg and 30 mg a day) with placebo
over six months. This study was eligible for inclusion, but did
not report data in suIicient detail for extraction and inclusion
in analyses. YaIe 2004 was a four-arm, parallel group trial in
which participants were treated for a median of 6.9 years. For
this comparison, we used data from the active intervention arm
in which participants were treated with 80 mg of zinc as zinc
oxide and 2 mg of copper as cupric oxide.• Population. The participants in Maylor 2006 were 387 people
aged 55 to 87 years. The cognitive inclusion criterion was MMSE >
23, but in fact mean MMSE among participants was > 28 with low
variability.The participants in YaIe 2004 were 2166 people with
age-related macular degeneration. Their median age at baseline
was 69 years (range 55 to 80 years). There was no baseline
cognitive assessment.
Studies of selenium
Kryscio 2017 (PREADVISE) was a 2 x 2 factorial study of vitamin
E and selenium supplements. For this comparison (selenium
versus placebo), we considered only the 3711 participants in the
selenium only and placebo only groups. The participants who
received vitamin E and (vitamin E + selenium) were considered
in the antioxidant vitamins versus placebo comparison. This was
an ancillary trial to SELECT, the primary aim of which was the
prevention of prostate cancer.
Studies of supplementation with B vitamin, antioxidant vitamin
and mineral combinations ('complex multivitamins')
We included three studies with 6306 participants in which the
interventions were supplements which included both B vitamins
and antioxidant vitamins, with or without additional minerals
(Cockle 2000, Grodstein 2013, Wolters 2005). For ease of reference,
we called these 'complex multivitamins'. Only the two smaller trials
(Cockle 2000, Wolters 2005, combined n = 359) were designed to
assess cognition.
• Study design. Cockle 2000 and Wolters 2005 were small, two-
arm, placebo-controlled, parallel group studies lasting 24 weeks
and six months respectively. Grodstein 2013 reported the
multivitamin data from a cognitive substudy (n = 5947) of the
large Physicians' Health Study II (PHS-II), which is described
under 'antioxidant vitamins' above. It had a 2 x 2 x 2 x 2 factorial
design. The mean time from randomisation to first cognitive
assessment was 2.5 years (range 0.18 to 5.3 years) and to final
cognitive assessment 8.5 years (range 0.3 to 14.2 years).• Interventions.* In Cockle 2000, the daily dose of the experimental
intervention contained: vitamin A palmitate 3334 IU,
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thiamine mononitrate (B1) 14 mg, riboflavin (B2) 16 mg,
pyridoxine (B6) 22 mg, vitamin B12 0.03 mg, vitamin C 600
mg, dl-alpha-tocopherol acetate (vitamin E) 100 mg, folic acid
4 mg, d-biotin 2 mg and nicotinamide 180 mg. The authors
stated that "[t]he dosing was calculated to provide the
equivalent of one US RDA (National Research Council, 1980)
of vitamin A and ten US RDAs of the remaining vitamins." The
study was planned to last for 48 weeks, but due to very high
dropout aPer week 24, no data were reported aPer 24 weeks.* In Grodstein 2013, the experimental intervention was
Centrum Silver ® (Pfizer). Its composition is shown in
Appendix 4.* In Wolters 2005, the experimental intervention was Nobilin
Q10 ® (Medicom Pharma) providing daily doses of 150
mg vitamin C (calcium ascorbate), 50 mg magnesium
(magnesium carbonate), 36 mg vitamin E (D- alfa-tocopherol
acetate), 34 mg niacin (nicotinamide), 16 mg pantothenic
acid, 9 mg ß-carotene, 3.4 mg pyridoxine (pyridoxine
hydrochloride), 3.2 mg riboflavin, 2.4 mg thiamine (thiamine
mononitrate), 400 µg folic acid (pteroyl glutamic acid), 200 µg
biotin, 60 µg selenium (selenium-enriched yeast), and 9 µg
cobalamin (cyanocobalamin).• Population.* Cockle 2000 randomised 139 participants, Grodstein 2013
randomised 5947, and Wolters 2005 reported results for 220
(not clear how many were randomised).* Wolters 2005 included women only and Grodstein 2013
included men only.* The participants in Cockle 2000 had a mean MMSE at
baseline of 28.8 ± 1.5 years. There was no baseline cognitive
assessment in Grodstein 2013. In Wolters 2005, baseline
cognitive assessment supported the authors' assertion that
subjects were cognitively healthy.* The age of participants at baseline was median 63 years in
Wolters 2005, median 70 years in Cockle 2000 and mean 72
years in Grodstein 2013.
Excluded studies
Forty-five studies were excluded (See Characteristics of excluded
studies). Studies were excluded if they did not meet the inclusion
criteria relating to: population (ACTRN12607000321448, Alavi 2014,
Anonymous 2003, Benton 1995, Corless 1987, De Jager 2012, Flicker
2011, Hvas 2004, Imaoka 2016, Krikorian 2010, Kwok 2017, Li 2015,
Macpherson 2012, Murray-Kolb 2011, NCT00903695, NCT02185222,
Petersen 2005, Smith 1999, Van UIelen 2007), outcomes (Abbasi
2013, Ford 2008, Miller 2016, NCT02467153), intervention (Arwert
2003, Bryan 2002, Chan 2010, Chew 2015; Dhesi 2004, Harris
2015, NCT01095211, NCT01708005, Ng 2017, Ong 2016, Pase 2015,
Pathansali 2006, Pettersen 2017, Schietzel 2016, Summers 2010,
Wouters-Wesseling 2005), or study design (Cheng 2016, Quick 2013,
Rietsema 2014). One study was withdrawn prior to enrolment (Liu
2015). Maniam 2004 was a potentially eligible RCT described in
an abstract published in 2004, but we were unable to identify
any related full report. Some of the studies were excluded in this
review, but were included in the Cochrane review on vitamin and
mineral supplementation in people with mild cognitive impairment
(McCleery 2018).
Risk of bias in included studies
Our judgments about the risks of bias in the included studies are
detailed in the Characteristics of included studies tables and shown
graphically in Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
 
Allocation
Overall, selection bias was not a major concern. We judged all
studies to be at low or unclear risk of bias in this domain. In a
number of papers, our judgment was 'unclear' because there was a
lack of detail given about the allocation methods used, but in some
cases these were large, multicentre studies in which the methods
of random sequence generation and allocation concealment were
likely to have been adequate.
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
23
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Blinding
One study (Anand 2011) was explicitly an open-label study and
we therefore considered it to be at high risk of performance and
detection bias. All other studies were described by their authors as
being double-blind, although again there was, in some cases, a lack
of reporting of the methods used to ensure blinding, especially of
outcome assessment. In most cases, the experimental intervention
and placebo were described as being identical. We judged all
studies other than Anand 2011 to be at either low or unclear risk of
bias in these domains.
Incomplete outcome data
Incomplete outcome data posed a significant risk of bias to the
longer-term results. For some studies (Ford 2010, Grodstein 2013,
Kang 2008), we judged the risk to be low or unclear for shorter-term
outcomes, but high for longer-term outcomes when there had been
greater loss of participants to follow-up.
Selective reporting
The included studies had a variety of primary outcomes, In a
number of large studies, cognitive outcomes were not specified
in protocols, but were added at a later stage. However, in these
cases, simple cognitive measures were generally used and were
reported. We judged five studies to be at high risk of selective
reporting bias. Cockle 2000 did not report all the relevant outcomes
described in the Methods section of the paper. Maylor 2006 did not
report results in suIicient detail for inclusion in analyses. Stott 2005
mentioned functional outcomes in the trial registry entry which
were not reported in the paper. Toole 2004 reported MMSE scores
at 12 months but without the number of participants in each group,
so we could not include the data in meta-analysis, and did not
report the MMSE data at 24 months. Walker 2012 did not report all
outcomes in suIicient detail for inclusion.
Other potential sources of bias
We identified no high risks of bias due to other factors.
E:ects of interventions
See: Summary of findings for the main comparison B vitamins
compared to placebo for maintaining cognitive function in
cognitively healthy people in mid and late life; Summary of
findings 2 Antioxidants compared to placebo for maintaining
cognitive function in cognitively healthy people in mid and late
life; Summary of findings 3 Vitamin D3 compared to placebo for
maintaining cognitive function in cognitively healthy people in mid
and late life; Summary of findings 4 Zinc + copper compared to
placebo for maintaining cognitive function in cognitively healthy
people in mid and late life; Summary of findings 5 Complex
multivitamin compared to control for maintaining cognitive
function in cognitively healthy people in mid and late life
The minimum clinically important diIerence on cognitive tests for
healthy participants in prevention trials is unknown and is likely
to vary with the age of participants and the duration of follow-
up. We are therefore unable to judge the likely clinical importance
of diIerences detected on any cognitive test. When describing the
results, we refer to a diIerence between groups when P < 0.05.
B vitamins
We compared B vitamins to placebo at four time points: 3-12
months of treatment, > 1-2 years, > 2-5 years and > 5-10 years.
Some studies did not assess cognitive function at baseline and
reported final measurement data. Some studies reported only
change from baseline data. Because we were pooling outcomes
measured with a variety of instruments, we used standardised
mean diIerences and therefore pooled final measurement and
change from baseline data separately.
Negative SMDs favoured B vitamins; positive SMDs favoured
placebo.
Overall cognitive function
See Figure 3; Analysis 1.1
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Figure 3.   Forest plot of comparison: 1 B vitamins versus control, outcome: 1.1 Overall cognitive functioning.
 
3-12 months of supplementation:
Three studies providing final measurement data showed that
there is probably no eIect of B vitamins on overall cognitive
function (SMD 0.00, 95% CI -0.08 to 0.08, n = 2556; moderate-
certainty evidence). A fourth study (Toole 2004) also provided final
measurement MMSE data on 3097 participants, but did not report
the number of participants in each intervention group; it reported
no significant diIerence between groups (P = 0.19). Two smaller
studies providing change from baseline data confirmed that there
may be no eIect of B vitamins (SMD -0.03, 95% CI -0.26 to 0.19, n =
317; low-certainty evidence).
> 1-2 years of supplementation:
Five studies providing final measurement data showed that there
is probably no eIect of B vitamins (SMD -0.01, 95% CI -0.08 to 0.06,
n = 6956; moderate-certainty evidence). One study reporting only
change from baseline data similarly showed that there may be no
eIect of B vitamins (SMD 0.06, 95% CI -0.20 to 0.31, n = 241; low-
certainty evidence).
> 2-5 years of supplementation:
Four studies provided final measurement data and suggested that
there is probably no eIect of B vitamins (SMD -0.01, 95% CI -0.11 to
0.09, n = 3985; moderate-certainty evidence).
> 5-10 years of supplementation:
Three studies contributed data to this comparison; low-certainty
evidence indicated that there may be no eIect of B vitamins (SMD
-0.01, 95% CI -0.09 to 0.07, n = 10249).
Episodic memory
See Analysis 1.2
3-12 months of supplementation:
Four studies providing final measurement data showed that B
vitamins probably have no eIect on episodic memory (SMD 0.02,
-0.08 to 0.12, n = 1442; moderate-certainty evidence). Two studies
providing change from baseline data confirmed that there may be
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no eIect (SMD 0.04, 95% CI -0.15 to 0.23, n = 430; low-certainty
evidence).
> 1-2 years of supplementation:
Four studies providing final measurement data suggested there
may be no eIect of treatment (SMD 0.05, 95% CI -0.03 to 0.13, n =
5626; low-certainty evidence). The one study providing only change
from baseline data on this outcome confirmed an absence of eIect
(SMD 0.06, 95% CI -0.19 to 0.32, n = 241; low-certainty evidence).
> 2-5 years of supplementation:
Three studies providing final measurement data suggested there
may be no eIect of treatment (SMD -0.05, 95% CI -0.15 to 0.05, n =
3523; low-certainty evidence).
> 5-10 years of supplementation:
From one study, there was low-certainty evidence that there may
be little or no eIect of treatment (SMD -0.10, 95% CI -0.22 to 0.02,
n = 1053).
Executive function
See Analysis 1.3
3-12 months of supplementation:
From three studies providing final measurement data, the eIect
estimate slightly favoured placebo, but there was uncertainty
about the size and direction of the eIect (SMD 0.14, 95% CI -0.18 to
0.46, n = 536). A single study providing change from baseline data
also favoured placebo, but the certainty of this evidence was very
low (SMD 0.39, 95% CI 0.07 to 0.71, n = 171).
> 1-2 years of supplementation:
Very low-certainty evidence from three studies providing final
measurement data suggested no eIect of treatment (SMD -0.01,
95% CI -0.15 to 0.13, n = 2976). There was inconsistency in this
analysis in which one study (McMahon 2006) tended to favour
placebo.
> 2-5 years of supplementation:
Two studies providing final measurement data showed that there
may be no eIect of treatment (SMD -0.06, 95% CI -0.13 to 0.02, n =
2648; low-certainty evidence).
> 5-10 years of supplementation:
From one study, there was low-certainty evidence that there may
be no eIect of treatment (SMD 0.02, 95% -0.10 to 0.15, n = 1049).
Speed of processing
See Analysis 1.4
3-12 months of supplementation:
Two studies provided final measurement data on this outcome and
showed that there may be no eIect of treatment (SMD -0.04, 95%
CI -0.28 to 0.19, n = 289; low-certainty evidence). Pooled data from
three studies providing change from baseline data gave a similar
result, but with very low-certainty evidence (SMD 0.12, 95% CI -0.34
to 0.58, n = 487).
> 1-2 years of supplementation:
Two studies provided final measurement data and showed that
there is probably no eIect of treatment (SMD 0.03, 95% CI -0.09
to 0.15, n = 1030; moderate-certainty evidence). A further study
providing change from baseline data confirmed this (SMD -0.04,
-0.29 to 0.21, n = 241; low-certainty evidence).
> 2-5 years of supplementation:
One study provided final measurement data and showed no eIect
of treatment (SMD -0.08, 95% CI -0.22 to 0.06, n = 818; high-certainty
evidence).
Quality of life
> 1-2 years of supplementation:
Ford 2010 reported that participants in the B vitamin and placebo
groups did not diIer significantly on any of the four mental
summary scales of the SF-36 aPer 24 months.
No other included studies reported on quality of life.
Clinical global impression
No included studies reported on clinical global impression.
Functional performance
No included studies reported on functional performance.
Incidence of MCI or dementia
See Analysis 1.5.
Hankey 2013 (VITATOPS study) reported on the incidence of
cognitive impairment (defined as MMSE score < 24 during follow-
up on two or more occasions) aPer a median of 2.8 years
of supplementation. Of those who had at least two MMSE
measurements during follow-up, 50/908 (5.51%) in the B vitamin
group and 49/895 (5.47%) in the placebo group met this criterion
for cognitive impairment (RR 1.01, 95% CI 0.69 to 1.48, n = 1803;
moderate-certainty evidence).
Ford 2010 treated participants for two years, but also followed up
the participants who were still alive approximately eight years aPer
the baseline study assessment, assessing 73 of the 299 randomised
participants with the Telephone Interview for Cognitive Status scale
(TICS) and ascertaining dementia diagnoses from a population
register for all 172 survivors. Defining cognitive impairment as TICS
≤ 27, they found an OR 0.72 (95% CI 0.25 to 2.09) favouring the B
vitamin group. For either a dementia diagnosis or TICS ≤ 27, the
OR was 0.76 (95% CI 0.37 to 1.56) also favouring B vitamins. Due
to serious imprecision and risk of attrition bias, this was very low-
certainty evidence.
SEARCH 2010 investigators recorded diagnoses of dementia at final
follow-up (aPer a mean of 6.7 person-years) "based on reports from
a participant/relative or doctor, there was no further confirmation
or adjudication" (communication from author). The paper stated
that "similar numbers of participants in each treatment group were
reported to have developed dementia during follow-up (vitamins,
43 (0.7%), vs placebo, 38 (0.6%))".
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Serious adverse events
Most papers made only general statements about an absence of
serious adverse events in both treatment groups.
All-cause mortality
See Analysis 1.6
3-12 months of supplementation:
In one study (Dangour 2015), one participant died in the placebo
group and no participants in the B vitamin group.
> 1-2 years of supplementation:
In Toole 2004, in which all participants had a history of recent
ischaemic stroke, 99/1821 participants (5.4%) died in the B vitamin
group compared to 117/1847 participants (6.3%) in the comparator
group over 2 years of follow-up (RR 0.9, 95% CI 0.7 to 1.1, n = 3668).
> 2-5 years of supplementation:
In one study (Andreeva 2011), 24/585 participants (4.1%) died in
the placebo group and 44/586 participants (7.5%) in the B vitamin
group (RR 1.8 favouring placebo, 95% CI 1.17 to 3.08, n = 1171; very
low-certainty evidence).
> 5-10 years of supplementation:
In SEARCH 2010, in which all participants had a history of
myocardial infarction, 983/6033 participants (16.3%) died in the B
vitamin group compared to 951/6031 participants (15.8%) in the
placebo group over a mean of 6.7 years of follow-up (RR 1.03, 95%
CI 0.95 to 1.12, n = 12064; moderate-certainty evidence).
Mortality data was not clearly reported in any other study.
Antioxidant vitamins
We compared antioxidants to placebo at four time points: 3-12
months of treatment, > 2-5 years, > 5-10 years and >10 years. (We
had no data for the > 1-2 year time point).
Overall cognitive function
See Analysis 2.1; Figure 4
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Figure 4.   Forest plot of comparison: 2 Antioxidants versus control, outcome: 2.1 Overall cognitive functioning.
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Positive values favoured antioxidants; negative values favoured
placebo.
3-12 months of supplementation:
One study of vitamin E in middle-aged adults with type 2 diabetes
(Anand 2011) found a higher MMSE in the intervention group, but
this was the only open-label study and the certainty of this evidence
was very low due to risk of bias, imprecision and indirectness (MD
1.4, 95% CI 1.18 to 1.62, n = 74).
One study of beta-carotene (Grodstein 2007) included an older
population (mean age 73 years) who were treated for a mean of
12 months, but a range of two months to three years. Among
these participants, there was probably no eIect of beta-carotene on
overall cognitive function measured with the TICS (MD -0.14, 95%
CI -0.37 to 0.09, n = 1904; moderate-certainty evidence).
> 2-5 years of supplementation:
One study using a combination of vitamin C, E, and beta-carotene
(MRC/BHF 2002) found that there was probably no eIect of the
antioxidant treatment on the TICS aPer a mean five years of follow-
up (MD 0.09, 95% CI -0.05 to 0.23, n = 20536; moderate-certainty
evidence).
Kang 2009 was a factorial study which reported TICS results
separately for vitamin C, E, and beta-carotene aPer a mean of 3.5
years of treatment. It reported the mean diIerence (with 95% CI)
between each vitamin group and placebo, but reported only the
total number of participants (2824) and not the number in each
treatment group. This study showed that there may be no eIect
of vitamin C (MD 0.16, 95% CI -0.08 to 0.40, n not reported; low-
certainty evidence), vitamin E (MD 0.01, 95% CI -0.23 to 0.25, n not
reported; low-certainty evidence) or beta-carotene (MD -0.18, 95%
CI -0.42 to 0.06; n not reported; low-certainty evidence).
> 5-10 years of supplementation:
One study using a combination of vitamins C and E and beta-
carotene for a median of 6.9 years (YaIe 2004) found that there may
be no eIect on the modified MMSE (3MS) (MD 0.6, 95% CI -0.2 to
1.40, n = 1100; moderate-certainty evidence).
Kang 2009 also reported outcome data from a final assessment
aPer a mean of 8.9 years. However, again it reported only the total
number of participants (n = 1586) at this time point and not the
number in each group. A second study (Kang 2006) reported TICS
data aPer approximately 10 years of treatment with vitamin E. We
were unable to pool data vitamin E data from these two studies
because of the unknown number of relevant participants in Kang
2009. In Kang 2006, the first cognitive assessment was conducted
5.6 years (range 4.4 to 6.8) aPer randomisation and the last 4.0
(range 2.6 to 5.7) years later. The mean diIerence in TICS scores
between groups at final cognitive assessment was 0.04 points (95%
CI -0.12 to 0.21, n = 5226). The mean diIerence in cognitive decline
on the TICS between the vitamin E and placebo groups from first
to last cognitive assessment was 0.02 points (95% CI -0.02 to 0.06;
P = 0.31). In the vitamin E arm from Kang 2009, there was also no
evidence of an eIect on final TICS score (MD -0.16, 95% CI -0.49 to
0.16; n not reported, P = 0.33). We considered the overall certainty of
this evidence on vitamin E to be low. In the vitamin C arm from Kang
2009, there may have been a small beneficial eIect of vitamin C on
final TICS score (MD 0.46, 95% CI 0.14 to 0.78, n not reported, P =
0.006; low-certainty evidence). In the beta-carotene arm from Kang
2009, there was no evidence of an eIect of treatment (MD -0.13, 95%
CI -0.46 to 0.19, n not reported, P = 0.42; low-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 included 4052 participants who had been treated
with beta-carotene for a mean of 18 years (range 15 to 20
years), starting at a mean age of 56 years. There was moderate-
certainty evidence of a very small beneficial eIect of beta-carotene
treatment on the TICS (MD 0.18, 95% CI 0.01 to 0.35, n = 4052).
Episodic memory
See Analysis 2.2; Figure 5
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Figure 5.   Forest plot of comparison: 2 Antioxidants versus control, outcome: 2.2 Episodic memory.
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3-12 months of supplementation:
Grodstein 2007 found that there was probably no eIect of beta-
carotene (MD 0.01, 95% CI -0.05 to 0.08, n = 1904; moderate-
certainty evidence) on a composite verbal memory measure aPer a
mean of 12 months (range two months to three years).
> 2-5 years of supplementation:
From Kang 2009, there was probably a very small beneficial eIect of
vitamin C on the TICS 10-word recall test (MD -0.05, 95% CI -0.10 to 0;
n = 2824; low-certainty evidence), but probably no eIect of vitamin
E (MD -0.02, 95% CI -0.07 to 0.03, n = 2824; low-certainty evidence) or
beta-carotene (MD 0.01, 95% CI -0.05 to 0.07, n = 2824; low-certainty
evidence).
> 5-10 years of supplementation:
YaIe 2004, using combined vitamin C and E and beta-carotene,
found no evidence of an eIect on the delayed recall logical memory
test (MD -0.30, 95% CI -1.30 to 0.70, n = 1100; low-certainty
evidence).
A pooled analysis of two studies using vitamin E provided very low-
certainty evidence of no eIect (MD 0.02, 95% CI -0.05 to 0.09, n =
6812, 2 studies). There was low-certainty evidence from a single
study (Kang 2009) that there may be a small beneficial eIect of
vitamin C (MD -0.14, 95% CI -0.22 to -0.06, n = 1583) and no eIect of
beta-carotene (MD 0.02, 95% CI -0.05 to 0.09, n = 1583).
Kesse-Guyot 2011 treated participants for eight years with a
combination of vitamin C, vitamin E, beta-carotene, zinc, and
selenium and assessed cognition six years aPer the end of
treatment. On a delayed cued-recall test (the RI-48), there was a
small benefit for the vitamin group (MD 0.61, 95% CI 0.02-1.20, n =
4447, moderate-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 found evidence of a small beneficial eIect of beta-
carotene on a composite verbal memory measure aPer treatment
for a mean of 18 years (range 15 to 20 years), starting at a mean
age of 56 years (MD -0.06, 95% CI -0.11 to -0.02; n = 4052; moderate-
certainty evidence).
Executive function
See Analysis 2.3
3-12 months of supplementation:
There was moderate-certainty evidence from Grodstein 2007
that beta-carotene probably has no eIect on executive function
measured with a category fluency test aPer a mean of 12 months
(range two months to three years) (MD 0.07, 95% CI -0.48 to 0.62, n
= 1904).
> 2-5 years of supplementation:
There was low-certainty evidence from Kang 2009 of a small
detrimental eIect of vitamin E on category fluency (MD 0.42, 95%
CI 0.06 to 0.78, n = 2819) and of no eIect of vitamin C (MD -0.03, 95%
CI -0.39 to 0.33, n = 2819) or beta-carotene (MD 0.22, 95% CI -0.14 to
0.58, n = 2819).
> 5-10 years of supplementation:
YaIe 2004 found no evidence of an eIect of combined vitamin C and
E and beta-carotene on category fluency (MD -0.4, 95% CI -0.99 to
0.19, n = 1100; low-certainty evidence)
Pooled data on vitamin E from Kang 2006 and Kang 2009 showed
no evidence of an eIect on category fluency (MD 0.11, 95% CI -0.26
to 0.48, n = 6808; low-certainty evidence). Kang 2009 also found no
evidence of an eIect of vitamin C (MD -0.25, 95% CI -0.7 to 0.2, n
= 1583; low-certainty evidence) or beta-carotene (MD 0.01, 95% CI
-0.44 to 0.46, n = 1583; low-certainty evidence).
Kesse-Guyot 2011 treated participants for eight years with a
combination of vitamin C, vitamin E, beta-carotene, zinc, and
selenium and assessed cognition six years aPer the end of
treatment. There was no clear evidence of a diIerence between
groups on category fluency (MD 0.50, 95% CI -0.09 to 1.09, n = 4447,
moderate-certainty evidence).
> 10 years of supplementation:
Grodstein 2007 found that beta-carotene probably has no eIect
on executive function measured with a category fluency test aPer
treatment for a mean of 18 years (range 15 to 20 years) (MD 0.01,
95% CI -0.36 to 0.38, n = 4052; moderate-certainty evidence).
Speed of processing
> 5-10 years of supplementation:
Kesse-Guyot 2011 treated participants for eight years with a
combination of vitamin C, vitamin E, beta-carotene, zinc, and
selenium and assessed cognition six years aPer the end of
treatment. There was no diIerence between groups on time taken
to complete a trial-making task (TMT) (MD 0.00, 95% CI -0.59 to 0.59,
n = 4447, moderate-certainty evidence).
Incidence of dementia
See Analysis 2.4
> 2-5 years of supplementation:
One study (MRC/BHF 2002) reported the number of participants
who developed dementia during follow-up. All participants were at
high vascular risk. There were 62 events, 31 in each group (RR 1, 95%
CI 0.61 to 1.64, n = 20536; low-certainty evidence).
> 5-10 years of supplementation:
The mean duration of supplement use in Kryscio 2017 was 5.4 ±
1.2 years although follow-up continued for up to six years aPer
supplement discontinuation. The unadjusted cumulative incidence
of dementia was 3.95% in the vitamin E arm, 4.96% in the (vitamin
E + selenium) arm and 4.62% in the placebo arm. A modified ITT
analysis including all participants who had at least one follow-up
visit and adjusted for a variety of covariates showed that neither
arm had an incidence significantly diIerent from the placebo arm:
vitamin E HR 0.88 (95% CI 0.64 to 1.20, P = 0.41); (vitamin E +
selenium) HR 1.00 (95% CI 0.74 to 1.35, P = 0.98). We considered this
to be low-certainty evidence due to imprecision and indirectness.
All-cause mortality
See Analysis 2.5
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> 2-5 years of supplementation:
In one study (MRC/BHF 2002), 1389/10267 participants died in
the placebo group and 1446/10269 participants in the antioxidant
group (RR 1.04, 95% CI 0.97 to 1.11, n = 20536; moderate-certainty
evidence).
Serious adverse events
Kryscio 2017 was an ancillary study to SELECT, in which the
primary study was the incidence of prostate cancer. SELECT began
recruitment in 2002. By 2011, there was a statistically significant
17% increase in the risk of prostate cancer in the men taking vitamin
E only compared to those taking placebo only. APer a mean of seven
years of follow-up (mean 5.5 years taking supplements) there were
65 prostate cancer cases per 1000 men taking placebo only and 76
prostate cancer cases per 1000 men taking vitamin E only.
Other outcomes
Not reported.
Vitamin D
We considered data unsuitable for pooling because of the five-fold
diIerence in the daily dose of vitamin D3.
Overall cognitive function
See Analysis 3.1
There was moderate-certainty evidence from the small pilot study
(Aspell 2017) that the change in Montreal Cognitive Assessment
(MoCA) score over six months did not diIer between the vitamin D3
group (4000 IU on alternate days) and the placebo group (MD 0.76
points, SD not reported, n = 60, P = 0.186).
There was moderate-certainty evidence from one study (Rossom
2012) that there was probably no eIect of treatment with a daily
dose of 400 IU vitamin D3 + calcium carbonate on the modified
MMSE (3MS) at any time point up to a mean follow-up of 7.8 years.
3-12 months of supplementation:
MD 0, 95% CI -0.24 to 0.24, n = 4122.
> 1-2 years of supplementation:
MD 0, 95% CI -0.25 to 0.25, n = 3910.
> 2-5 years of supplementation:
MD -0.2, 95% CI -0.53 to 0.13, n = 3515.
> 5-10 years of supplementation:
MD -0.1, 95% CI -0.81 to 0.61, n = 918 (low-certainty evidence,
additional downgrade due to incomplete outcome data).
Episodic memory/executive function/speed of processing
Aspell 2017 reported results for executive function using the Trail
Making Task but no results for episodic memory, although the
trial registry entry indicated that it was to be measured with the
Wechsler Memory Scale. For change in TMT scores over six months,
there was probably little or no diIerence between the groups
(TMTB-A: MD 5.1, SD not reported, n = 60, P = 0.467).
In annual domain-specific cognitive assessments over
approximately three to eight years, the authors of Rossom
2012 reported that there were "no significant diIerences in any
domain-specific cognitive scores between treatment groups either
in unadjusted analyses or aPer adjustment for age, smoking,
baseline 3MS, and treatment assignment in the hormone or diet
modification trials." Results were not fully reported. They included
the California Verbal Learning Test (episodic memory), letter and
category fluency (executive function) and finger tapping (speed of
processing).
Incidence of MCI or dementia
In Rossom 2012, "[t]he incidence of MCI or all-cause dementia did
not diIer significantly between placebo and treatment groups, with
4.8% of calcium plus vitamin D subjects (62.2 per 10,000 person
years) and 5.1% of placebo subjects (65.9 per 10,000 person years)
developing cognitive impairment during a mean follow-up time of
7.8 years (HR 0.94, 95% CI 0.72 to 1.24; P = 0.68)". The survival curve
showed that the incidence did not diIer over the course of follow-
up. We considered this to be low-certainty evidence, downgraded
due to imprecision and indirectness (women only).
Other outcomes
Not reported.
Zinc and copper
For this comparison, the only data we were able to extract came
from YaIe 2004 which treated participants with 80 mg zinc and
2 mg copper daily for a median of 6.9 years. No usable data
were available from Maylor 2006, but the authors reported finding
no cognitive eIects of six months of supplementation with zinc
gluconate.
Overall cognitive function
See Analysis 4.1
> 5-10 years of supplementation:
One study (YaIe 2004) found no evidence of an eIect of treatment
on the modified MMSE (MD 0.6, 95% CI -0.19 to 1.39, n = 1072;
moderate-certainty evidence).
Episodic memory
See Analysis 4.2
> 5-10 years of supplementation:
One study (YaIe 2004) found no evidence of an eIect of treatment
on a delayed recall test (MD -0.7 95% CI -1.74 to 0.34, n = 1072;
moderate-certainty evidence).
Executive function
See Analysis 4.3
> 5-10 years of supplementation:
One study (YaIe 2004) found no evidence of an eIect of treatment
on category fluency (MD -0.3, 95% CI -0.89 to 0.29, n = 1072;
moderate-certainty evidence).
Incidence of dementia or MCI
YaIe 2004 reported that at the time of administration of the
cognitive test battery, 4.5% of participants had a 3MS score < 80,
which was the authors' definition of cognitive impairment, and that
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"there was no significant eIect of treatment group on likelihood
of having cognitive impairment." We considered this to be low-
certainty evidence.
Other outcomes
Not reported.
Selenium
For this comparison, the only data came from the selenium arm
of Kryscio 2017. The only outcome reported was incidence of
dementia. Supplements - in this case, selenium 200 mcg per day
- were taken for a mean of 5.4 ± 1.2 years although follow-up
continued for up to six years aPer supplement discontinuation.
The unadjusted cumulative incidence of dementia was 4.15% in
the selenium arm and 4.62% in the placebo arm. A modified ITT
analysis including all participants who had at least one follow-up
visit and adjusted for a variety of covariates showed no significant
diIerence in incidence between the selenium and placebo arms
(HR 0.83, 95% CI 0.61 to 1.13, P = 0.23, n = 7388). We considered this
to be low-certainty evidence due to imprecision and indirectness.
Complex multivitamins (containing B vitamins and
antioxidants +/- minerals)
Overall cognitive function
See Analysis 5.1
> 2-5 years of supplementation:
One study (Grodstein 2013) found no eIect of a complex
multivitamin on the TICS over a mean of 2.5 years of treatment
(range 0.18 to 5.3 years) (MD 0.04, 95% CI -0.09 to 0.18; n = 5947; low-
certainty evidence).
> 5-10 years of supplementation:
The same study found no eIect of the complex multivitamin on the
TICS over a mean of 8.5 years (range 0.3 to 14.2 years) (MD 0.12, 95%
CI -0.14 to 0.38; n = 2324; low-certainty evidence).
Episodic memory
See Analysis 5.2
3-12 months of supplementation:
One study (Cockle 2000) found no evidence of an eIect of treatment
on a word scan (recognition) test (MD 33.17, 95% CI -28.12 to 94.46;
n = 124; low-certainty evidence). Another study (Wolters 2005) used
a pattern recognition subtest of the Berliner Amnesie test (BAT) and
reported the results as medians with 5th to 95th percentiles; the
diIerence between groups was 'not significant' (no P value given).
> 2-5 years of supplementation:
One study (Grodstein 2013) found no evidence of an eIect of
treatment on a composite verbal memory score aPer a mean of 2.5
years (range 0.18 to 5.3 years) (MD -0.01, 95% CI -0.05 to 0.03; n =
5942; low-certainty evidence).
> 5-10 years of supplementation:
One study (Grodstein 2013) found no evidence of an eIect of
treatment on a composite verbal memory score aPer a mean of 8.5
years (range 0.3 to 14.2 years) (MD -0.01, 95% CI -0.07 to 0.05; n =
2324; low-certainty evidence).
Executive function
See Analysis 5.3
> 2-5 years of supplementation:
One study (Grodstein 2013) found no evidence of an eIect of
treatment on verbal fluency aPer a mean of 2.5 years (range 0.18
to 5.3 years) (MD -0.02, 95% CI -0.33 to 0.29; n = 5942; low-certainty
evidence).
> 5-10 years of supplementation:
One study (Grodstein 2013) found no evidence of an eIect of
treatment on verbal fluency aPer a mean of 8.5 years (range 0.3 to
14.2 years) (MD -0.22, 95% CI -0.65 to 0.21; n = 2324; low-certainty
evidence).
Speed of processing
See Analysis 5.4
3-12 months of supplementation:
One study (Cockle 2000) found no evidence of an eIect of treatment
on a total reaction time (TRT) (MD -14.71, 95% CI -57.22 to 27.80; n =
127; low-certainty evidence). Another study (Wolters 2005) used the
symbol search subtest from the WAIS-III and reported the results
as medians with 5th to 95th percentiles. The vitamin group was
significantly faster than the placebo group (P = 0.015) at baseline
and this diIerence persisted at the end of the intervention (P =
0.01).
Other outcomes
Not reported.
D I S C U S S I O N
Summary of main results
B vitamins
Fourteen studies with 27,882 participants contributed data. Only
two studies lasted for longer than five years, although between
them these included more than 10,000 participants. We found no
evidence that giving B vitamin supplements to cognitively healthy
adults, mainly in their 60s and 70s, had any eIect on global
cognitive function or on episodic memory, executive function, or
speed of processing. There were very sparse data on adverse eIects
or on incidence of cognitive impairment or dementia, quality of life,
functional performance, or clinical global impression.
Antioxidant vitamins (vitamins C and E, and beta-carotene)
Eight studies with 47,840 participants contributed data. Six studies
had a mean treatment duration longer than five years. Two studies
followed participants up for more than 10 years. The results of these
trials were more mixed than for B vitamins. There was low-certainty
evidence that vitamin C supplements may have a small beneficial
eIect on episodic memory aPer 2 to 5 years of treatment and on
overall cognitive function aPer 5 to 10 years, although eIects were
not seen at other time points. There were no longer-term data on
vitamin C. For vitamin E, there was low-certainty evidence of a small
detrimental eIect on executive function aPer 2 to 5 years and no
data beyond 10 years. For beta-carotene, there was no evidence of
any eIects up to 10 years, but moderate-certainty evidence from
one large study with a duration of 15 to 20 years of small benefits
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
33
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
on overall cognitive function and episodic memory aPer a mean
of 18 years of treatment. There were very few cognitive data from
trials using combinations of antioxidant vitamins. There was no
evidence of an eIect of 5 to 10 years of antioxidant combination
treatment in two trials, but one trial which assessed participants six
years aPer the end of an 8-year treatment period (using vitamins C,
E, beta-carotene plus zinc and selenium) reported a small benefit
on episodic memory. Two studies found no eIect of antioxidant
vitamins on the incidence of dementia. Other review outcomes
were not reported in these trials.
Vitamin D
One large trial in this comparison provided low to moderate-
certainty evidence of no eIect on cognitive outcomes or the
incidence of MCI or dementia of a relatively low dose of vitamin
D3 with calcium carbonate in any time period up to 10 years. It
provided no evidence on other review outcomes. There was also a
small pilot trial which used a much higher dose of vitamin D3 and
found no evidence of cognitive eIects over six months.
Zinc and copper
One study contributed usable data, providing low-certainty
evidence of no eIect on cognitive outcomes or the incidence of
cognitive impairment aPer 5 to 10 years, but no evidence on other
outcomes.
Selenium
One study found no evidence of an eIect of approximately five
years of selenium supplementation on the incidence of dementia,
but there was no information on other outcomes.
Complex multivitamins (B vitamins and antioxidants +/-
minerals)
Two small, short-term studies and one large study with a mean
duration of treatment of 8.5 years at final follow-up found no eIects
of complex multivitamins on cognitive outcomes. There was no
evidence on other review outcomes.
Overall completeness and applicability of evidence
Our principal interest was in whether or not vitamin
supplementation could be of benefit to the general middle-aged
or older population in terms of maintaining cognitive function or
preventing dementia in late life. Some general points can be made
about the evidence across all the interventions.
Many of the included studies, especially the larger and longer
ones, were not designed primarily with cognitive outcomes in mind
and did not assess cognition at baseline. It is therefore possible
that some participants may not have been cognitively healthy
at baseline, although we considered it unlikely that people with
known dementia would have been recruited. In some cases, limited
cognitive assessments, using measures which lack sensitivity to
detect change in cognitively healthy people, were added to existing
studies some years aPer onset. Participation in these studies was
oPen restricted in ways which reflected the original aims, e.g.
recruitment limited to one gender, or to people with particular
comorbidities or risk factors, so the evidence was oPen not directly
applicable to the older population in general. Only three studies
specifically assessed the incidence of dementia. Studies which
were designed to assess cognition tended to be shorter (less than
two years), which may not be long enough to detect eIects. If
cognitive eIects are detected on this timescale, it is not clear
what implications this has for the incidence of dementia. There
are problems inherent in combining short-term studies, in which
separation of groups may only be seen if the intervention leads
to cognitive improvement (or harm), and studies which are long
enough to detect a change in the trajectory of age- or pathology-
related decline. We considered it important to separate studies into
groups of diIerent durations, but our time divisions were inevitably
somewhat arbitrary and this decision greatly limited the numbers
of studies which could be combined.
There is no well developed understanding of the mechanisms by
which any of these interventions might aIect cognition, which
may be the reason that studies used a wide variety of doses
and treatment combinations. This makes it diIicult to compare
studies and leaves open the possibility that diIerent doses or
combinations could have diIerent eIects.
B vitamins
The body of evidence on vitamin B supplements addresses
our review question only indirectly. Many studies restricted
participation to those with particular comorbidities or who had
some evidence of low vitamin B levels or exposure at baseline.
Four of the 13 studies allowed inclusion of participants younger
than 60 years, but in all cases, the mean age of participants was
> 60 years so the data do not adequately address the eIects of
supplementation in midlife. We excluded very short-term studies (<
3 months), but the majority of included studies treated participants
for 2 years or less, which may not be long enough to detect
any eIect. The particular vitamin B subtypes and their doses
diIered between studies and in several studies, particularly those
with factorial designs, some participants receiving B vitamins also
received other potentially active interventions. The studies were
too heterogeneous to allow these various characteristics to be
explored in subgroup analyses.
Antioxidant vitamins
We considered vitamin C, vitamin E, and beta-carotene in this
group. The evidence on cognitive eIects of antioxidant vitamins
is very largely from studies which had other primary aims and
to which very limited cognitive assessment was added aPer the
studies were underway. In two of the large trials, all participants
were at high vascular risk. However, the age of participants at
recruitment was generally lower and the duration of the trials
was generally longer than the B vitamin trials, so this body
of evidence may be more informative about the potential of
prolonged treatment to protect cognitive function against decline.
Only two of these studies assessed incidence of dementia so most
of the results have no more than indirect implications for dementia
prevention.There was substantial variation in the doses of vitamins
used. Again, the use of factorial designs in some studies meant the
comparator groups included participants exposed to a variety of
treatments.
Vitamin D
One study used a combination of vitamin D and calcium
carbonate. Mean follow-up was 7.8 years. All participants were
postmenopausal women, but inclusion criteria were otherwise
broad. The dose of vitamin D was relatively low (400 IU/day). This
was one of very few studies that used a rigorous method to assess
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for incident MCI or dementia. The other study used a higher dose of
vitamin D3 (4000 IU on alternate days), but was small and provided
only preliminary evidence on supplementation with this dose.
Minerals (zinc and copper, selenium)
We found limited data from two studies of mineral supplements.
One used a combination of zinc and copper oxides. It was designed
to look for an eIect on age-related macular degeneration, but
there is no reason to think that this limits generalisibility of the
cognitive results. Cognitive assessment was aPer a median of 6.9
years. Dementia incidence was not an outcome. The other was a
selenium-only arm of a factorial study in which dementia incidence
was the only relevant outcome reported. It found no evidence of an
eIect of selenium.
Complex multivitamins with or without minerals
There were three included studies in this category. One used a
combination of B vitamins and antioxidant vitamins. Two used
commercially available multivitamin and mineral combinations.
Two studies were very small and lasted less than a year. In the large
study, all participants were men, treated for a mean of 8.5 years.
Dementia incidence was not an outcome.
Quality of the evidence
The large studies were generally well-conducted and we did not
consider that risk of bias was a major threat to the results, although
there were some gaps in reporting in all domains. Uncertainty
about the risk of selection bias and concerns about attrition bias led
us to downgrade the certainty of some results due to possible study
limitations. We considered much of the evidence to be indirect
with respect to our review question because participation in many
studies was restricted, e.g. by comorbidities, baseline biochemistry,
or gender. Overall, we considered the certainty of the evidence
behind almost all eIect estimates to be moderate or low with
respect to our review question.
Potential biases in the review process
Particularly for B vitamins, bias may arise from pooling studies
which diIered in participants (e.g. with or without elevated
homocysteine at baseline) and interventions (various constituents
and doses). This 'broad brush' approach may disguise eIects.
Agreements and disagreements with other studies or
reviews
A comprehensive systematic review and meta-analysis of the
cognitive eIects of several years of treatment with B vitamins
was published by the B-Vitamin Treatment Trialists' Collaboration
in 2014 (Clarke 2014). It included 11 trials for which data were
available by September 2010. All the included trials were also
included in this review. The authors investigated the eIect of
the interventions on homocysteine levels as well as on cognition.
Although they found that the treatments eIectively lowered
homocysteine levels (by slightly more than 25%), they also found
no evidence of significant eIects on global ('MMSE-type') cognitive
function, domain-specific cognitive function, or cognitive aging.
We are not aware of similar systematic reviews of the eIects of
treatment with non-B vitamins or minerals.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We found no evidence to support recommending any vitamin or
mineral supplement to middle-aged or older adults who wish to
maintain their cognitive function or prevent dementia.
Implications for research
All of the studies in this review diIered in their population,
interventions, and outcomes. Therefore, many questions about
possible eIects of diIerent doses or treatment combinations
on diIerent participants remain unanswered. In particular, there
are very few data on the long-term eIects of supplementation
started in midlife. Identifying the most important questions is
likely to depend on a better understanding of the pathophysiology
of cognitive decline and dementia and of the mechanisms by
which vitamins and minerals might modify these processes.
Moving forward, there is a place both for investigating possible
mechanisms in smaller trials, which can incorporate highly
sensitive cognitive assessments and possibly biomarker outcomes,
and for larger, longer, pragmatic trials in which it may be
necessary to rely on simpler and less sensitive outcome measures.
Considering the data in this review, the only real signals of eIect
were from long-term studies of antioxidant vitamins (vitamin C and
beta-carotene) so these might be considered the most promising
candidates for further research.
A C K N O W L E D G E M E N T S
The protocol for this review was largely based on a general template
constructed for the development of a larger series of protocols and
reviews covered by a National Institute for Health Research (NIHR)
Systematic Reviews Programme Grant. The common protocol
covered four types of intervention, for which some evidence exists
that these may modify the risk of developing cognitive impairments
or dementia. These include vitamin or mineral supplementation
(or vitamin and mineral supplementation), exercise, cognition,
and dietary interventions. The general protocol was inspired by a
generic protocol approved by the Cochrane Musculoskeletal Group
for another series of reviews (Da Costa 2012; Da Costa 2014; Nüesch
2009a; Reichenbach 2010; Rutjes 2009a; Rutjes 2009b; Rutjes 2010).
The authors are grateful to Professors Lisette de Groot, Simone
Eussen, and Jane Armitage for responding to enquiries about their
work and providing additional data.
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Characteristics of included studies [ordered by study ID]
 
Methods 2-arm, open-label RCT, with 3 months duration of treatment and follow-up.
Participants Location: Ootacamund, Tamil Nadu India. Single centre
Recruitment: outpatient department, Government headquarters hospital, Ootacamund
Sample size:
• Number randomised: 38 in intervention, 36 in comparison• Number completed: 38 in intervention, 36 in comparison
Participant baseline characteristics:
• Age: mean 54.65 ± 8.44 intervention and 56.61 ± 8.17 in comparison• Total MMSE: 25.16 ± 0.66 in intervention, 25.3 ± 0.37 in comparison• Gender: male/female 15/23 intervention and 14/22 in comparison• Others: Most of the participants were from an economically deprived background, non-vegetarians.
Inclusion criteria:
• Type 2 diabetes with no comorbidities• Age between 35 and 65 of either sex• On oral hypoglycaemic agents (metformin, glibenclamide and combination)• Duration of disease less than or equal to 10 years• HbA1c > 9%
Exclusion criteria:
• Dementia• Antidepressant therapy• Type 1 diabetes• Juvenile diabetes• Pregnancy/lactation• Significant hepatic and renal dysfunction
Interventions Intervention group (n = 38): vitamin E 600 mg once daily for three months
Comparator group (n = 36): treatment-as-usual for three months
Treatment received by both groups: oral hypoglycaemic agents (glibenclamide 5 mg, metformin 500
mg) for three months
Outcomes Outcomes of interest in the review:
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Cognitive outcome: MMSE (Tamil version); MMSE 18–23 classified as MCI and 24-30 classified as no cog-
nitive impairment
Notes Funding Sources: "Nil".
Declarations of interest: none declared.
Other: population was from a government hospital clinic in India and "most of the enrolled patients
were coming under economically deprived background."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Enrolled patients were randomized by using computer assisted ran-
domization procedure and assigned to control group and intervention group"
Comment: adequate generation of a randomised sequence
Allocation concealment
(selection bias)
Unclear risk Comment: no description of allocation concealment. The study was open-la-
bel. Unknown whether allocation for the next patient to be enrolled could be
known in advance.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Quote: "open-label trial"
Comment: did not describe control group receiving placebo of Vitamin E. No
description of blinding and described as an 'open-label' study.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Comment: no description of measures used, if any, to blind personnel involved
in measuring outcomes. Since outcome measures depended on patient per-
formance, risk of bias was judged to be high.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: There was no description of the completeness of outcome data for
each main outcome, nor of exclusions from the analysis.
Selective reporting (re-
porting bias)
Low risk Comment: no evidence of selective reporting bias
Other bias Low risk No other risk of bias detected.
Anand 2011  (Continued)
 
 
Methods Multicentre, randomised, placebo-controlled, 2 x 2 factorial trial
An ancillary study of SU.FOL.OM3
Participants Main study took place from 2003-2009. Quote: "As part of the SU.FOL.OM3 assessment battery, the F-
TICS-m was administered during 2007-2009 only to participants who had completed 4 years of fol-
low-up."
Location: 257 participating centres in France
Recruitment: recruitment of subjects done through a network of 417 cardiologists and neurologists
from all over France, working either in general hospitals, independently or in rehabilitation centres.
Treatment with tablets at home.
Sample size: 1881 participants were eligible for the cognitive study (had completed 4 years of fol-
low-up in main study); 1748 completed the cognitive assessment.
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· Number randomised in SU.FOL.OM3:
• 620 in group A (B vitamins and Omega-3 PUFA)• 633 in group B (Omega-3 PUFA)• 622 in group C (B vitamins)• 626 in group D (placebo)
· Number completing cognitive study:
• 438 in group A (B vitamins and Omega-3 PUFA)• 439 in group B (Omega-3 PUFA)• 446 in group C (B vitamins)• 425 in group D (placebo)
Group A (B Vitamins and Omega -3 PUFA) baseline characteristics:
• age (y): 61.6 ± 8.8• gender, n (%) female: 80 (18.3)
Group B (Omega-3 PUFA) baseline characteristics:
• age: 60.1 ± 8.7• gender, n (%) female: 88 (20.0)
Group C (B vitamins) baseline characteristics:
• age (y): 61.4±8.7• gender, n (%) female: 93 (20.9)
Group D (Placebo) baseline characteristics:
• age (y): 60.9±8.9• gender, n (%) female: 96 (22.6)
Inclusion criteria:
Men and women aged 45–80 y with a recent (1-12 months prior to inclusion) myocardial infarction (MI),
unstable angina, or ischaemic stroke were eligible for participation.
There was no diagnostic criterion used to detect dementia/cognitive impairment. Instead, participants
were given the Issac’s Set Test at baseline and results were stated as a Mean ± SD.
Exclusion criteria:
Patients incapable of understanding the study protocol or who refused to sign the informed consent,
patients with a pathology that might interfere with homocysteine or omega-3 fatty acid metabolism,
in particular, those that use methotrexate for the treatment of a cancer or rheumatoid arthritis, chron-
ic renal failure (plasma level of creatinine > 200 μmol/L or creatinine clearance < 40 mL/min), patients
with a non-cardiovascular pathology with a suspected survival time less than the 5 years period of the
study (solid cancer, evolved dementia, leukaemia) and patients taking B vitamins or omega-3 fatty
acids.
Interventions Intervention (n = 1748): Study supplements were given as 2 capsules administered orally once per
day. The supplements were provided in a package containing 53 blisters of 7 × 2 capsules, each corre-
sponding to one week of both treatments. A year’s supply was given at baseline and given again at each
annual follow-up appointment for 5 years in total.
Group A (B vitamins and Omega-3 PUFA): 5-methyltetrahydrofolate (folate, 0.56 mg) and vitamins B6 (3
mg) and B12 (0.02 mg) and eicosapentaenoic and docosahexaenoic acids (600 mg) in a 2:1 ratio
Group B (Omega-3 PUFA): eicosapentaenoic and docosahexaenoic acids (600 mg) in a 2:1 ratio
Andreeva 2011  (Continued)
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Group C (B Vitamins): 5-methyltetrahydrofolate (folate, 0.56 mg) and vitamins B6 (3 mg) and B12 (0.02
mg)
Group D (placebo): 2 placebo Capsules
Comparator group (n = 425): 2 placebo tablets given once daily. The placebo capsules looked and
tasted identical to the active supplements (taken from SU.FOL.OM3 trial paper).
Use of additional interventions (common to all treatment arms): no
Outcomes Outcomes of interest in the review:
Global cognitive functioning: French version of the modified Telephone Interview for Cognitive Status
(F-TICS-m)
Episodic memory: delayed recall subdomain from F-TICSm
Notes Funding sources: The SU.FOL.OM3 trial was supported by the French Ministry of Research
(grant R02010JJ), the Ministry of Health, Sodexo, Candia, Unilever, Danone, Roche Laboratories, Merck
EPROVA AG, and Pierre Fabre Laboratories.
Declarations of interest: none declared
Treatment adherence: Compliance with treatment was self-reported in the biannual questionnaires
(or by telephone interview). Compliance was defined as taking at least 80% of the allocated treatment.
(taken from SU.FOL.OM3 trial paper).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "We used computerized block randomisation (block size = 8) with strat-
ification by sex, age (45–54, 55–64, and 65–80 y), prior CVD, and city of resi-
dence.”
Comment: adequate method of random sequence generation.
Allocation concealment
(selection bias)
Low risk Comment: no information. Centralised, computerised system, likely to be ade-
quately concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “The placebo capsules looked and tasted identical to the active supple-
ments"
Comment: probably blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: did not mention blinding of study personnel including outcome as-
sessors
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: 24.8% of participants in SU.FOL.OM3 were lost to follow-up over the
first 4 years and before the onset of the cognitive study. These participants ap-
peared to be well balanced between groups.
133/1881 (7%) participants eligible for the cognitive study were excluded: 72
(3.8%) were unable to complete the cognitive assessment and 61 refused to
participate. Treatment allocations of these participants were not reported.
Cognitive data were reported for 69.9% of the randomised participants.
Selective reporting (re-
porting bias)
Unclear risk Quote: “No changes to the outcomes of interest were made after launching the
trial"
Andreeva 2011  (Continued)
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Comment: The authors have stated no changes to the outcomes were made,
however, these were not previously published in a protocol as this is an an-
cillary study and the main study protocol did not mention any cognitive out-
comes.
Other bias Low risk No other risks identified
Andreeva 2011  (Continued)
 
 
Methods 2-arm, parallel group RCT
Participants Location: one site in Ireland
Recruitment: no details provided
Number randomised: 60
Participant characteristics:
• age: mean 68.5 years (SD 4.9 years)• gender: 53.3% female
Inclusion criteria: community dwelling
Exclusion criteria: low or high serum vit D (defined as < 15nmol/L or > 125nmol/L), current use of sup-
plemental vit D ≥ 800 IU/day, screen positive for cognitive impairment using the Telephone Cognitive
Screen (TCogS), hypercalcaemia, hyperparathyroidism, epilepsy, stroke, renal disease, schizophrenia,
bipolar affective disorder, recurrent psychotic depression, alcohol and drug abuse within the past 5
years, anti-convulsants, anti-psychotic medications, significant hearing difficulties even when wearing
hearing aids, illness that caused permanent decrease in memory or other mental function
Interventions 50 mcg/day of vitamin D3 administered as 4000 IU on alternate days or placebo
Outcomes Overall cognitive function: Montreal Cognitive Assessment (MoCA)
Executive function: (Trails Making Task A & B, B-A)
Episodic memory: Wechsler Memory Scale - in trial registry entry, not reported
Attention and visual reasoning: 2 validated measures (not included in review)
Notes Described as a pilot study. Only conference abstract available.
18.3% of participants were deemed vitamin D deficient at baseline according to Institute of Medicine
guidelines.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomised", no additional details
Allocation concealment
(selection bias)
Unclear risk No details
Blinding of participants
and personnel (perfor-
mance bias) 
Low risk From trial registry entry: masking: double (participant, investigator)
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk From trial registry entry: masking: double (participant, investigator)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk "A retention rate of 93.8% was achieved." No information on treatment assign-
ment of missing participants
Selective reporting (re-
porting bias)
High risk Trial registry entry included a measure of episodic memory which was not re-
ported with other results in the conference abstract
Other bias Low risk No other risks identified
Aspell 2017  (Continued)
 
 
Methods 2-arm, parallel group, double-blind, placebo-controlled RCT
(Intended duration was 48 weeks, but due to very high dropout after 24 weeks, no data were reported
beyond 24 weeks).
Participants Location: One site in UK
Recruitment: subjects recruited by newspaper advertisement
Number randomised: 69 in intervention, 70 in comparison
Participant baseline characteristics:
• Age:* overall: median 70 years* placebo: mean 70.2 (5.4) and median 70 (60-81)* intervention: mean 70.7 (5.6 and median 70 (60-81)• Gender:* overall: 51 males and 88 females* placebo (24 males and 46 females)* intervention (27 males and 42 females)• Main diagnosis: All subjects were in good physical and mental health and had no history of significant
disease or mental illness, as determined by a medical examination and health questionnaire.• MMSE:* intervention: 28.9 (SD:1.4)* placebo: 28.6 (SD:1.5)
Inclusion criteria: not reported
Exclusion criteria: not reported
Interventions Intervention (n = 69): Multivitamin supplements: two gelatine capsules orally each day. Each capsule
contained vitamin A palmitate 3334 IU, thiamine mononitrate 14 mg, riboflavin 16 mg, pyridoxine 22
mg, vitamin B12 0.03 mg, vitamin C 600 mg, dl-alpha-tocopherol acetate 100 mg, folic acid 4 mg, d-bi-
otin 2 mg and nicotinamide 180 mg.
Quote: "The dosing was calculated to provide the equivalent of one US RDA (National Research Council,
1980) of vitamin A and ten US RDAs of the remaining vitamins."
Capsules supply were provided at baseline and, in patients who were compliant, a second supply was
given at week 12 for an intended treatment duration of 24 weeks.
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Comparator group (n = 70): matching placebo (rape seed oil)
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: Relationship between vitamin status and cognitive function.
"At each visit, treatment compliance, blood vitamin levels and Critical Flicker Fusion, Choice Reaction-
TimeTask, Sternberg Memory ScanningTask, Word ScanTask, and the Profile Of Mood States question-
naire were carried out".
"MMSE, Sundrom Kurtz Test, National Adult Reading Test, Alice Heim's 4, Alice Heim's 5 and the Geri-
atric Depression Scale were assessed at baseline and at week 48."
Eligible cognitive outcomes:
• episodic memory measured with Sternberg Memory Scanning Task (msec), lower values indicated
benefit• episodic memory measured with Word scan task (msec), lower values indicated benefit*• speed of processing measured with Total reaction time (msec), lower values indicated benefit*• speed of processing measured with Recognition reaction time (msec), lower values indicated benefit• speed of processing measured with Motor reaction time (msec), lower values indicated benefit
* outcome data used in statistical analyses
Notes Quote: "the objectives of the study were to examine the relationship between vitamin status and cogni-
tive functioning and mood in healthy, elderly volunteers and to assess the subsequent impact of multi-
vitamin supplementation on these measures".
Funding sources: none stated
Declarations of interest: none stated, but second author from Roche Pharmaceutical
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Subjects were allocated to each treatment group according to a pre-
determined randomization schedule."
Comment: insufficient information about the sequence generation method
Allocation concealment
(selection bias)
Unclear risk Quote: “Subjects were allocated to each treatment group according to a pre-
determined randomization schedule."
Comment: insufficient information about allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The study was a double-blind, placebo-controlled, parallel group
study with each subject receiving a multivitamin supplement or placebo daily
for up to 24 weeks."
Quote: "Treatments were given orally as two soP gelatine capsules containing
either multivitamins or matching placebo (rape seed oil)".
Comment: The study was reported as double-blinded with the use of matching
placebo.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "at each visit, treatment compliance, blood vitamin levels and Critical
Flicker Fusion, Choice Reaction Time Task, ...were carried out".
Comment: It was not reported whether outcome assessment was blinded.
Cockle 2000  (Continued)
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: ‘Due to circumstances not related to the study treatment, there was a
significant dropout of subjects after the first six months of this study, with no
participants continuing through to visit 4. Data from 139 subjects was avail-
able at baseline, from 127 subjects at visit 1 and from 90 subjects at visit 2. Due
to the high dropout of subjects between visit 2 and visit 3, data from the latter
visit was not included."
Comment: There were 12 dropouts (8.6%) at visit 1 (12 weeks) and 49 dropouts
(35.8%) at visit 2 (24 weeks). Outcome data were completely missing from
planned visits 3 and 4 (36 and 48 weeks).
Selective reporting (re-
porting bias)
High risk Comment: A number of tests of cognition and functioning reported in the
Methods to have been measured at baseline and 48 weeks were not reported
(including MMSE).
Other bias Low risk No other risks identified
Cockle 2000  (Continued)
 
 
Methods 2-arm, double-blinded, multicentre, parallel group RCT, with 12 months of treatment and follow-up
Participants Location: 7 general practices in South East England
Recruitment: recruited at GP by mail, baseline appointment and 12-month follow-up at King’s College
Hospital, London, treatment one tablet daily at home
Sample size:
· Number randomised: 99 in intervention, 102 in comparison
· Number completed: 91 in intervention, 92 in comparison
Group A (B vitamins) baseline characteristics:
• age (mean ± SD): 79.9±3.5• gender (n) : 46 males, 54 females• main diagnosis: no diagnosis
Group B (placebo) baseline characteristics:
• age: 80.1 ± 3.7• gender: 48 males, 54 females• main diagnosis: no diagnosis
(Inclusion criteria:)
Age: ≥ 75 years, Participants with a Mini-Mental State Examination score > 24 (maximum score 30) were
asked to provide a blood sample to assess serum vitamin B12 and haemoglobin concentration. Those
with moderate vitamin B12 deficiency who did not have anaemia (serum vitamin B12 concentrations ≥
107 and < 210 pmol/L were eligible to join the trial.
The diagnostic criterion used for dementia/cognitive impairment screening was the MMSE. Only those
with a score > 24 were eligible to join the trial.
(Exclusion criteria:) Diabetes, dementia, epilepsy, alcohol addiction, pacemakers (and other implant-
ed metallic devices where central neurophysiologic testing was contraindicated), residents of nursing
homes, diagnosis of pernicious anaemia, current consumption of vitamin B12 supplements and those
who had received a vitamin B12 injection within the previous 6 months. Individuals with very low vi-
tamin B12 concentrations (< 107 pmol/L, which is a cutoff typically used for deficiency) or who were
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shown to have anaemia (haemoglobin concentration, 110 g/L for women and 120 g/L for men) were ex-
cluded.
Interventions Intervention (n = 97): vitamin B12 (cyanocobalamin), oral administration, 1 mg tablet/day, 12 months
Comparator group (n = 97): placebo tablet administered once daily identical to intervention in shape,
size, colour, smell, taste, and identically packaged
Use of additional interventions (common to both treatment arms): not reported
Outcomes Outcomes of interest in the review:
• Episodic memory measured with California Verbal Learning Test at delayed recall, with higher values
indicating benefit• Executive function measured with verbal fluency, with higher values indicating benefit• Speed of processing measured with Choice Reaction time, with lower values indicating benefit
Notes Funding sources: Supported by the Food Standards Agency (N05072) and the Department of Health.
National Health Service.
Research and Development and King’s College Hospital Trust Research and Development provided ser-
vice support costs.
Declarations of interest: none declared
Treatment adherence: Adherence was measured by counting the number of tablets returned at the
end of the study.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Allocation codes were obtained from a central computerized random-
ization service."
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: “Allocation codes were obtained from a central computerized random-
ization service."
Comment: adequate method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “All study personnel were blinded to the treatment allocation."
“Allocated treatment consisted of a single tablet administered daily that was
identical in size, shape, color, smell, and taste for both the intervention and
placebo and packaged into identical pots.”
Comment: As all participants were given identical tablets this ensured blinding
was maintained.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “All study personnel were blinded to the treatment allocation."
“Allocated treatment consisted of a single tablet administered daily that was
identical in size, shape, color, smell, and taste for both the intervention and
placebo and packaged into identical pots.”
Comment: Study mentions personnel were blinded to treatment allocation
and due to identical tablets this would have maintained appropriate blinding.
Incomplete outcome data
(attrition bias) 
Low risk Comment: Cognitive outcome data were available for 184/201 participants
(92%). Dropout rates and reasons were similar in both groups.
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All outcomes
Selective reporting (re-
porting bias)
Low risk Comment: followed study protocol, no reporting bias found
Other bias Low risk Comment: none found
Dangour 2015  (Continued)
 
 
Methods 2-arm, placebo-controlled, randomised clinical trial, with 3-year duration of treatment
Participants Location: Gelderland region in the Netherlands, single centre
Recruitment: Division of Human Nutrition, Wageningen University, Wageningen, Netherlands
Number randomised: 406 in intervention, 413 in comparison
Participant baseline characteristics:
• Age at baseline (years), mean (SD):* placebo: 60 (6)* folic acid: 60 (5)• Male, n (%):* placebo: 292 (70%)* folic acid: 294(72%)• MMSE (points):* placebo: 29 (28-30)* folic acid: 29(28-30)
Inclusion criteria:
• Participants were men and post-menopausal women aged 50–70 years.• More than 80% self-reported compliance during a 6-week placebo run-in period was required.
Exclusion criteria:
• homocysteine concentration less than 13 micromol/L and greater than 26 micromol/L• self-reported medical diagnosis of renal or thyroid disease• self-reported use of medications that influence folate metabolism• participants reportedly used B vitamin supplements or drugs that could affect atherosclerotic pro-
gression
Interventions Intervention (n = 405): 800 μg per day folic acid.
Comparator group (n = 413): placebo
Outcomes Cognitive outcomes:
5 cognitive tests were used: word learning test, concept shifting test, Stroop colour-word test, verbal
fluency test, letter digit substitution test
These 5 tests were used to construct 5 a priori defined cognitive domains using z-scores: memory, sen-
sorimotor speed, complex speed, information processing speed, and word fluency
Outcomes used in this review were:
1. Global cognitive function (average of 5 domains);
Durga 2007 
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
55
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
2. Episodic memory: Memory (Z15-Word Learning test ‘total immediate recall’+Z15-Word Learning Test ‘maximum
immediate recall’+Z15-Word Learning Test ‘delayed recall’)/3)
3. Executive function: Word fluency (ZVerbal Fluency test)
4. Speed of processing: Information processing speed (ZLetter Digit Substitution test )
Notes Funding sources: The research was funded by a grant from the Netherlands Organisation for Health
Research and Development (ZonMw, grant number 20010002), Wageningen University, and Wagenin-
gen Centre for Food Sciences. Wageningen Centre for Food Sciences is an alliance of major Dutch food
industries, research institutes and the Dutch government. Wageningen Centre for Food Sciences does
long-term strategic research for the development of new and innovated food with attention to health
aspects.
Declarations of interest: Jane Durga currently works at Nestle Research Center in Lausanne, Switzer-
land and Petra Verhoef currently works at the Unilever Food and Health Research Institute in Vlaardin-
gen, the Netherlands. The work at both food companies entails examining the health benefits of a va-
riety of food ingredients, including folic acid. However, the study reported in the current manuscript
was completed and submitted to The Lancet before the authors joined the companies, when they were
still employed by Wageningen University and Wageningen Centre for Food Sciences. All authors declare
that they have no conflict of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were allocated treatment or placebo with permuted blocks
of sizes four and six, which varied randomly. Specialised staI who were not in-
volved in the study allocated and labelled the capsule boxes with participants’
unique sequence number. Participants in the same household received the
same treatment."
Comment: Method of sequence generation was not reported.
Allocation concealment
(selection bias)
Low risk Quote: "Specialized staI who were not involved in the study allocated and la-
belled the capsule boxes with participants’ unique sequence number".
Comment: appropriate allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The folic acid and placebo capsules ... were indistinguishable in ap-
pearance". 70% of participants in the folic acid group and 71% in the placebo
group thought they had been allocated to folic acid.
Comment: well blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: All staI, including all authors, were unaware of group assignment
until completion of the trial and after data analyses.
Quote: outcome assessment well blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: 17 participants lost to follow-up were assigned the median test score of
the total population at the end of the study.
Comment: Although there were imputations, the small proportion of loss to
follow-up unlikely to affect results.
Selective reporting (re-
porting bias)
Unclear risk Quote: From clinicaltrials.gov: "Cognitive performance at year 3 (cognitive do-
mains: simple speed, cognitive flexibility, and memory; and information pro-
cessing speed and semantic memory)".
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Comment: unclear if the domains reported were prespecified (authors were
contacted for further information)
Other bias Low risk No other risks detected
Durga 2007  (Continued)
 
 
Methods 3-arm, parallel-group, randomised, placebo-controlled trial, 24 weeks duration
Participants Location: the Netherlands
Recruitment: free-living older persons and older persons living in care-facility homes, recruited via
mailed health questionnaires
Number randomised: 195 randomised, of whom 119 had CDR 0 at baseline and were included in this
review
"Randomization was stratified according to MMA concentration at the screening visit (< and > 0.45
µmol/L), age (< and > 80), sex and MMSE score (< and > 24 points)."
Vitamin B12: 38
Vitamin B12 + folic acid: 38
Placebo: 43
Participant baseline characteristics:
• Age, mean (SD):* vitamin B12: 80.42 (5.52)* vitamin B12 + folic acid: 80.82 (4.18)* placebo: 79.86 (4.74)• .Gender* vitamin B12: female 29/38 (76%)* vitamin B12 + folic acid: female 29/38 (76%)* placebo: female 34/43 (79%)• Baseline cognitive function - MMSE score (mean (SD))* vitamin B12: 28.18 (1.43)* vitamin B12 + folic acid: 28.34 (1.40)* placebo: 27.93 (1.80)
Inclusion criteria: aged ≥ 70 y. Mild vitamin B12 deficiency defined as (1) a serum vitamin B12 concen-
tration between 100 and 200 pmol/L, or (2) a serum vitamin B12 concentration between 200 and 300
pmol/L, a plasma MMA concentration ≥ 0.32 μmol/L, and a serum creatinine concentration ≤ 120 μmol/
L. Ingested 90% or more of capsules during a 2-week placebo run-in period prior to randomisation.
Exclusion criteria: history of cobalamin deficiency, use of cobalamin (> 50 µg/day) or folic acid (> 200
µg/day) supplementation or injections, surgery or diseases of the stomach or small intestine, anaemia,
dementia, life-threatening diseases, or severe hearing or visual problems
Interventions Intervention:
1. vitamin B12: 1000 µg vitamin B12 (cyanocobalamin) per day orally for 24 weeks
2. vitamin B12 and folic acid: 1000 µg vitamin B12 (cyanocobalamin) plus 400 µg folic acid per day orally
for 24 weeks
Comparator group:
• Placebo capsule
Eussen 2006 
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The placebo capsules contained AVICEL PH102 (Medipulp GmbH, Aschaffenburg, Germany) as a filler.
Use of additional interventions (common to all treatment arms): not reported
Outcomes Cognitive function
Cognitive function was assessed before and after 24 wk of treatment with the use of an extensive neu-
ropsychologic test battery that included the domains of attention, construction, sensorimotor speed,
memory, and executive function.
Cognitive function was assessed by 6 trained and registered neuropsychologists during the run-in peri-
od (baseline) and at week 24 of the intervention during a 1.5–2-h session.
Neuropsychological test battery included:
• finger tapping, computerised• motor planning 2 and 3, computerised• Figure of Rey copy, immediate recall and delayed recall• 15-word learning immediate recall, delayed recall and recognition• Trail-making test, part A and part B• Digit span forward and backward• Raven• Stroop test• Similarities, WAIS• Word fluency, letter• Word fluency, animals
Depression measured with GDS
Biochemical measures: vitamin B12, MMA, holoTC, homocystine, RBC folate
Compliance was checked by counting the number of unused capsules remaining in capsule dispensers
and by verifying pill counts in the participants’ diaries. Mean compliance was 99%.
Notes Professor Simone Eussen and Professor Lisette de Groot kindly provided data separately on partici-
pants with CDR 0 at baseline for inclusion in this review.
Study supported by grants from ZON-MW, The Hague, Netherlands; Kellogg's Benelux, Zaventem, Bel-
gium; Foundation to Promote Research into Functional Vitamin B12 Deficiency and the European
Union BIOMED Demonstration Project; Nutricia Health Foundation, Wageningen, Netherlands.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomized", no further information
Allocation concealment
(selection bias)
Unclear risk No information
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quotes: "The capsules given to the separate treatment groups were identical
in appearance, smell and taste." "The study had a double-blind design."
Comment: participants and personnel blind to allocation
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "The study had a double-blind design." No specific mention of outcome
assessors".
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Comment: outcome assessors probably blind to allocation
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Incomplete outcome data varied between cognitive tests. For included out-
comes, data available for minimum of 82% of participants.
In study as a whole, "16% ... were unable to complete the trial, mostly because
of illness, and the dropout rate was slightly higher in the vitamin B12 + folic
acid group than in the other groups." Dropout in whole study: 10/64 B12, 15/66
B12 + folic acid, 8/65 placebo.
Comment: major effect of differential dropout unlikely
Selective reporting (re-
porting bias)
Low risk All outcomes mentioned in methods fully reported
Other bias Low risk No other biases identified
Eussen 2006  (Continued)
 
 
Methods 2-arm, double-blinded, parallel group RCT, with 2 years duration of treatment and 8-year follow-up
The average follow-up time (time to event) was 8.3 years in both groups.
Participants Location: Australia, number of sites not reported
Recruitment: community-representative hypertensive men 75 years and older randomly selected from
a large population-based study of abdominal aortic aneurysm screening (Health in Men Study)
Participants were recruited from July 18, 2000, to February 6, 2002.
Number randomised: 150 in intervention, 149 in comparator
Participant (baseline) characteristics:
• Age, mean (SD):* placebo: 78.7 (2.7)* vitamin: 79.3 (2.8)• Baseline cognitive function* ADAS-cog, mean (SD)□ placebo: 11.8 (6.0)□ vitamin: 11.0 (5.1)• MMSE score, mean (SD)* placebo: 27.6 (1.9)* vitamin: 27.5 (1.8)
Inclusion criteria: community-representative hypertensive men 75 years and older
Exclusion criteria: Beck Depression Inventory (BDI) score ≥ 18 or a Mini-Mental State Examination
(MMSE) score ≤ 24, illness likely to cause severe disability or death within 12 months (for example,
metastatic cancer, Parkinson disease, or a history of stroke), non-English speaking, living in residential
care facilities, or patients who were already taking vitamin B supplements
Interventions Intervention (n = 150):
Vitamins: one capsule containing 400 µg B12, 25 mg B6, 2 mg folic acid, every morning for 2 years
Comparator group (n = 149):
Placebo, one identical oral capsule every morning for 2 years
Ford 2010 
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Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: to ascertain whether treatment with vitamins B12, B6, and folic acid over 2 years
would improve cognitive performance (change in the cognitive subscale of the Alzheimer’s Disease As-
sessment Scale) compared with placebo in older men
Secondary Outcomes:
Longer-term impact of B vitamin supplementation by comparing performance on the TICS as well as a
diagnosis of dementia registered in the Western Australian Data Linkage System (WADLS) until Septem-
ber 30, 2009
A diagnosis of dementia was recorded if the death certificate contained one of the following ICD-10
codes: F00 (dementia in AD), F01 (vascular dementia), F03 (unspecified dementia), and G30 (AD). Ad-
ditionally, a dementia diagnosis was sought from records of inpatient admissions and outpatient con-
tacts.
Secondary measures of interest included also the California Verbal Learning Test, Mini-Mental State Ex-
amination, Digit Cancellation Test, Clock Drawing Test*, TICS, changes in biochemical parameters (total
plasma homocysteine, vitamin B12 and quality of life (Short Form (SF)–36).
Eligible cognitive outcomes:
• global cognitive function measured with ADAS-cog at 1 and 2 years, with higher values indicating ben-
efit• global cognitive function measured with MMSE at 1 and 2 years, with higher values indicating benefit*• episodic memory measured with California Verbal Learning Test 1 (CVLT 1) at 1 and 2 years, with higher
values indicating benefit• episodic memory measured with California Verbal Learning Test 2 (CVLT 2) at 1 and 2 years, with higher
values indicating benefit*• semantic memory measured with Clock Drawing Test at 1 and 2 years, with higher values indicating
benefit*• speed of processing measured with Digit Cancellation Test (DCT) at 1 and 2 years, with higher values
indicating benefit*
Function outcome extracted: none reported
Quality of life outcome: SF-36
Safety outcome: none reported
* outcome data used in statistical analyses
Notes Funding sources, quote: “Supported by the National Health and Medical Research Council of Australia
(139123 to L.F.). The vitamin and placebo tablets were provided free of charge by Blackmores Ltd".
Declarations of interest, quote: "Dr. Ford reports no disclosures. Dr. Flicker serves as Internal Med-
icine Editor for Geriatric Medicine, Associate Editor for BMC Geriatrics, on the editorial board of the
Australasian Journal on Ageing, and as Editor of the Cochrane Dementia and Cognitive Improvement
Group; and receives/has received research support from Pfizer Inc. and NHMRC. Dr. Alfonso and J.
Thomas report no disclosures. Dr. Clarnette serves on scientific advisory boards for Lundbeck Inc., Pfiz-
er Inc., and Novartis; serves as an editorial advisor to Geriatric Medicine in General Practice; and esti-
mates that 10% of his practice at Fremantle Hospital consists of cognitive testing. Dr. Martins serves
as Senior Editor for the Journal of Alzheimer’s Disease; serves as a consultant for and holds stock in
Alzhyme Ltd.; and receives research support from Commonwealth Scientific and Industrial Research
Organisation (Australia). Dr. Almeida has received funding for travel from Blackmores Ltd."
Treatment adherence
Men who consumed at least 75% of the study tablets during this 2-year trial were considered compli-
ant. Compliance was determined by pill count and medication diaries.
Ford 2010  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Participants were given consecutive numbers and allocated to ac-
tive vs placebo arms based on computer-generated random permuted blocks.
Blocks consisted of 8 subjects (4 subjects allocated to each group) so as to
minimize the risk of having unbalanced entry into each arm of the study during
the period of recruitment."
Comment: adequate method of sequence generation
Allocation concealment
(selection bias)
Low risk Quote: “An external and independent academic controlled the randomization
procedures of the trial."
Comment: adequate method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “Vitamins and placebo were administered in the form of identical oral
capsules."
"Participants and investigators were blinded to the group membership of men
in the trial until the last follow-up assessment was completed. There were no
breaches of protocol".
Comment: participants and personnel blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Participants and investigators were blinded to the group membership
of men in the trial until the last follow-up assessment was completed."
Comment: outcome assessment blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "32 (21%) men in the intervention and 26 (17%) in the placebo group
withdrew consent or were lost during the trial."
Comment: For the primary outcome, an ITT analysis was presented and attri-
tion bias was considered as low.
For the secondary outcome of cognitive impairment or dementia at long-term
follow-up : "Seventy-three of these men took part in a later telephone survey
in 2008 and completed the Telephone Interview for Cognitive Status (TICS)
questionnaire", "41 (27%) in the intervention group and 32 (21%) in the place-
bo group". Data on dementia diagnosis were available on all 172/299 (57.5%)
participants who were alive in 2008.
Comment: high risk of attrition bias for this long-term secondary outcome
Selective reporting (re-
porting bias)
Low risk Comment: All outcomes specified in the Methods were reported in the Results.
Protocol not available
Other bias Low risk No other risks identified
Ford 2010  (Continued)
 
 
Methods Substudy of the Physicians’ Health Study II, a randomised, double-blind, placebo-controlled, 2 x 2 x 2 x
2 factorial trial testing ß-carotene, vitamin E, ascorbic acid, and a multivitamin for their role in prevent-
ing chronic diseases including total and prostate cancer, cardiovascular disease, and age-related eye
disease among 14,641 male physicians aged 50 years or older
Grodstein 2007 
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The trial was done from 1997 to 1 June 2011. The cognitive function substudy began in 1998. Those eli-
gible for the cognitive substudy were PHS II participants older than 65 years in November 1998.
The Physicians’ Health Study II was a continuation of the Physicians’ Health Study, which began in 1982
and had randomised male participants to low-dose aspirin and ß-carotene. Participants included those
continuing their original ß-carotene assignment from the Physicians’ Health Study and newer recruits
randomised from 1998 onwards.
Participants Location: not reported
Recruitment: The Physicians’ Health Study II. Quote: "In July 1997, invitations to enrol in PHS II were
mailed to eligible participants from PHS I who had been part of an earlier trial of aspirin and ß-carotene
among 22071 physicians aged 40 to 84 years in 1982. Second, in July 1999, invitation letters were
mailed to a new group of male physicians identified from a list provided by the American Medical Asso-
ciation."
Quote: "PHS I participants who are willing and eligible for participation in PHS II will retain their ran-
domized ß-carotene assignment from PHS I and will be also randomized to vitamin E..."
"new physician participants will be randomly assigned to the same interventions"
Number randomised:
• 2967 ß-carotene (2031 continuing from PHS and 936 newer recruiters)• 2989 placebo (2021 continuing from PHS and 968 newer recruiters)
Participant (baseline) characteristics (at entry PHS III):
All participants were men.
Age, mean:
• Patients from PHS at entry in PHS II• ß-carotene: 70.9• placebo: 71.0• Newly recruited• ß-carotene: 72.9• placebo: 72.8
Inclusion criteria: not reported
Exclusion criteria: history of cirrhosis or active liver disease, patients receiving anticoagulants, or re-
ported a serious illness that may interfere with study participation
Men were also required to forgo current use of multivitamins or individual supplements containing
more than 100% of the recommended daily allowance of vitamin E, vitamin C, ß-carotene, or vitamin A
during PHS II follow-up
For those newly recruited: no history of cancer, active liver disease, current renal disease, peptic ulcer,
or gout
Quote: "Only physicians who comply with the pill-taking regimen at least two-thirds of the time and re-
main willing and eligible to participate will be subsequently randomized".
Interventions Intervention:
1. ß-carotene (Lurotin, 50 mg on alternate days, or its placebo; BASF, Florham Park, New Jersey);
2. vitamin E (synthetic alfa-tocopherol, 400 IU on alternate days, or its placebo; BASF);
3. ascorbic acid (synthetic ascorbic acid, 500 mg daily, or its placebo; BASF);
4. multivitamin (Centrum Silver or its placebo daily; Pfizer, New York, New York)
NB: Grodstein 2007 reported on the ß-carotene and Grodstein 2013 on multivitamin supplementation.
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Comparator group: placebo ß-carotene.
Exposure to study intervention:
2031 patients in ß-carotene and 2021 placebo continued from the PHS study (started in 1982) in which
they were receiving ß-carotene versus placebo ß-carotene. As most of the cognitive assessments were
done in 2001, some of the patients continuing from PHS had been exposed to ß-carotene (or placebo ß-
carotene) for about 19 years, whereas the "new recruiters" had been exposed from 1997 to 2001, thus
for about 4 years.
The mean time from randomisation to cognitive assessment was 18 years (range, 15-20 years) in 4052
continuing participants from the PHS,and was 1 year in 2021 new recruits (range, 2 months–3 years).
Quote: "PHS participants, who remained blinded to beta carotene assignment."
Quote: "Treatment assignment to beta carotene or beta carotene placebo was retained from the PHS
(although participants may have stopped taking beta carotene during the 18-month interval between
studies), and the men were newly randomized to receive vitamin E, ascorbic acid, multivitamin, or
placebo."
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes:
A global composite score averaging 5 tests of global cognition, verbal memory, and category fluency.
The cognitive battery included the Telephone Interview for Cognitive Status (TICS); immediate and de-
layed recall on the East Boston Memory Test (EBMT); delayed recall of a 10-word list; and a category flu-
ency task.
The cognitive function substudy began in 1998.
The beta carotene arm of the PHS II continued until May 2003, its planned stopping date, but most of
the assessments were done in 2001.
Quote: "Second cognitive assessments were begun in 2002. The beta carotene arm was terminated pri-
or to completion of second assessments (second and third assessments were planned to allow further
data collection in the continuing trial of other vitamins). Nonetheless, some data from the second in-
terview were available (n = 4074, with 88.3% participation of those who were contacted before termina-
tion of the beta carotene study)."
Eligible cognitive outcomes:
• global cognitive function measured with TICS*• episodic memory (verbal memory) measured using an average of z-scores* for immediate and delayed
recall on the EBMT and delayed recall of a 10-word list• executive functioning measured with category fluency: animals named during 1 minute*
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
Notes Funding source: “This study was supported by grants from the National Institutes of Health (CA34944,
CA40360, CA97193, HL26490, HL34595, and AG15933), and from BASF Corporation (Florham Park, New
Jersey), Wyeth (New Jersey), and DMS (New Jersey). Dr Grodstein was partially supported by a New
Scholars in Aging award from the Ellison Medical Foundation. Role of the Sponsor: No supporting orga-
nization had any role in the study design; conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, or approval of the manuscript."
Declaration of interest: “None reported".
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Treatment adherence:
ß-carotene study:
"Overall, 79.3% reported taking at least 2 of 3 of their study pills; this was similar in those assigned to
active treatment (79.1%) or placebo (79.5%), and in the continuing participants from the PHS (79.2%)
vs new recruits (79.4%)".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
"Randomization..using a computer-generated list of random numbers".
Comment: adequate method of random generation
Allocation concealment
(selection bias)
Unclear risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
Comment: method of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
Comment: method of blinding not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
"An Endpoint Committee of physicians blinded to the participants' treatment
assignment, will review the medical records for final confirmation of a report-
ed diagnosis".
Comment: The method of blinding of outcome assessment for the cognitive
substudy was not reported. The statement about the Endpoint Committee is
contained in the design paper which, however, does not mention any cogni-
tive outcome.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "of the 7045 age-eligible patients, 271 were no longer active PHSII par-
ticipants (3.8%) and 4 were deceased (0.06%). Of the remaining 6770, we were
unable to reach 315 (4.7%). Of the 6455 participants contacted, 5956 (92.3%)
completed a cognitive assessment: 4052 from the original PHS and 1904 new
recruits.." "Participation (in the cognitive substudy) was virtually identical in
those assigned to beta-carotene (92.0%) vs placebo (92.6%) and in continuing
participants (from the PHS) (92.1%) vs new recruits (to PHS II) (92.7%)."
Selective reporting (re-
porting bias)
Low risk Comment: no differences found between the protocol (clinicaltrials.gov Identi-
fier: NCT00270647) and article. In addition, all outcomes specified in the Meth-
ods were reported in the Results.
Other bias Low risk No other source of bias identified
Grodstein 2007  (Continued)
 
 
Methods Substudy of the Physicians’ Health Study II, a randomised, double-blind, placebo-controlled, 2 x 2 x 2 x
2 factorial trial testing ß-carotene, vitamin E, ascorbic acid, and a multivitamin for their role in prevent-
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ing chronic diseases including total and prostate cancer, cardiovascular disease, and age-related eye
disease among 14641 male physicians aged 50 years or older.
The trial was done from 1997 to 1 June 2011. The cognitive function substudy began in 1998.
Participants Location: not reported
Recruitment: The Physicians’ Health Study II. Quote: "In July 1997, invitations to enrol in PHS II
were mailed to eligible participants from PHS I who had been part of an earlier trial of aspirin and be-
ta-carotene among 22,071 physicians aged 40 to 84 years in 1982. Second, in July 1999, invitation let-
ters were mailed to a new group of male physicians identified from a list provided by the American
Medical Association."
The substudy of cognitive function was conducted among PHS II participants aged 65 years or older.
Number randomised: 2980 in multivitamin, 2967 in placebo
Participant (baseline) characteristics:
All participants were men.
• Age, mean (SD):* multivitamin: 71.6 (6.0)* placebo: 71.6 (5.9)
Inclusion criteria: not reported
Exclusion criteria: history of cirrhosis or active liver disease, patients receiving anticoagulants, or re-
ported a serious illness that may interfere with study participation
Men were also required to forgo current use of multivitamins or individual supplements containing
more than 100% of the recommended daily allowance of vitamin E, vitamin C, ß-carotene, or vitamin A
during PHS II follow-up.
For those newly recruited: no history of cancer, active liver disease, current renal disease, peptic ulcer,
or gout.
Quote: "Only physicians who comply with the pill-taking regimen at least two-thirds of the time and re-
main willing and eligible to participate will be subsequently randomized".
Interventions Intervention:
1. ß-carotene (Lurotin, 50 mg on alternate days, or its placebo; BASF, Florham Park, New Jersey);
2. vitamin E (synthetic alfa-tocopherol, 400 IU on alternate days, or its placebo; BASF);
3. ascorbic acid (synthetic ascorbic acid, 500 mg daily, or its placebo; BASF);
4. multivitamin (Centrum Silver or its placebo daily; Pfizer, New York, New York)
NB: Grodstein 2007 reported on the ß-carotene and Grodstein 2013 on multivitamin supplementation.
Comparator group: placebo multivitamin
Use of additional interventions (common to both treatment arms): Because of the factorial design,
some participants were also taking vitamin E and/or vitamin C.
Exposure to study intervention: Mean time from randomisation to initial cognitive assessment was
2.5 years (range, 0.18 to 5.3 years) and mean time from randomisation to the final cognitive assessment
was 8.5 years (range, 0.3 to 14.2 years).
Outcomes Primary Outcomes:
A global composite score averaging 5 tests of global cognition, verbal memory, and category fluency.
Grodstein 2013  (Continued)
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The cognitive battery included the Telephone Interview for Cognitive Status (TICS); immediate and de-
layed recall on the East Boston Memory Test (EBMT) (verbal memory); the delayed recall of a 10-word
list (verbal memory); and a category fluency task.
The cognitive function substudy began in 1998. Up to 4 repeated cognitive assessments by telephone
interview were completed over 12 years.
Quote: "The beta-carotene group of the PHS II continued as planned through May 2003... Treatment
and follow-up of the vitamin E and C components continued through August 2007...The multivitamin
intervention continued through 1 June 2011.."
Eligible cognitive outcomes:
• global cognitive function measured with TICS• episodic memory (verbal memory) measured using an average of z-scores* for immediate and delayed
recall on the EBMT and delayed recall of a 10-word list• executive functioning measured with category fluency: animals named during 1 minute
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
Notes Funding sources, Quote: “National Institutes of Health, BASF, Pfizer, and DSM Nutritional Products."
"By grants CA 097193, CA 34944, CA 40360, HL 26490, HL 34595, AG 15933, and T32-AG000158 from the
National Institutes of Health, and an investigator-initiated grant from BASF. Study agents and pack-
aging were provided by BASF and Pfizer, and study packaging was provided by DSM Nutritional Prod-
ucts."
Declarations of interest, quote: “Disclosures can be viewed at www.acponline.org/authors/icm-
je/ConflictOfInterestForms.do?msNum_M13-1340." Several authors reported some conflicts of interest.
Treatment adherence:
"83.5% of the multivitamin group and 84.2% of the placebo group reported taking at least two thirds of
their study pills".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
"Randomization..using a computer-generated list of random numbers".
Comment: adequate method of random generation
Allocation concealment
(selection bias)
Low risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
Comment: method of allocation concealment not reported, but likely to be ad-
equate
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
Comment: method of blinding not reported
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Quote: “The PHS II is a randomized, double-blind, placebo-controlled, 2x2x2x2
factorial trial".
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All outcomes "An Endpoint Committee of physicians blinded to the participants' treatment
assignment, will review the medical records for final confirmation of a report-
ed diagnosis".
Comment: The method of blinding of outcome assessment for the cognitive
substudy was not reported. The statement about the Endpoint Committee is
contained in the design paper which, however, does not mention any cogni-
tive outcome.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk There was good retention of participants from the first to the second (96%)
and the third (90%) assessments.
Quote: “the fourth assessment was not attempted in many participants be-
cause of trial completion (that is, 2700 (45%) of the initial 5947 who completed
the initial interview were invited to participate at the fourth assessment before
the trial closed on 1 June 2011)".
Comment: 3623 (61%) patients had none of the assessments at last visit so we
considered there was a high risk of attrition bias for the final assessment only
(time point > 5 to 10 years).
Selective reporting (re-
porting bias)
Low risk Comment: No differences identified between the protocol ClinicalTrials.gov:
NCT00270647) and the article. All outcomes specified in the Methods were re-
ported in the Results.
Other bias Low risk No other risks identified
Grodstein 2013  (Continued)
 
 
Methods Prespecified substudy of the VITATOPS trial, a randomized, 2-arm, parallel group, placebo-controlled
trial
Participants Location: international, multicentre (20 countries from 4 continents)
Number randomised: 8164 participants with recent stroke or TIA randomised in VITATOPS. This sub-
study was of the 2214 participants who were cognitively unimpaired - defined as MMSE ≥ 24 six months
after the qualifying cerebrovascular event - and who had 1 or more further MMSEs during follow-up.
1110/2214 allocated to B vitamins
1104/2214 allocated to placebo
Participant (baseline) characteristics:
• gender: 67.3% male• age, mean (SD): 63.6 (11.8)• baseline cognitive function:• B vitamins group MMSE 28.05 (SD 1.76)• placebo group MMSE 28.09 (SD 1.77)
Inclusion criteria: "patients presenting within 7 months of stroke (ischaemic or haemorrhagic) or TIA
(eye or brain), as defined by standard criteria, are eligible" (for VITATOPS). For cognitive substudy,
MMSE ≥ 24 six months after the qualifying cerebrovascular event and ≥ 1 further MMSE measured dur-
ing follow-up.
Exclusion criteria: patients taking folic acid or vitamin B6 on medical advice; taking methotrexate for
any reason; pregnant or at risk of pregnancy; limited life expectancy
Interventions Intervention (n = 1110):
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Folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 μg
Comparator (n = 1104):
Placebo
Outcomes Primary outcome for this prespecified substudy was a new diagnosis of cognitive impairment (MMSE
score < 24 on ≥ 2 follow-up visits ≥ 6 months after the qualifying stroke.
Secondary outcomes were tHcy, the mean MMSE, cognitive decline (i.e. a decline from baseline, ≥ 6
months after the qualifying stroke, of ≥ 3 points in the MMSE score on ≥ 2 follow-up visits), composite of
cognitive impairment and decline.
Notes Funded by National Health and Research Council of Australia, the UK Medical Research Council, the
Biomedical Research Council of Singapore, the National Heart Foundation of Australia, the Royal Perth
Hospital Medical Research Foundation, and the Health Department of Western Australia.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "After baseline data have been provided by the investigator and it is
confirmed that the patient meets the study eligibility criteria, a central 24-hour
telephone service or an interactive website ... uses random permuted blocks
stratified by hospital to allocate a treatment pack number."
Allocation concealment
(selection bias)
Low risk Quote: "After baseline data have been provided by the investigator and it is
confirmed that the patient meets the study eligibility criteria, a central 24-hour
telephone service or an interactive website ... uses random permuted blocks
stratified by hospital to allocate a treatment pack number."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "the tablets being either vitamin supplements or matching placebo"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No specific information about site investigators. Likely blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "The 2214 cognitively unimpaired participants who underwent subse-
quent cognitive testing were more likely to be white, have a qualifying TIA and
lacunar syndrome at baseline, and less likely to have experienced an early re-
current stroke within 1 year of randomization ... compared with the 394 cogni-
tively unimpaired participants who did not proceed to further cognitive test-
ing."
" ..there was no significant difference in the prevalence of baseline characteris-
tics among the 2214 cognitively unimpaired participants allocated B vitamins
(n = 1110) compared with placebo (n = 1104), with the exception of atrial fibril-
lation (9.1% B vitamins versus 6.5% placebo; P = 0.022)."
Selective reporting (re-
porting bias)
Low risk Prespecifed cognitive outcomes fully reported
Other bias Low risk No other risks identified
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Methods Cognitive substudy of the Women's Health Study, a randomized, placebo-controlled, 2 x 2 factorial trial
of vitamin E and low-dose aspirin with follow-up to approximately 10 years
Participants Location: USA, number of sites not reported
Recruitment: female health professionals
Number randomised: 3184 in intervention, 3193 in comparator
Participant (baseline) characteristics:
• Age at randomisation:* vitamin E group: 66.2 (± 4)(range 60.4-89.9)* placebo: 66.3 (± 4.1)(range 60.4-87.1)• Age at initial cognitive assessment:* vitamin E group : 71.8 (± 4)(range 66.1-95.5)* placebo: 71.9 (± 4.1)(range 66.0-92.8)• · Gender: women 100%• · Baseline cognitive function: not assessed
Inclusion criteria: Women 65 years or older participating in the Women's Health Study. Inclusion cri-
teria for the main study: "Women were eligible if they were 45 years of age or older; had no history of
coronary heart disease, cerebrovascular disease, cancer (except non-melanoma skin cancer), or other
major chronic illness; had no history of side effects to any of the study medications; were not taking as-
pirin or nonsteroidal antiinflammatory medications (NSAIDs) more than once a week (or were willing to
forego their use during the trial); were not taking anticoagulants or corticosteroids; and were not taking
individual supplements of vitamin A, vitamin E, or beta carotene more than once a week."
Exclusion criteria: not reported for the cognitive substudy
Interventions Intervention (n = 3184):
Vitamin E supplementation (600 IU α-tocopherol acetate; Natural Source Vitamin E Association, La
Grange Ill) on alternate days
Comparator group (n = 3193):
Placebo
Participants also randomised to aspirin 100 mg on alternate days in 2 x 2 factorial design
Use of additional interventions (common to both treatment arms): not reported
Outcomes The first cognitive assessment was a mean of 5.6 years (range 4.4 to 6.8 years) after randomisation and
the final assessment was a mean of 4 years (range 2.6 to 5.7 years) later. We considered that all assess-
ments fell into our duration category of > 5-10 years of treatment and, following the protocol, used the
latest, i.e. the final, assessment only.
Primary Outcomes: global composite score averaging performance on general cognition, verbal mem-
ory and category fluency
Tests used:
• Telephone Interview of cognitive status (TICS)• East Boston Memory test immediate and delayed recall• Delayed recall of the TICS 10-word list
Secondary Outcomes: composite score of verbal memory, averaging performance across 4 measures
of verbal memory
Cognitive assessments of general cognition, verbal memory, and category fluency were administered
by telephone at 2-year intervals by trained nurses.
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Time from randomisation to final cognitive assessment: approximately 10 years
Eligible cognitive outcomes:
• global cognitive function measured at approximately 10 years, with higher values indicating benefit• executive functioning measured at approximately 10 years, with higher values indicating benefit• episodic memory measured with TICS 10-word test delayed recall at approximately 10 years, with
higher values indicating benefit
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
Notes Primary aim of study was to investigate effects of interventions on the primary prevention of cardio-
vascular disease and cancer. At the time of initiation of the cognitive substudy, participants had been
treated for a mean of 5.6 years since randomisation.
Funding sources, quote: “This work was supported by grants CA47988 and AG15933 from the National
Institute of Health", "The funding agency did not play any role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; and preparation, review, or approval
of the manuscript".
Declarations of interest, For the sub-study: none reported. For the main study, quote: "Dr. Ridker re-
ports having received grant support from Bayer. Dr. Cook reports having served as a consultant to Bay-
er. Dr. Gaziano reports having served as a consultant to, and receiving grant support from, Bayer and
McNeil. Dr. Hennekens reports having served as a consultant to Bayer and McNeil and receiving grant
support from Bayer".
Treatment adherence
Quote: "compliance was comparable between the 2 groups: as of the final cognitive assessment, the
percentage that reported taking at least two thirds of the assigned pill was 75.4% for the vitamin E
group and 76.9% for the placebo group".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment: method of random sequence generation not reported. Probably ad-
equate
Allocation concealment
(selection bias)
Unclear risk Comment: method of allocation concealment not reported. Probably ade-
quate
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "The WHS is a double-blind, .... RCT."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: for the substudy on cognitive function, blinding of outcome assess-
ment was not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Comment: 18% of patients randomised and included in the substudy were not
included in the analysis at last assessment.
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Selective reporting (re-
porting bias)
Unclear risk Comment: All outcomes in the Methods were reported in the results. Protocol
not available
Other bias Low risk No other risks identified
Kang 2006  (Continued)
 
 
Methods WAFACS study. A 2 x 2 x 2 x 2 factorial, randomised, placebo-controlled trial of 3 antioxidants (vitamin E,
vitamin C, and ß-carotene) and B vitamins with 6.6 years of treatment and 5.4 years of follow-up of cog-
nitive function.
The WAFACS study was started in 1998 and continued the WACS study (Kang 2009) with the introduc-
tion of a fourth arm treated with folic acid, vitamin B6, and vitamin B12.
Surviving participants of the WACS were invited to participate in the WAFACS.
When the folic acid, vitamin B6, and B12 arm was added, this combination or its placebo was combined
in a retained factorial design with the vitamin C tablet or placebo.
Participants Location, Country: United States of America, number of sites not reported. Inclusion from December
1998 to July 2000
Recruitment: female health professionals
Number randomised: 1071 in intervention, 1093 in comparison, but 1002 and 1007 considered at
baseline because had available baseline cognitive assessment
Participant (baseline) characteristics:
• Mean age ± SD (range) at randomisation:* vitamin: 71.3 ± 4.2 (65.3–89.9)* placebo:71.3 ± 4.2 (65.3–90.0)• Mean age ± SD (range) at initial cognitive assessment:* vitamin: 72.5 ± 4.2 (66.1–90.9)* placebo: 72.5 ± 4.2 (66.1–91.2)• · Gender: women 100%• · Main diagnosis: female health professionals aged ≥ 40y with cardiovascular disease or ≥ 3 coronary
risk factors
Inclusion criteria:
This was a substudy of cognitive function among 2009 participants aged ≥ 65 years from the Women’s
Antioxidant and Folic Acid Cardiovascular Study, a randomised placebo-controlled trial designed to
test the effect of a combination of B vitamins on secondary prevention of cardiovascular disease in fe-
male health professionals aged ≥ 40 years with cardiovascular disease or ≥ 3 coronary risk factors.
The substudy was initiated a mean of 1.2 years after randomisation.
Exclusion criteria: not reported for the substudy
Exclusion criteria in the main study, quote: "Women were excluded if they had a history of cancer (ex-
cluding non-melanoma skin cancer) within the past ten years, any serious non-CVD illness, or were cur-
rently using warfarin or other anticoagulants. To be eligible for the folic acid/vitamin B6/B12 compo-
nent, potential participants in the ongoing eight-arm trial had to be additionally willing to forgo indi-
vidual supplements of folic acid, vitamin B6, and vitamin B12 at levels beyond the US recommended
daily allowance".
Interventions Intervention (n = 1002):
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2.5 mg folic acid/day, 50 mg vitamin B6/day, and 1 mg vitamin B12/day
Quote: "5442 women were assigned to 16 treatment assignments that were combinations of the 3 an-
tioxidants" and 1 B vitamin supplement.
Quote: "Every 12 mo, the women were sent a year’s supply of monthly calendar packs containing active
agents or placebo."
Comparator group (n = 1007): placebo.
Use of additional interventions (common to both treatment arms): not reported.
Outcomes Outcomes of interest in the review:
Primary Outcomes: global composite score averaging all 5 test results measuring general cognition,
verbal memory, and category fluency using z scores
Quote: "We assessed cognitive function using a telephone cognitive battery with 5 tests measuring gen-
eral cognition, verbal memory, and category fluency. "
The following tests were used:
• For general cognition, Telephone Interview of Cognitive Status (TICS);• For verbal memory, delayed recall of the TICS 10-word list and the immediate and delayed recalls of
the East Boston Memory Test;• For category fluency, women were asked to name as many animals as possible in 1 min.
Secondary Outcomes: verbal memory composite score, calculated by averaging 4 measures of verbal
memory (the immediate and delayed recalls of both the East Boston Memory Test and the 10-word list).
Telephone cognitive function testing was administered up to 4 times over 5.4 years.
The average time from randomisation to the initial cognitive assessment was 1.2 years (range: 0.7–1.7
years), and from randomisation to the last assessment was 6.6 years (range: 6.3– 6.9 years)."
Eligible cognitive outcomes:
• global cognitive function measured with TICS at the initial cognitive assessment (1.2 years); the sec-
ond cognitive assessment (around 3 years of follow-up) and the fourth cognitive assessment (6.6 years
follow-up), with higher values indicating benefit*• episodic memory: composite(delayed East Boston memory, immediate East Boston memory, delayed
TICS-10) at the initial cognitive assessment (1.2 years); the second cognitive assessment (around 3
years of follow-up) and the fourth cognitive assessment (6.6 years follow-up)• executive functioning measured with Category fluency, animal naming test at the initial cognitive as-
sessment (1.2 years); the second cognitive assessment (around 3 years of follow-up) and the fourth
cognitive assessment (6.6 years follow-up), with higher values indicating benefit*.
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
Notes Funding sources, quote: “Folic acid, vitamin B-6, vitamin B-12, and placebos were provided by the
BASF Corporation (Mount Olive, NJ)”.
"Supported by grants AG15933 and HL47959 from the National Institutes of Health".
Declarations of interest, quote: “None of the authors declared a conflict of interest."
"Other Financial Disclosures: Dr Gaziano has received investigator initiated study support in the form of
vitamin pills and packaging from Wyeth. Dr Buring has received investigator initiated study support in
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the form of vitamin pills and packaging from Natural Source Vitamin E Association. Dr. Manson has re-
ceived investigator-initiated study support in the form of vitamin pills and packaging from Cognis and
BASF."
Treatment adherence
Quote: "Compliance was comparable (83%) in the 2 treatment groups". This statement, however,
seems to have referred to the main study and not to this substudy on cognitive function,
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: no information
Comment: method of random sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Quote: no information
Comment: method of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: Protocol: "Participants and investigators will be blinded to treatment
assignment."
Comment: method of blinding not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “The telephone cognitive interviews were administered by trained in-
terviewers".
From the main study: "An endpoints committee of physicians who were blind-
ed to randomized treatment assignment adjudicated all primary and sec-
ondary cardiovascular outcome events. Study medications and end point as-
certainment were continued in a blinded fashion until the scheduled end of
the trial, July 31, 2005."
Comment: It was not specifically reported whether cognitive assessors were
blinded, but we considered this to be highly likely.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: “Participants received 3 follow-up cognitive assessments approximate-
ly every 2 y.... 94% completed at least one follow-up assessment, and 83%
completed ≥ 3 of 4 assessments. In the fourth assessment, 24% of participants
were not contacted for their assessment because only a short interval had
passed between their third interview and the end of the trial in July 2005."
Comment: Although the authors provided some explanation for not seeing
some patients at last visit (visit 4), the number of patients not undergoing cog-
nitive evaluation was considerable: 956/2009 (47.5%) at visit 4 and 314/2009
(15.6%) at visit 3. RIsk of bias related to incomplete outcome data considered
high for visit 4.
Selective reporting (re-
porting bias)
Low risk Comment: All outcomes reported in the Methods were presented in the Re-
sults. In addition, the outcomes reported in the protocol were reported as well
in the article.
Other bias Low risk Quote: “155 women (7%) were unreachable, had declined participation, or had
died; thus, 2009 (93%) women completed the initial telephone cognitive as-
sessment."
Comment: inclusion was probably not consecutive, however, reasons for not
including in the substudy were given and the number excluded appeared bal-
anced between the 2 groups.
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Methods 2 x 2 x 2 factorial, randomised, placebo-controlled trial of 3 antioxidants (vitamin E, vitamin C, and ß-
carotene) with 8.9 years (range 7.8–9.6) of follow-up.
Participants Location: Country: USA and Puerto Rico, no of sites etc. not reported. From December 1998 to July
2000
Quote: "From November 1994 to October 1996 an introductory letter, informed consent form, and
enrolment questionnaire were mailed to female health professionals who were originally identified
through state licensing boards and professional organizations in the continental United States, Alaska
and the Commonwealth of Puerto Rico".
"Potential candidates were also drawn from a cohort of women with prevalent CVD participating in the
long-running Nurses' Health Study".
Recruitment: female health professionals
Number randomised:
2824 in cognitive substudy
• overall, vit E: 1428;• overall, vit C: 1406;• overall, betaCarot: 1406;• placebo vit E, C, betaCarot: 353;• placebo vit E: 1396;• placebo vit C: 1418;• placebo betaCarot: 1418.
Participant (baseline) characteristics:
Mean age (± SD, range) at randomisation:
• overall, vit E: 69.1 (4.3; 62.6–87.4)• placebo vit E: 69.0 (4.2; 62.6–87.9)• overall, vit C: 69.0 (4.2; 62.6–86.9)• placebo vit C: 69.1 (4.3; 62.6–87.9)• overall, betaCarot: 69.1 (4.3; 62.6–87.9)• placebo betaCarot: 69.0 (4.2; 62.6–87.6)
Mean age (± SD, range) at initial cognitive assessment:
• overall, vit E: 72.6 (4.3; 66.1–90.9)• placebo vit E: 72.5 (4.2; 66.1–91.3)• overall, vit C: 72.5 (4.2; 66.1–90.5)• placebo vit C: 72.6 (4.3; 66.1–91.3)• overall, betaCarot: 72.6 (4.3; 66.2–91.3)• placebo betaCarot: 72.5 (4.2; 66.1–91.2)
Gender: women 100%
Main diagnosis: female health professionals aged ≥ 40y with cardiovascular disease or ≥ 3 coronary risk
factors
Inclusion criteria: This was a substudy of cognitive function among 2824 participants aged ≥ 65 years
from the Women’s Antioxidant Cardiovascular Study, a randomised placebo-controlled trial designed
to test the effect of a antioxidants on secondary prevention of cardiovascular disease in female health
professionals aged ≥ 40 years with cardiovascular disease or ≥ 3 coronary risk factors.
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Exclusion criteria: not reported for the substudy
Exclusion criteria in the main study, quote: "Women were excluded if they had a history of cancer (ex-
cluding non-melanoma skin cancer) within the past ten years, any serious non-CVD illness, or were cur-
rently using warfarin or other anticoagulants. To be eligible for the folic acid/vitamin B6/B12 compo-
nent, potential participants in the ongoing eight-arm trial had to be additionally willing to forgo indi-
vidual supplements of folic acid, vitamin B6, and vitamin B12 at levels beyond the US recommended
daily allowance".
Only women who were compliant (taking at least two-thirds of the pill) during the 12-week pre-ran-
domisation run-in period were randomised.
Interventions Intervention (overall, vitamin E: 1428; overall, vitamin C: 1406; overall, betaCarot: 1406)
Vitamin E at a dose of 402 mg (600 IU) every other day, ß-carotene (50 mg every other day) and vitamin
C (500 mg daily)
Every 12 months, the women were sent a year’s supply of monthly calendar packs containing active
agents or placebo.
Comparator group: placebo (placebo vitamin E, vitamin C, ß-carotene: 353; placebo vit E: 1396; place-
bo vitamin C: 1418; placebo ß-carotene: 1418)
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: global composite score averaging all 5 test results measuring general cognition,
verbal memory, and category fluency using z scores.
Quote: " We assessed cognitive function by telephone and administered 5 tests measuring general cog-
nition, verbal memory and category fluency."
The following tests were used:
• Telephone Interview of Cognitive Status (TICS)• delayed recall of the TICS 10-word list and the immediate and delayed recalls of the East Boston Mem-
ory Test (data not extractable per instrument)• category (animal) fluency
Secondary Outcomes: 'verbal memory' composite score, calculated by averaging 4 measures of the
immediate and delayed recalls of both the East Boston Memory Test and the TICS 10-word list.
Telephone cognitive function testing was administered up to 4 times over 5.4 years.
The substudy was initiated a mean of 3.5 years after randomisation. Quote: "The average time from
randomization to the initial cognitive assessment was 3.5 years (range 3.1–4.7), and from randomiza-
tion to the last assessment was 8.9 years (range 7.8–9.6)".
Eligible cognitive outcomes:
• global cognitive function measured with TICS• executive function measured with category fluency
Notes Also known as the WACS study.
Funding sources, quote: "Vitamin E and its placebo were provided by Cognis Corporation (LaGrange,
IL); all other agents and their placebos were provided by BASF Corporation (Mount Olive, NJ)." "This
work is supported by grants AG15933, HL046959 from the National Institutes of Health."
Declarations of interest, quote: “none." "Other Financial Disclosures: Dr Gaziano has received inves-
tigator initiated study support in the form of vitamin pills and packaging from Wyeth. Dr Buring has
received investigator initiated study support in the form of vitamin pills and packaging from Natural
Source Vitamin E Association. Dr. Manson has received investigator-initiated study support in the form
of vitamin pills and packaging from Cognis and BASF."
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Treatment adherence
"average compliance (defined as taking at least two-thirds of assigned study medications) during fol-
low-up was 83% and did not differ significantly between the two groups". This statement, however,
seemed to have referred to the main study and not to this substudy on cognitive function.
"At the end of the study, compliance (defined as taking at least two-thirds of study pills) was compara-
ble across all groups (range 64–68%)."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “randomized in a 2 × 2 × 2 factorial design."
Comment: method of random sequence generation not reported. Probably ad-
equate
Allocation concealment
(selection bias)
Unclear risk Comment: method of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “matching placebo"
Comment: same study as Kang 2008 (reported vitamin B arm) in which more
detailed description of the methods stated that "Participants and investiga-
tors will be blinded to treatment assignment."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “The telephone cognitive interviews were administered by trained in-
terviewers, who were masked to the participants’ randomized treatment as-
signment."
From the main study: "An endpoints committee of physicians who were blind-
ed to randomized treatment assignment adjudicated all primary and sec-
ondary cardiovascular outcome events. Study medications and end point as-
certainment were continued in a blinded fashion until the scheduled end of
the trial, July 31, 2005."
Comment: Physicians were blinded to treatment assignment in the main
study. The nurses were the assessors in this cognitive substudy and were ap-
parently not aware of treatment assignment.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk In this review, we used outcome data from the first cognitive assessment (af-
ter a mean of 3.5 years) - this included 2824 of 3170 eligible participants (89%)
- and the fourth cognitive assessment (after a mean of 8.9 years) - this includ-
ed 1586 participants (50%). No information was given about the treatment as-
signments of missing participants. We considered there to be an unclear risk of
attrition bias for the first assessment and a high risk for the final assessment.
Selective reporting (re-
porting bias)
Low risk Comment: All outcomes reported in the Methods were presented in the Re-
sults. In addition, the outcomes specified in the protocol were reported in the
article.
Other bias Low risk No other risks identified
Kang 2009  (Continued)
 
 
Methods Substudy of the SU.VI.MAX, a randomised, double-blind, placebo-controlled, primary prevention trial
Kesse-Guyot 2011 
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Participants Location: France, number of sites not reported for the cognitive substudy
Recruitment: selected French participants aged 45–60 years who were enrolled in the SU.VI.MAX study
(1994–2002). Quote: "A total of 12,741 individuals were included for a planned follow-up of 8 y. At the
end of the supplementation (2002), a total of 6850 subjects who agreed to participate in a post-supple-
mentation follow-up were included in the SU.VI.MAX 2 study, which sought to investigate the effect of
nutrition on the quality of aging."
Sample size:
Number randomised: 6850 of the 12741 people randomised in the SU.VI.MAX study had agreed to par-
ticipate in the follow-up study (SU.VI.MAX 2), which included a cognitive evaluation, but the authors re-
ported only on the 5583 participants who were aged 45-60 years at the onset of the treatment period.
Number completed: 4447 (see Inclusion criteria below*)
Participant (baseline) characteristics:
• Age at baseline: placebo (n = 2071): 52.1 ± 4.6, supplementation (n = 2376): 52.1 ± 4.5• Age at cognitive evaluation: placebo (n = 2071): 65.5 ± 4.6, supplementation (n = 2376): 65.5 ± 4.5• Male sex: placebo: 52.2% (n = 1080), supplementation: 51.7% (n = 1229)
*Inclusion criteria: Quote: "Of the 6850 participants in the SU.VI.MAX 2 study, for the current analysis
we selected participants who were 45–60 y old at baseline, had undergone a cognitive evaluation, and
had available baseline data for serum antioxidants, smoking status, and alcohol consumption."
Exclusion criteria: not reported
Interventions Intervention (n = 2376): daily vitamin C (120 mg), beta-carotene (6 mg), vitamin E (30 mg), selenium
(100 µg), and zinc (20 mg) in combination
Comparison (n = 2071): placebo
N.B. Intervention period was 8 years (1994-2002). Cognitive outcomes in SU.VI.MAX 2 were measured in
2007-9, a mean of 5.9 (± 0.4) years after the end of the intervention in both groups.
Outcomes Outcomes of interest in the review:
1. Episodic memory: RI-48 test
2. Executive function: category fluency
3. Speed of processing: time taken to complete the Delis-Kaplan trail-making test (TMT)
Notes Funding source: "Supported by the Agence Nationale de Recherche (no. ANR-05-PNRA- 010), Direction
Générale de la Santé (Ministry of Health), Mederic, Sodexo, Ipsen, the Mutuelle Générale de l’Education
Nationale (MGEN), and Pierre Fabre. Mederic and MGEN are French health insurance organizations that
are complementary to the national health insurance system. Ipsen and Pierre Fabre are private phar-
maceutical companies. They provided financial support for the overall implementation of the research
project. Sodexo, a catering company, provided financial support for several teamwork events with re-
searchers and study participants. Because French public research is independent, the sponsors were
not involved in the analysis or interpretation of the findings."
Declarations of interest: "None of the authors had a conflict of interest".
Treatment adherence: "At the end of the trial phase (2002), 84% of the participants reported having
taken at least three-fourths of the capsules independent of the allocated supplementation group".
Risk of bias
Bias Authors' judgement Support for judgement
Kesse-Guyot 2011  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Quote: “Random treatment allocation was performed by block-sequence gen-
eration stratified by sex and age group."
Comment: Should be adequate, since team included statisticians and comput-
ing staI who handled the data.
Allocation concealment
(selection bias)
Low risk Quote: “Randomization was concealed from subjects and all investigators ex-
cept for the few who were in charge of capsule labelling."
Comment: Should be adequate.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Capsules were prepared in 52 weekly packages of 7 capsules and de-
livered each year in a box labelled with the participant’s number and a 10-digit
lot number"
"..a matching placebo".
"The absence of an easy way to distinguish antioxidant from placebo capsules
was tested in a pilot study", "double-blind"
Comment: Blinding of participants and personnel seemed adequate.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “Once a possible event is suspected, all relevant records,...are collected
from the hospitals, laboratories, or institutions or from the participants by the
SU.VI.MAX medical investigators and are examined at the study coordinating
centre".
Comment: It was not reported if outcome assessment was blinded for adverse
events. However, the blinding should be adequate for cognitive function since
the patients and investigators were well blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: 1136 of 5583 (20%) of the eligible patients were not included in the
analysis because of missing cognitive data.
Selective reporting (re-
porting bias)
Unclear risk Comment: Cognitive outcomes were not mentioned in the protocol of the
main study.
Other bias High risk Participants in this study were those who responded to an invitation 6 years
after the end of the parent study. The authors described this subsample of the
original trial population as "more compliant and health conscious, as shown
by the comparison between included and excluded subjects." This may work
to reduce any difference between groups.
Kesse-Guyot 2011  (Continued)
 
 
Methods PREADVISE (Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial)
Ancillary study to SELECT (primary aim prevention of prostate cancer)
Began as a double-blind RCT in 2002, transformed into a cohort study from 2009-15
Randomised, double-blind, 2 x 2 factorial design
Participants Location: 130 SELECT clinical sites in the US, Canada and Puerto Rico
Recruitment: 7540 non-dementia men already enrolled in SELECT were recruited into PREADVISE be-
tween 2002 and 2008. 7338 had at least one follow-up visit. 4271 consented to continue annual tele-
Kryscio 2017 
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phone follow-up after the RCT was closed and supplements stopped in 2009/10. Of these, 3786 were
screened by telephone at least once.
Number randomised: 7540
Participant characteristics:
Age: Mean (SD) 67.5 (5.3) at PREADVISE baseline
Gender: all participants were male
Inclusion criteria: SELECT participants aged 62 years and over (age 60 years if black)
Exclusion criteria: dementia, active neurologic and/or neuropsychiatric conditions that affect cog-
nition, as well as history of serious head injury (> 30-minute loss of consciousness within the last five
years prior to enrolment) and substance abuse
Interventions Supplements were taken for 5.4 ± 1.2 years
2 x 2 factorial design: vitamin E 400 IU/day, selenium 200 mcg/day, placebo
Outcomes Dementia incidence was the primary outcome of PREADVISE.
It was determined by one of two methods. First tier screening was the Memory Impairment Screen
(MIS). A score ≤ 5/8 triggered a second tier screen which was the expanded Consortium to Establish a
Registry in Alzheimer's Disease (CERADe) battery during the RCT and the modified Telephone Interview
for Cognitive Status (TICSm) during the cohort study.
Method 1: Participants with T score ≤ 35 on CERADe or total score ≤ 35 on TICSm were encouraged to
obtain a memory work-up and share medical records with PREADVISE. Medical records were reviewed
by a team of 2-3 expert neurologists and 2-3 expert neuropsychologists to determine a consensus diag-
nosis.
Method 2: Participants who did not obtain a memory work-up were assessed by additional measures
collected during the study: AD8 Dementia Screening Interview, self-reported medical history, self-re-
ported medication use, and cognitive test scores including the MIS, CERAD T Score, NYU Paragraph De-
layed Recall, and TICSm. An AD8 ≥ 1 (at any time during follow-up) plus a self-reported dementia diag-
nosis, use of a memory enhancing prescription drug (i.e. donepezil, rivastigmine, galantamine, meman-
tine), or cognitive score ≥ 1.5 standard deviations below expected performance yielded a dementia di-
agnosis. The diagnosis date was assigned to the earliest event.
Notes "PREADVISE was ancillary to SELECT, a randomized controlled trial of the same antioxidant supple-
ments for preventing prostate cancer. SELECT closed in 2009 due to a futility analysis." "The RCT was
scheduled to continue supplements until 2012 but in September 2008, the SELECT Data and Safety
Monitoring Committee recommended that supplements be discontinued due to lack of efficacy on
prostate cancer incidence. Study sites closed over the next two years, during which time both PREAD-
VISE and SELECT transitioned into cohort studies. RCT participants were asked to continue in the co-
hort study .."
PREADVISE had intended to recruit 10,400 men to achieve 80% power to detect a hazard ratio of 0.6.
Power was reduced by under-recruitment, loss of sites and participants when RCT closed, and difficul-
ties with case ascertainment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Randomized". No details. Large multisite cancer prevention trial. Likely ade-
quate
Kryscio 2017  (Continued)
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Allocation concealment
(selection bias)
Low risk No details. Large multisite cancer prevention trial. Likely adequate
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk "Double-blind". No details. Likely adequate
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Double-blind". No details. Likely adequate
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk The transition from RCT to cohort study was associated with loss of approxi-
mately half the participants to follow-up. "Fortunately ... the major cost was
sample size (reduction in person-years of follow-up) since no new large selec-
tion biases were introduced."
"All PREADVISE participants who completed at least one follow-up visit were
included in the current analyses (intent-to-treat analysis, ITT), whether they
participated in just the RCT or both the RCT and cohort studies."
Selective reporting (re-
porting bias)
Low risk  
Other bias Low risk "... despite randomization occurring at SELECT baseline rather than PREAD-
VISE enrolment, there were no perceivable differences between study arms in
terms of medical history, APOE ɛ4 genotype, or initial MIS."
Kryscio 2017  (Continued)
 
 
Methods 2-arm, double-blinded, parallel group RCT, 4 months treatment and follow-up
Participants Location: one centre, Goteborg, Sweden
Recruitment: outpatient clinic
Number randomised: 126 in intervention, 69 in comparison.
Participant (baseline) characteristics in Vitamin (n = 126) and placebo (n = 69)
Age:
• vitamin 75.7 (± 4.7);• placebo 75.6 (± 4.0)• whole group (n = 209) mean age: 76 years and 5 months. Median 76 years (range 70-93)
Gender (males %):
• vitamin: 38% (48/126)• placebo: 44% (30/69)
Inclusion criteria: community-dwelling subjects. Inclusion criteria not reported
Exclusion criteria: quote: "Those who had taken any vitamin supplements during the last 3 months or
pharmacological doses of vitamin B12, folic acid and/or vitamin B6 during the last 3 years were not al-
lowed to enter the study".
Interventions Intervention (n = 126):
Lewerin 2005 
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Daily tablet containing 500 µg cyanocobalamin, 800 µg folic acid, and 3 mg vitamin B6 hydrochloride
(manufactured and supplied by Recip AB, Årsta, Sweden)
Comparator group (n = 69): daily oral placebo
The duration of treatment was 4 months.
Use of additional interventions (common to both treatment arms):
Use of cardiovascular medication:
• vitamin: 47%• placebo: 49%
Use of antiepileptics, neuroleptics, or antidepressants (%)
• vitamin: 22%• placebo: 23%
Outcomes Outcomes evaluated: postural-Locomotor-Manual test and cognitive tests
Postural-Locomotor-Manual test:
• Movement time• Postural phase• Locomotor phase• Manual phase• Simultaneity index
Cognitive tests:
• Digit span forward• Digit span backward• Identical forms• Visual reproduction• Synonyms• Block design• Digit symbol• Thurstone’s picture memory test• Figure classification
No clear distinction between primary and secondary outcomes
In Lewerin 2003, cognitive and functional tests not reported in the Methods
Cognitive testing was conducted by the same psychologist at baseline and after 4 months.
Follow-up: 4 months (measurements before and after treatment). Mean or median follow-up not re-
ported
Eligible cognitive outcomes:
• executive functioning measured with synonyms at 4 months, on a scale from not reported to 30 with
higher values indicating benefit*• episodic memory measured with Thurstone's picture memory test at 4 months, on a scale from not
reported to 28 with higher values indicating benefit• episodic memory measured with identical forms (Dureman 1959) at 4 months, on a scale from not
reported to 60 with higher values indicating benefit• episodic memory measured with Wechsler visual reproduction at 4 months, on a scale from not re-
ported to 14 with higher values indicating benefit*
Lewerin 2005  (Continued)
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• working memory measured with Wechsler digit span forward at 4 months, on a scale from not reported
to 9 with higher values indicating benefit• working memory measured with Wechsler digit span backward at 4 months, on a scale from not re-
ported to 8 with higher values indicating benefit*• speed of processing measured with Wechsler digit symbol at 4 months, on a scale from 0 to 90 with
higher values indicating benefit*• speed of processing measured with Thurstone's figure classification at 4 months, on a scale from not
reported to 30 with higher values indicating benefit
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
* outcome data used in statistical analyses
Notes Funding sources, quote: "Supported by grants from the Hjalmar Svensson Foundation, the Göteborg
Medical Society, the Medical Faculty at Göteborg University, the Wilhelm and Martina Lundgren Foun-
dation, and the Magnus Strandqvist Foundation. Recip AB supported the study and provided the vita-
min and placebo tablets".
Declarations of interest, quote: “None of the authors had a personal or financial conflict of interest
with respect to this study".
Treatment adherence: quote "To ensure compliance, all subjects received a specified blinded number
of tablets, and at the end of the study, the number of remaining tablets was compared with the initial
number and planned intake during the study".
Data on treatment adherence were not clearly reported in the results.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “Of these 195 subjects, 126 were randomly assigned to receive vitamin
therapy and 69 to receive placebo."
Comment: method of random sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Quote: “Of these 195 subjects, 126 were randomly assigned to receive vitamin
therapy and 69 to receive placebo."
Comment: method of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “and all subjects in the placebo group received an identical (other than
the vitamin content) placebo tablet. " To ensure compliance, all subjects re-
ceived a specified blinded number of tablets..."
"The tablet was identical in shape and composition to the placebo tablet apart
from the vitamin content"; "double-blind" study.
Comment: Both participants and physicians were apparently blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: “Cognitive testing was conducted by the same psychologist (GS) at
baseline and after 4 mo."
Comment: Blinding of outcome assessors was not reported.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "From flow diagram, 30/209 (14%) did not provide cognitive outcome
data."
Lewerin 2005  (Continued)
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Comment: no information about group allocation of excluded participants
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol not available
Other bias Low risk Comment: no other risks identified
Lewerin 2005  (Continued)
 
 
Methods 3-arm, parallel group, randomised, placebo-controlled trial with 6 months duration of treatment and
follow-up
Participants Location: Two centres (Coleraine, UK and Clermont-Ferrand, France) recruited younger participants
(55-70 years) and another two centres (Rome, Italy and Grenoble, France) recruited older participants
(70-87 years).
Recruitment: Participants were recruited through posters, leaflets, local television and radio, and
community groups and organizations serving older individuals living independently.
Sample size:
Number randomised: 201 younger participants (55-70 years), 232 older participants (70–87 years)
Number completed study with compliance > 80% and included in analysis: 188 younger, 199 older
Participant baseline characteristics (baseline characteristics provided only for study completers):
Age in years, mean (SD):
• 15 mg/d: younger 61.4 (4.55), older 74.3 (3.91)• 30 mg/d: younger 61.7 (4.57), older 74.6 (3.89)• placebo: younger 62.3 (4.09), older 74.2 (3.58)
Gender, males/females:
• 15 mg/d: younger 30/30, older 34 /32• 30 mg/d: younger 31/34, older 34 /32• placebo: younger 32/31, older 35 /32
Inclusion criteria:
1. men and women aged between 55 and 87 years;
2. BMI between 20 and 30 kg/m2
3. good health;
4. MMSE score greater than 23;
5. geriatric depression scale score less than 6.
Exclusion criteria:
“Participants were excluded from further involvement in the study according to the following criteria:
(l) tobacco consumption of more than 10 g/day; (2) alcohol consumption of more than 30 (men) or 20
(women) g/day; {3) unconventional dietary habits (for example, vegetarians, vegans); (4) use of a min-
eral supplement during the preceding 3 months; (5) use of more than three (55-70 years) or four (70-87
years) prescription drugs per day; (6) use of antidepressants, laxatives, or hormone replacement ther-
apy; (7) pathological diseases, including cancer and diabetes. For participants satisfying the inclusion
criteria, a biochemistry profile was performed, which included a full blood profile and tests of kidney
and liver function. On the basis of these data, participants were excluded if there was insufficient renal
and hepatic performance, malabsorption or inflammatory chronic pathologies, and were included if
there was negative serology for the HIV and hepatitis C viruses.”
Maylor 2006 
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Quote: “49 % of the initial 842 volunteers being excluded from the study at screening on the basis of
cognitive impairment, depression, pathological conditions, medications, and so on”.
Interventions Intervention
Intervention A: Zn supplementation as zinc gluconate 15 mg/day, two tablets at the same time each
day (usually after breakfast) for 6 months
Intervention B: Zn supplementation as zinc gluconate 30 mg/day, two tablets at the same time each
day (usually after breakfast) for 6 months
Comparator group: placebo/zinc gluconate 0 mg/day, two tablets at the same time each day (usually
after breakfast) for 6 months
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes: Cognitive measures (Cambridge Automated Neuropsychological Test Battery,
CANTAB)
Visual memory was tested by pattern recognition memory; working memory was tested by spatial span
and spatial working memory (SWM); and attention was tested by reaction time and matching to sample
visual search (MTS).
Quote: “Cognitive Function was assessed in the laboratory at baseline (before supplementation) and
after 3 and 6 months of supplementation, using different (parallel) versions of the CANTAB tests on
each occasion."
Secondary Outcomes: serum and urinary zinc
Quote: “Participants fasted overnight for 12h before blood and urine samples were taken on each of
these occasions to determine Zn levels.”
Notes Funding sources, quote: “European Commission 'Quality of Life and Management of Living Resources'
FiPh Framework Programme. contract no. QLKl-CT-2001-00168.”
Declarations of interest: not reported
Treatment adherence
“Compliance was less than 80% for three older participants and so they were also excluded.”
Outcome data were not reported separately for the Zinc and placebo groups
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Participants were assigned to one of three levels of Zn supplementa-
tion (placebo or 0 mg/d, 15 mg/d and 30 mg/d) according to the same stan-
dardised random order in each centre."
Comment: not described how sequence generation was done. The possibility
that this was quasi-randomised could not be ruled out.
Allocation concealment
(selection bias)
Unclear risk As above
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Quote: “…Zn supplementation (0, 15 or 30 mg/d) was administered as zinc glu-
conate, participants taking two tablets at the same time each day (usually af-
ter breakfast) for 6 months. (Tablets were identified by a code so that neither
the experimenter nor the participants knew the dose. The code was not bro-
ken until the study had been completed and all the data had been entered into
computer files ready for analysis)".
Maylor 2006  (Continued)
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Comment: Although a placebo was mentioned, there was no description of its
appearance or whether it could be distinguished from the zinc supplements.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Comment: as above. Unclear whether blinding was adequate
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: There was no description of the completeness of outcome data for
each main outcome, including attrition and exclusions from the analysis.
Selective reporting (re-
porting bias)
High risk Comment: CANTAB data for the different interventional groups was shown
graphically only. Number of participants for each outcome was not reported.
Other bias Unclear risk Baseline characteristics were shown only for participants who completed the
trial.
Maylor 2006  (Continued)
 
 
Methods 2-arms, placebo-controlled, randomised clinical trial with intervention of 2 years and follow-up dura-
tion of 2 years. No mean or median (range) follow-up reported.
Participants Location: Dunedin, New Zealand, number of centres involved unclear
Recruitment: Department of Human Nutrition, University of Otago
Number randomised: 138 in intervention, 138 in comparison
Participant (baseline) characteristics:
Age, years, mean (SD)
• placebo (n=126): 73.4 ± 5.7• vitamin (n=127): 73.6 ± 5.8
Female sex, n (%):
• placebo (n=126): 65 (52)• vitamin (n=127): 47 (37)
Inclusion criteria:· age of 65 years or older. Those with a fasting homocysteine concentration of at
least 13 µmol/L and a normal plasma creatinine concentration (133 µmol/L (1.5 mg/dL) in men and 115
µmol/L (1.3 mg/dL) in women) were invited to participate in the trial.
Exclusion criteria:
• ineligible if they had suspected dementia;• were taking medications known to interfere with folate metabolism (e.g. oral hypoglycaemic agents
or antiepileptic agents);• were taking vitamin supplements containing folic acid, vitamin B12, or vitamin B6;• were being treated for depression;• had diabetes or had a history of stroke or transient ischaemic attacks.
Quote: "Five participants (three in the placebo group and two in the vitamin group) had a baseline
MMSE score of less than 26."
Interventions Intervention (n=138):
McMahon 2006 
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Treatment capsules contained the filler plus 1000 μg of folate (the calcium salt of l-5-methyltetrahydro-
folate), 500 μg of vitamin B12 (cobalamin), and 10 mg of vitamin B6 (pyridoxine) (Merck Eprova).
Comparator group (n=133): placebo.
The placebo capsules contained a blend of magnesium stearate and microcrystalline cellulose as a
filler.
All capsules were gelatin-coated, identical in colour and shape, and packaged in blister packs.
Outcomes Primary outcomes: scores on tests of cognition including Mini–Mental State Examination, Wechsler
Paragraph Recall test, Category Word Fluency test, Rey Auditory Verbal Learning Test, trials I–V, Rey Au-
ditory Verbal Learning Test, trial VII, Raven’s Progressive Matrices, Controlled Oral Word Association
Test, Part B of the Reitan Trail Making Test, the National Adult Reading Test (at baseline).
Secondary Outcomes: biochemical measurements, including plasma concentrations of homocys-
teine, folate, and vitamin B12
Eligible cognitive outcomes:
• global cognitive function measured with MMSE at 1 and 2 years, with higher values indicating benefit• executive functioning measured with Raven's Progressive Matrices at 1 and 2 years, with higher values
indicating benefit• executive functioning measured with Part B of the Reitan Trail Making at 1 and 2 years, with lower
values indicating benefit• executive function measured with Category Word Fluency test (total no. of words generated in three
1-min tests) at 1 and 2 years, with higher values indicating benefit• episodic memory measured with Rey Auditory Verbal Learning, Trials I-V at 1 and 2 years, with higher
values indicating benefit*• episodic memory measured with Wechsler Paragraph Recall test at 1 and 2 years, with higher values
indicating benefit• episodic memory measured with Rey Auditory Verbal Learning, Trial VII at 1 and 2 years, with higher
values indicating benefit
Notes Funding sources: supported by an Otago Research Grant, Merck Eprova for providing the vitamin and
placebo capsules
Declarations of interest: No potential conflict of interest relevant to this article was reported.
Treatment adherence:
Compliance was assessed by counting returned capsules. Data on compliance were not reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Before randomization, all eligible participants were stratified ac-
cording to the median values for age and homocysteine concentration in the
screening population. Random decimals between 0 and 1 were generated for
each person in each of the four strata. Those below the median of the random
numbers in each stratum were assigned to the vitamin group, and the remain-
der were assigned to the placebo group."
Comment: adequate method of sequence generation
Allocation concealment
(selection bias)
Unclear risk Quote: "Random decimals between 0 and 1 were generated for each person
in each of the four strata. Those below the median of the random numbers in
each stratum were assigned to the vitamin group, and the remainder were as-
signed to the placebo group."
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Comment: unclear method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "We conducted a two-year, double-blind, placebo-controlled, random-
ized clinical trial".
"All capsules were gelatin-coated, identical in color and shape, and packaged
in blister packs."
Comment: Participants and personnel were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "One of the authors administered all the cognitive tests."
Comment: unclear whether outcome assessment was blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: < 10% of randomised patients were not included in the analysis.
Selective reporting (re-
porting bias)
Low risk Comment: All the primary and secondary outcomes mentioned in the Methods
and protocol were reported.
Other bias Low risk Comment: none identified
McMahon 2006  (Continued)
 
 
Methods 2 x 2 factorial randomised placebo-controlled study of antioxidant vitamins and simvastatin. Mean du-
ration of follow-up 5 years
Participants Location: 69 Hospitals in the UK
Recruitment: Medical collaborators from 69 UK hospitals appointed senior nurses to run special clinics
for the study. With the permission of their relevant consultant colleagues, records of patient discharges
and of special wards or clinics were used to identify potentially eligible candidates for the study. The
coordinating centre used this information to seek agreement, in the name of the local collaborator,
from general practitioners to invite patients to the local study clinic.
Sample size:
• Number randomised: 10,269 in intervention, 10,267 in comparison• Number completed: 10,241 in intervention, 10,228 in comparison
Participant (baseline) characteristics:
Inclusion criteria:
1. Male or female aged 40 to 80 years;
2. High risk of coronary heart disease death over the next 5 years:• (i) coronary disease: definite or probable clinical diagnosis of myocardial infarction, unstable angi-
na, stable angina, PTCA or CABG;• (ii) occlusive disease of non-coronary arteries: clinical, angiographic, or ultrasound diagnosis of
carotid artery stenosis (e.g. transient ischaemic attack or non-disabling stroke not thought to
be haemorrhagic), carotid endarterectomy, leg artery stenosis (e.g. intermittent claudication) or
surgery;• (iii) diabetes mellitus: clinical diagnosis of insulin-dependent or non-insulin-dependent diabetes;• or (iv) treated hypertension: use of antihypertensive drug therapy in male aged 65 years or over (in
order to be at sufficiently high risk of vascular events);
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3. No clear indications for the study treatments: the patient is not already taking HMG CoA reductase
inhibitors or high-dose vitamin E supplements, and neither the patient nor the patient’s doctor con-
siders there to be any definite need to do so;
4. No clear contraindications to the study treatments:• (i) baseline plasma cholesterol: < 3.5mmol.L-1;• (ii) chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. alanine transam-
inase > 1·5 x upper limit of normal);• (iii) severe renal disease or evidence of renal impairment (i.e. creatinine > 2 x upper limit of normal);• (iv) inflammatory muscle disease (such as dermatomyositis or polymyositis) or creatine kinase >
3 x upper limit of normal;• (v) concurrent treatment with cyclosporin (or a condition likely to result in organ transplantation
and the need for cyclosporin);• (vi) concurrent treatment with fibrates or high-dose niacin. (N.B. patients on cholesterol-lowering
diets or drugs — other than HMG CoA reductase inhibitors, fibrates or high-dose niacin — could still
be entered in the study);• or (vii) child-bearing potential (i.e. premenopausal woman who is not sterilised or using a reliable
method of contraception);
5. No other predominant medical problem:• (i) severe heart failure or some importantly life-threatening condition other than vascular disease
(such as very severe chronic airways disease or any cancer other than non-melanoma skin cancer);• (ii) psychiatric disorder, senility or physical disability (such as severely disabling stroke);• Or (iii) recent history of alcohol or drug abuse;
6. Eligible patients who completed a pre-randomisation run-in phase on active treatment were random-
ly allocated to receive simvastatin (40 mg daily) or matching placebo tablets and, in a ‘2 x 2 factorial’
design, antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or
matching placebo capsule.
Exclusion criteria:
People were ineligible if they had life-threatening conditions, such as chronic liver disease, severe re-
nal disease, severe heart failure, severe chronic airways disease, or diagnosed cancer (other than non-
melanoma skin cancer). Those taking high-dose vitamin E supplements were not randomised.
Interventions Intervention (n=10,241): 600 mg synthetic vitamin E, 250 mg vitamin C and 20 mg β-carotene adminis-
tered orally once per day for an average of 5 years
Comparator group (n=10,228): “Matching placebo in specially prepared calendar packs”
Use of additional interventions (common to both treatment arms): factorial design also included
simvastatin
Outcomes Outcomes of interest in the review:
Global cognitive function measured with TICSm
(The main comparisons for antioxidant vitamin supplementation were analyses of total coronary heart
disease events and of fatal coronary heart disease events during the scheduled treatment period. Cog-
nitive function was a secondary outcome. Quote: "It had been suggested that antioxidant vitamins (in
particular, vitamin E) might slow cognitive decline, so the modified Telephone Interview for Cognitive
Status (TICS-m) questionnaire was administered to participants during their final follow-up").
Notes Funding sources: “The study was funded by the UK Medical Research Council, the British Heart Foun-
dation, Merck & Co (manufacturers of simvastatin: J Tobert, R Tomiak, J Young, A Tate, E John, F Walk-
er, G Warner) and Roche Vitamins Ltd (manufacturers of the vitamins: R Salkeld, E Stöcklin, M Wahl).”
Declarations of interest: “P Sleight has received honoraria and costs for participating in meetings.”
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Treatment adherence: Compliance with study treatment was assessed at each follow-up by reviewing
the calendar packed capsules remaining and for those who had stopped, the reasons for doing so were
sought.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “The central telephone randomisation system used a minimisation al-
gorithm to balance the treatment groups with respect to eligibility criteria and
other major prognostic factors."
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Comment: "central telephone randomisation system"
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment: “identical tablets”
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: Outcome assessors at study centres not aware of treatment alloca-
tion.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment: Relatively low dropout rate and high number of participants com-
pleted follow-up at 5 years.
Selective reporting (re-
porting bias)
Low risk Comment: single cognitive outcome measure reported
Other bias Low risk Comment: no other risks identified
MRC/BHF 2002  (Continued)
 
 
Methods Women's Health Initiative Memory Study
Post hoc analysis of a 2-arm randomised double-blind placebo-controlled trial
Participants Location: US multicentre
Recruitment: Forty Women’s Health Initiative (WHI) clinical centres across the United States. Partici-
pants were enrolled between 1994 and 1999.
Number randomised: 2034 in intervention, 2109 in comparison
Participant (baseline) characteristics:
• Age: mean 71 years (65-80)* vitamin D/calcium: mean 70.7 years* placebo: mean 70.9 years• Gender: women 100%• Main diagnosis: postmenopausal women aged 65 and older without probable dementia or cognitive
impairment at baseline
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Inclusion criteria: women aged 65 and older without probable dementia or cognitive impairment at
baseline who participated in the WHI Calcium and Vitamin D Trial
Other inclusion criteria specified in the main study: Eligible women were 50 to 79 years of age at the ini-
tial screening and had no evidence of a medical condition associated with a predicted survival of less
than three years and no safety, adherence, or retention risks.
Exclusion criteria: diseases associated with significant risk of mortality (invasive cancer in the previ-
ous 10 years; any history of breast cancer or a suspicion of breast cancer at the time of screening; acute
myocardial infarction, stroke, or transient ischaemic attack in the previous 6 months; known chronic
active hepatitis or severe cirrhosis), safety (blood cell count indicative of disease, severe hypertension,
current use of oral corticosteroids), and adherence or retention (unwillingness or inability to complete
baseline study requirements)
Interventions Intervention (n=2034):
1000 mg of calcium carbonate and 400 IU of vitamin D3
Two tablets per day in divided doses and with meals
Comparator group (n=2109): placebo
Two tablets per day in divided doses and with meals
Supplements or placebo were provided by GlaxoSmithKline.
Active tablets, chewable or swallowable (after July 1997), contained 500 mg of elemental calcium (as
calcium carbonate) and 200 IU of vitamin D.
Use of additional interventions (common to both treatment arms):
Use of personal supplemental calcium up to 1000 mg/day and vitamin D up to 600 IU/day in addition to
the study tablets was allowed.
Calcium supplement use, n (%):
• vitamin D/calcium: 1061 (52.2)• placebo 1196 (56.7)
Vitamin D supplement use, n (%):
• vitamin D/calcium: 929 (45.7)• placebo 1047 (49.6)
See also Notes below
Outcomes Outcomes of interest to the review:
Quote: "The Women's Health Initiative Calcium and Vitamin D trial (CaD) was designed to determine
whether calcium plus vitamin D3 supplementation prevents hip fracture and colorectal cancer".
WHIMS (the Women's Health Initiative Memory Study) was an ancillary study.
Primary outcomes of WHIMS: classifications of probable dementia, mild cognitive impairment and
cognitively normal
Quote: "A diagnosis of dementia was based on Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, criteria."
Quote: "A diagnosis of MCI was based on accepted criteria at the time of WHIMS initiation, operational-
ly defined as performance in the 10th or lower percentile on at least one Consortium to Establish a Reg-
istry for Alzheimer’s Disease (CERAD) test based on CERAD norms, a report from the designated infor-
mant of functional impairment on the part of the participant that was not severe enough to interfere
Rossom 2012  (Continued)
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with basic activities of daily living, no evidence of a psychiatric or medical condition that could account
for the cognitive decline, and absence of adjudicated dementia."
Secondary outcomes: global cognitive function as assessed annually using the Modified Mini Mental
State Examination (3MS) and domain-specific cognitive functions as assessed annually in a subset of
1420 CaD participants using the WHISCA cognitive battery
The WHISCA cognitive battery included the Digit Span Forward and Backward Test, the Primary Mental
Abilities Vocabulary test, the Card Rotations Test, letter and semantic fluency tests, the California Ver-
bal Learning Test, the Benton Visual Retention Test, and the Finger Tapping Test.
Depressive symptoms were measured using the Burnham screening algorithm.
Probable dementia or MCI were assessed during a mean follow-up of 7.8 years.
Domain-specific measures of cognitive function were obtained in the 1420 women enrolled in the CaD
trial and WHISCA seen for an average of 4.9 (treatment) and 5.0 (placebo) annual visits through 2007.
Eligible cognitive outcomes:
• global cognitive function measured with Modified MMSE (3MS)• episodic memory measured with Benton Visual Retention Test• episodic memory measured with California Verbal Learning Test• speed of processing measured with finger tapping• executive function measured with letter and category fluency at 5 years
Notes "All WHIMS participants ... were also participants in the WHI Hormone Therapy trials. Some were also
participants in a third trial of dietary modification to compare a low-fat eating pattern to a usual ad-li-
bitum diet."
Funding sources, quote: "The WHI program is funded by the National Heart, Lung, and Blood Insti-
tute, National Institutes of Health, U.S. Department of Health and Human Services through Contracts
N01WH22110, 24152, 32100–2, 32105–6, 32108–9, 32111–13, 32115, 32118–32119, 32122, 42107–26,
42129–32, and 44221."
"Sponsor’s Role: The sponsors did not play any role in the design or conduct of the study; collection,
management, analysis, or interpretation of the data; or preparation, review, or approval of the manu-
script".
Declarations of interest, quote: "Dr. Rossom’s work on this manuscript was supported in part by
the Veterans Health Administration through Clinical and Health Services Research and Development
Grants 04SCRCOE-001 and HFP-98–001. Dr. JoAnn Manson and colleagues at Brigham and Women’s
Hospital, Harvard Medical School, are recipients of funding from the National Institutes of Health to
conduct the VITamin D and OmegA-3 TriaL, a large-scale randomized trial of vitamin D and omega-3s in
the prevention of cancer and cardiovascular disease".
Treatment adherence
"Adherence was assessed annually in a structured interview and by weighing remaining pills."
Adherence (defined as ≥ 80%):
• vitamin D/calcium: 1446 (72.3%)• placebo: 1566 (75.5%)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Eligible women were randomly assigned in a double-blind fashion to
receive supplements or placebo (provided by GlaxoSmithKline) in equal pro-
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portions with use of a permuted-block algorithm stratified according to clini-
cal center and age".
Comment: method of random sequence generation not reported, probably ad-
equate
Allocation concealment
(selection bias)
Unclear risk Quote: “Eligible women were randomly assigned in a double-blind fashion to
receive supplements or placebo (provided by GlaxoSmithKline) in equal pro-
portions with use of a permuted-block algorithm stratified according to clini-
cal center and age".
Comment: method of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “1,000 mg of calcium carbonate and 400 IU of vitamin D or identical
placebos." , “Eligible women were randomly assigned in a double-blind fash-
ion".
Comment: Participants and personnel were apparently blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “A central adjudication panel of experts at the WHIMS Clinical Coor-
dinating Center (Wake Forest School of Medicine, Winston-Salem, NC) made
classifications."
Comment: not reported but assessors were probably blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: “All primary outcomes were analyzed on a time to-event basis accord-
ing to the intention-to-treat principle."
Comment: All patients included in the post hoc analysis were considered for
the main outcome whereas only a subset was analysed for cognitive tests.
Selective reporting (re-
porting bias)
Low risk Comment: All outcomes described in the methods or protocol (ClinicalTrial-
s.gov number, NCT00000611) were reported in the results.
Other bias Low risk No other risks identified
Rossom 2012  (Continued)
 
 
Methods 2 x 2 factorial placebo-controlled randomised trial
Participants Location: UK multicentre
Recruitment: potentially eligible patients identified from hospital discharge records of 88 UK hospi-
tals. Randomisation took place between September 1998 and October 2001.
Number randomised: 6033 B vitamins, 6031 placebo
Participant (baseline) characteristics:
• Age: mean age 64.2 (8.9) years* B vitamins: 1885 < 60y; 2414 ≥ 60y and < 70y; 1734 ≥ 70y* placebo: 1880 < 60y; 2414 ≥ 60y and < 70y; 1737 ≥ 70y• Gender:* B vitamins: 83% male* placebo: 83% male• Main diagnosis: myocardial infarction
Inclusion criteria: aged 18-80 years, myocardial infarction > 3 months before screening, taking a statin
or clear indication for statin therapy
SEARCH 2010 
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Exclusion criteria: clear indication for folic acid, contraindications to study treatments, other predom-
inant medical problem which might limit compliance with 5 years of study treatment
Interventions Participants randomised in 2 x 2 factorial design to (folic acid 2mg + vitamin B12 1mg) or placebo and
to simvastatin 20 mg or 80 mg
Outcomes Outcomes relevant to this review: TICSm, verbal fluency test, diagnosis of dementia. All cognitive out-
comes measured at final follow-up, after a mean of 6.7 (1.5) person-years.
Notes "The study was funded by Merck (manufacturers of simvastatin and suppliers of the vitamins)." "The
funders had no role in the design and conduct of the study; collection, management, analysis and inter-
pretation of the data; and preparation, review and approval of the manuscript."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The central telephone randomization system used a minimization al-
gorithm to balance the treatment groups with respect to major prognostic fac-
tors".
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: "central telephone randomisation system"
Comment: adequate method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk Comment: no information regarding participants and personnel blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All such information is reviewed by coordinating center clinical staI,
blind to study treatment allocation, and events are coded according to pre-
specified criteria".
Comment: outcome assessors were blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: For 3173/12064 (26%) of the eligible patients, TICSm was not avail-
able.
Selective reporting (re-
porting bias)
Low risk Comment: no cognitive outcomes were included in the original protocol pub-
lished in 1998. Additional information was obtained from the authors: "The
cognitive assessment was added during the study (before any unblinding) and
included in the Data Anaysis Plan but had not been specified in the original
Protocol." We considered there to be a low risk of this introducing any bias.
Other bias Low risk Comment: no other risks identified
SEARCH 2010  (Continued)
 
 
Methods Factorial 2 X 2 x 2, randomised, placebo-controlled, double-blind study with 3 active treatments with
12-week treatment and 1-year follow-up
Participants Location: United Kingdom and the Netherlands, 2 centres
Stott 2005 
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Recruitment: hospital-based
Number randomised: 185
Participant (baseline) characteristics:
• Age, mean ± SD:* placebo: 72.8 ± 5.4* folic acid plus vitamin B12: 72.9 ± 6.0* riboflavin (vitamin B2): 74.6 ± 5.3* vitamin B6: 74.7 ± 6.1* folic acid plus vitamin B12 plus vitamin B2: 76.5 ± 8.0* folic acid plus vitamin B12 plus vitamin B6: 72.6 ± 6.4* vitamin B6 plus vitamin B2: 74.2 ± 6.8* folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 74.0 ± 6.5• Gender (male/female):* placebo: 14/10* folic acid plus vitamin B12: 12/11* riboflavin (vitamin B2): 10/13* vitamin B6: 11/12* folic acid plus vitamin B12 plus vitamin B2: 10/13* folic acid plus vitamin B12 plus vitamin B6: 12/11* vitamin B6 plus vitamin B2: 10/13* folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 9/14• · Main diagnosis: patients aged "65 y with ischemic vascular disease"
Inclusion criteria: age ≥ 65 y and Ischaemic vascular disease, defined as one or more of the following:
history of angina pectoris, previous acute myocardial infarction, evidence of major ischaemia or pre-
vious acute myocardial infarction on the basis of a 12-lead electrocardiogram, ischaemic stroke, tran-
sient ischaemic attack, intermittent claudication, or surgery for peripheral arterial disease
Exclusion criteria: acute vascular event < 1 wk previously; major surgery < 1 mo previously; any oth-
er major acute illness < 1 mo previously; severe renal impairment (serum creatinine > 400 µmol/L); se-
vere hepatic impairment; malignancy within the previous year (excluding local skin cancer); severe
congestive heart failure (New York Heart Association class IV); total anterior cerebral infarct with major
residual disability; malabsorption; inability to give informed consent (e.g. due to dementia or dyspha-
sia); major cognitive impairment (Mini-Mental State Examination score < 19); existing treatment with ri-
boflavin, vitamin B6, vitamin B12, or folic acid preparations; haemoglobin concentration < 10 g/dL; and
mean cell volume > 100 fL plus either a low red blood cell folate concentration (< 280 ng/mL) or a low
serum vitamin B12 concentration (< 250 pg/mL)
Interventions Intervention:
Folic acid 2.5 mg plus vitamin B12 400 mcg; vitamin B6 25 mg; riboflavin (vitamin B2) 25 mg; placebo in
a 2 x 2 x 2 factorial design
1. folic acid plus vitamin B12: 23
2. vitamin B6: 23
3. riboflavin (vitamin B2): 23
4. folic acid plus vitamin B12 plus vitamin B2: 23
5. folic acid plus vitamin B12 plus vitamin B6: 23
6. vitamin B6 plus vitamin B2: 23
7. folic acid plus vitamin B12 plus vitamin B2 plus vitamin B6: 23
Comparator: placebo: 24
Intervention or placebo were continued for 12 weeks. The daily dose was provided in a total of 2 cap-
sules (1 red and 1 white), irrespective of patient group.
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Quote: "The patients initially entered a single-blind, placebo, run-in phase lasting between 2 and 4
weeks. Patients who successfully completed the run-in phase were randomly allocated".
Use of additional interventions (common to both treatment arms): not reported
Outcomes Overall cognitive function was assessed by using the Telephone Interview for Cognitive status (TICSm)
at both baseline visits and at 6 and 12 months; attention and speed of information processing were as-
sessed by using the Letter Digit Coding Test (at both baseline visits and 12 months).
Serious adverse events, including incident vascular events, were recorded at each review.
Notes Funding sources, quote: “Supported by a grant from the Healthcare Foundation (reference 112/57)."
Declarations of interest, quote: “None of the authors had any conflicting or competing interests, and
the funder of the study had no role in data collection, analysis, or interpretation of the data or in the
writing of the report."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Allocation was determined at a site remote from the clinical study
(Robertson Centre for Biostatistics) in randomized permuted blocks of 8, strat-
ified by hospital center."
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: “Allocation was determined at a site remote from the clinical study
(Robertson Centre for Biostatistics) in randomized permuted blocks of 8, strat-
ified by hospital center."
Comment: adequate method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “Treatment allocation was concealed from the patients and the investi-
gators (double-blind)."
Comment: adequate method of participants and personnel blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “Treatment allocation was concealed from the patients and the investi-
gators (double-blind)."
Comment: adequate method of outcome assessment blinding
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment: Numbers of participants missing outcome data calculated from ta-
bles. 18/185 (10%) missing data for TICSm at 1 year. 39/185 (21%) missing da-
ta for LDCT at 1 year. Dropouts not mentioned in paper. No reasons for missing
data given. Presumed completers analysis.
Selective reporting (re-
porting bias)
High risk Quote: from ISRCTN registry “Retrospectively registered”
“Primary outcome measures:
1. Serum HCY, plasma von Willebrand factor, vitamin levels (red cell folate,
serum vitamin B12, B2, and B6)
2. Piloting of telephone follow-up of cognition (Telephone Interview for Cogni-
tive Status (TICSm)) and of disability (Barthel Index and short Instrumental Ac-
tivities for Daily Living (ADL) scale). Secondary outcome measures: not provid-
ed at time of registration."
Comment: Disability and IADL (relevant to this review) not reported in paper.
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Other bias Low risk Comment: no other risks identified
Stott 2005  (Continued)
 
 
Methods 2-arm, parallel group, double-blind, randomised controlled trial (the Vitamin Intervention for Stroke
Prevention (VISP) Trial)
Participants Location: 56 centres in USA, Canada and Scotland
Recruitment: university-affiliated hospitals, community hospitals, private neurology practices, and
Veterans Affairs medical centres
Number randomised: 3680 (1853 in low-dose vitamin group, 1827 in high-dose vitamin group)
Participant (baseline) characteristics:
• Age, mean (SD):* low-dose: 66.2 (10.8)* high-dose: 66.4 (10.8)• Gender:* low-dose: 37.2% female* high-dose: 37.7% female• Baseline cognitive function, MMSE mean (SD):* low-dose: 26.9 (3.3)* high-dose: 26.9 (3.4)
Inclusion criteria: non-disabling ischaemic stroke (Modified Rankin Stroke Scale ≤ 3) with onset ≤ 120
days before randomisation; total homocysteine level ≥ 25th percentile for North American stroke popu-
lation; age ≥ 35 years, compliance ≥ 75% with low-dose vitamins for 1 month before randomisation
Exclusion criteria: potential sources of emboli, other major neurological illness, life expectancy < 2
years, untreated anaemia or untreated B12 deficiency, systolic blood pressure > 185 mmHg or diastolic
blood pressure > 105 mmHg, refractor depression, severe cognitive impairment, alcoholism or other
substance abuse, use within 30 days of medications that affect total homocysteine level, childbearing
potential, participation in another trial with active intervention, general anaesthesia or hospital stay of
≥ 3 days, invasive cardiac or carotid procedures within 30 days of randomisation
Interventions Intervention (n=1827)
High-dose multivitamin formulation contained the reference daily intakes recommended by the US
Food and Drug Administration for vitamins except for its content of folic acid, vitamin B6 and vitamin
B12. Folic acid 2.5 mg, vitamin B6 25 mg, vitamin B12 0.4 mg.
Comparator (n=1853)
Low-dose multivitamin formulation contained the reference daily intakes recommended by the US
Food and Drug Administration for vitamins (contained folic acid 20 μg, vitamin B6 0.2 mg, vitamin B12 6
μg)
Outcomes Outcomes relevant to review:
mean MMSE at 1-year follow-up
Notes "All eligible participants were given the low-dose vitamin formulation for 1 month to determine compli-
ance, assessed by pill counts. Only persons taking at least 75% of the vitamins during the run-in phase
were eligible to be randomized."
Risk of bias
Toole 2004 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Participants were randomized to the high-dose or low-dose vitamin
groups within strata defined by clinic, sex and age (≥ 70 years, < 70 years). Per-
muted block randomization (with block size randomly selected as 4 or 6) was
used."
Allocation concealment
(selection bias)
Low risk Quote: "The allocation of participants was programmed by the statistical co-
ordinating center, encrypted, and entered into a data entry program installed
on a study computer at each site. After computer verification that all eligibility
criteria had been met, participants were randomly assigned 1 of 20 medication
codes. Allocation information was accessible only to the drug distribution cen-
ter, which bottled and distributed the vitamins to clinics, and to selected coor-
dinating center personnel who could assist with randomization in case of com-
puter failure."
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Both pill formulations were manufactured (Magno-Humphries Labora-
tories, Tigard, Ore) to be indistinguishable by external colour, weight or disso-
lution in water. No request was ever made to break the blind."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Both pill formulations were manufactured (Magno-Humphries Labora-
tories, Tigard, Ore) to be indistinguishable by external colour, weight or disso-
lution in water. No request was ever made to break the blind." No information
specifically on site investigators. Blind probably maintained.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Mean MMSE score available for 3097/3680 (84.2%) participants at 1-year fol-
low-up. No information on missing participants, including group allocation.
Selective reporting (re-
porting bias)
High risk Protocol-specified MMSE at 24 months not reported. Number of participants
with MMSE score in each treatment group at 12 months not reported.
Other bias Low risk No other risks identified
Toole 2004  (Continued)
 
 
Methods Multicentre, double-blind, randomised, placebo-controlled trial, with 2-year duration of treatment and
2-year duration of follow-up
Participants Location: 3 research centres in the Netherlands: VU University Medical Center (Amsterdam), Erasmus
Medical Center (Rotterdam), and Wageningen University (WU, Wageningen)
Recruitment: Dutch elderly men and women who participated in the B-PROOF (B-Vitamins for the Pre-
vention of Osteoporotic Fractures) study which assessed the efficacy of oral supplementation with 400
µg folic acid and 500 µg vitamin B in the prevention of fractures, with cognitive performance as sec-
ondary outcome.
Most participants were recruited via registries of municipalities in surroundings of the research centres.
The study was conducted between October 2008 and March 2013.
Number randomised: 1516 in intervention, 1511 in comparison
Participant (baseline) characteristics:
Van der Zwaluw 2014 
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• Age (mean, SD):* total population (n=2919): 74.1 years (6.5)* cognitive sub-sample (n=856):□ B vitamin (n=425): 72.6 years (5.7)□ placebo (n=431): 72.6 years (5.8)• Gender (males, n %):* total population (n=2919): 1459 (50)* cognitive sub-sample (n=856):□ B vitamin (n=425): 244 (57)□ placebo (n=431): 255 (59)• Main diagnosis: not reported
Inclusion criteria: age 65 years or older, having an elevated plasma homocysteine level (12–50 µmol/
L), being competent to make own decisions, and having a compliant tablet intake (≥ 85%) in the run-in
period
Exclusion criteria: cancer diagnosis within the last 5 years except for basal cell carcinoma and squa-
mous cell carcinoma, bedridden, serum creatinine level > 150 µmol/L, current or recent (< 4 months)
use of intramuscular injections of vitamin B12 or folic acid supplementations (> 300 µmol), and partici-
pation in other intervention studies
6% of the study population had a MMSE < 25.
Interventions Intervention (n=1516):
B vitamin group: 400 µg folic acid and 500 µg vitamin B12 daily
Comparator group (n=1511): placebo.
Treatment was continued for 2 years.
Use of additional interventions (common to both treatment arms): Both tablets contained 15 µg
(600 IU) vitamin D3.
Outcomes Outcomes of interest in review:
Quote: "The primary goal of the B-PROOF study was [to] assess the efficacy of oral supplementation
with folic acid and vitamin B12 in the prevention of fractures, with cognitive performance as a sec-
ondary outcome."
The 'primary' outcome of the cognitive study was "the difference between treatment groups in perfor-
mance on episodic memory after 2 years of supplementation."
'Secondary' cognitive outcomes were "differences in performance at follow-up on attention and work-
ing memory, information processing speed, executive function, and single test scores."
Quote: "Cognitive performance was assessed at baseline and at the end of the intervention period by
well-trained research assistants following a standard protocol. We used the MiniMental State Exami-
nation (MMSE) and an extensive, sensitive, and validated neuropsychological test battery" ..that "con-
sisted of the Rey Auditory Verbal Learning Test (RAVLT), Digit Span forward and backward, Trail Making
Test (TMT) parts A and B, Stroop Color-Word Test, Symbol Digit Modalities Test, and Letter Fluency (3
letters)".
Quote: "To compare results of the individual cognitive tests and to limit the number of dependent vari-
ables, crude test scores were clustered into compound scores for the 4 neuropsychological domains".
"For all 4 cognitive domains, predefined interaction terms of treatment with sex, baseline age (< 80, ≥
80 years), plasma HCY (< 14.4, ≥ 14.4 µmol/L), and APOE genotype (APOE e4 or not) were tested".
Cognitive outcomes:
• global cognitive function measured with MMSE at 2 years, with higher values indicating benefit
Van der Zwaluw 2014  (Continued)
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
98
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
• executive functioning measured with Trial making test (part B/partA) at 2 years, with lower values
indicating benefit• executive functioning measured with Stroop Interference (part 3 - (part 1 + part 2/2/)) at 2 years, with
lower values indicating benefit• working memory measured with Digit span backward at 2 years, with higher values indicating benefit• working memory measured with Digit span forward at 2 years, with higher values indicating benefit• episodic memory measured with RAVLT-Decay (delayed recall trial 5) at 2 years, with higher values
indicating benefit• episodic memory measured with RAVLT- trials I-V, immediate Recall max 75 words at 2 years, with
higher values indicating benefit• episodic memory measured with RAVLT- trial 9 Recognition max 30 words at 2 years, with higher values
indicating benefit• speed of processing measured with Trail making part A at 2 years, with lower values indicating benefit• speed of processing measured with Stroop 1 and 2 mean at 2 years, with lower values indicating ben-
efit• speed of processing measured with Symbol digit modalities test at 2 years, with higher values indi-
cating benefit• verbal fluency measured with Verbal Fluency - total no at 2 years, with higher values indicating benefit
Notes Funding sources, quote: “B-PROOF was supported and funded by The Netherlands Organization for
Health Research and Development (ZonMw, grant 6130.0031), the Hague; unrestricted grant from
NZO (Dutch Dairy Association), Zoetermeer; MCO Health, Almere; NCHA (Netherlands Consortium
Healthy Ageing) Leiden/Rotterdam; Ministry of Economic Affairs, Agriculture and Innovation (project
KB-15-004-003), the Hague; Wageningen University, Wageningen; VU University Medical Center, Ams-
terdam; and Erasmus Medical Center, Rotterdam. All organizations are based in the Netherlands. The
sponsors had no role in the design or implementation of the study, data collection, data management,
data analysis, data interpretation, or in the preparation, review, or approval of the manuscript."
Declarations of interest, quote: “The authors report no disclosures relevant to the manuscript."
Treatment adherence
"Average compliance to treatment was 90%, and 84% of all participants had an overall compliance ≥
80%. Compliance was equal for both treatment groups".
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomization was done by an independent person by means of com-
puter-generated randomization numbers in stratified permuted blocks of size
4, stratified by study center, sex, age (65–79 years, ≥ 80 years), and HCY levels
(12–17 mmol, ≥ 18 mmol)".
Comment: computer-generated sequence
Allocation concealment
(selection bias)
Low risk Quote: “Randomization was done by an independent person".
Comment: allocation probably concealed
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “Participants and employees of the study were blinded until data
analyses were finished."
Comment: participants and personnel blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “Participants and employees of the study were blinded until data
analyses were finished."
Comment: outcome assessors blinded
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Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: from CONSORT flow diagram, 22-24% attrition from each group
Comment: significant loss of participants, but reasons given and appeared bal-
anced between groups
Selective reporting (re-
porting bias)
Low risk Comment: No differences identified in the outcomes reported in the protocol
(clinicaltrials.gov: NCT00696514) and the article. All outcomes specified in the
Methods were reported in the Results.
Other bias Low risk Comment: no other apparent sources of bias
Van der Zwaluw 2014  (Continued)
 
 
Methods 2 x 2 x 2 factorial design, parallel group, double-blinded, multicentre, duration of treatment 24 months,
duration of follow-up 24 months
Participants Location: Australia. 3 sites: 2 urban and 1 rural
Recruitment: The population-based sample was recruited by a direct mailing of a screening survey
and consent form to 105,000 randomly selected adults aged from 60 to 74 years.
Number randomised: 453 in intervention, 456 in comparison
Participant (baseline) characteristics:
• Age, mean (±SD):* overall: 65.94 ± 4.24* folic acid-vitamin B12: 65.92 ± 4.30* placebo: 65.97 ± 4.18• Gender, male, n (%):* overall: 358 (39.8)* folic acid-vitamin B12: 181 (40.5)* placebo: 177 (39.1)• Main diagnosis: elevated psychological distress (Kessler Distress 10 Scale > 15)
Inclusion criteria: cohort of community-dwelling older 60–74 y adults with elevated psychological dis-
tress (Kessler Distress 10–Scale; scores > 15); did not engage in physical activity at public health–rec-
ommended levels as indicated by International Physical Activity Questionnaire scores; did not take folic
acid, vitamin B12, or vitamin B complex supplements; had no history of dementia, bipolar disorder,
or current suicide risk; had competent literacy skills; and did not have a medical condition that would
contraindicate exercise or folic acid use
Exclusion criteria: High likelihood of a depressive disorder with K10 scores of ≥ 30 were excluded.
Those individuals with low concentrations of red blood cell folate (< 250 nmol/L) and vitamin B12 (<130
nmol/L), and abnormal thyroid stimulating hormone concentrations (0.35-5.0 mU/L) were excluded be-
cause participation may have led to potentially adverse outcomes.
Interventions Intervention:
1) Daily oral dose of one tablet consisting of 400 µg folic acid + 100 µg vitamin B12 supplementation
(Matchland Pty Ltd, t/a New Products Development –ABN57052101176, Brisbane, Australia) for 24
months
The protocol changed to 2 daily oral doses (200 µg folic acid + 50 µg vitamin B12 each) from July 2007.
Comparator group:
Drug: placebo.
Walker 2012 
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Placebo tablets were manufactured by the same producers of the folic acid + vitamin B12 tablets and
were identical except for the omission of the active substances under investigation.
Use of additional interventions (common to both treatment arms):
Due to the factorial design, in both vitamin and placebo groups, approximately half the participants re-
ceived an intervention to promote physical activity and approximately half info about nutrition for old-
er adults; and approximately half received a mental health literacy intervention and approximately half
received arthritis and pain management info.
Outcomes Outcomes of interest in the review:
Primary outcomes:
• TICSm total score
Secondary outcomes:
• TICSm subscores: 1) orientation; 2) registration, recent memory, and delayed recall (immediate and
delayed recall reported separately); 3) attention/calculation; and 4) semantic memory, comprehen-
sion, and repetition• Processing speed measured with BTACT• IQCODE
Notes Funding sources, quote:“Supported by beyond blue: the national depression initiative and the Aus-
tralian Government Department of Health and Ageing. HC was supported by a National Health and
Medical Research Council (NHMRC) fellowship no. 525411. JGW was supported by NHMRC Capacity
Building Grant 418020".
"The sponsors had no role in the design and conduct of the study; collection, management, analysis,
and interpretation of the data; or preparation, review, or approval of the manuscript."
Declarations of interest, quote: “None of the authors had any conflicts of interest."
Treatment adherence
"Adherence was monitored by telephone assessment at 14 time points and by blood assay at baseline
and at 12- and 24-mo assessments."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomisation followed the screening assessment with block size
fixed at eight and using strata comprising location, gender and high (19) and
low (16–18) K10 depression scores (conducted by A.J.M.) using an automated
computerised system."
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: “using an automated computerised system".
Comment: adequate method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “Participants, interviewers, investigators and the survey administrators
were masked to active intervention and folic placebo (sic) allocation.”
Comment: Participants and personnel were blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: “Participants, interviewers, investigators and the survey administrators
were masked to active intervention and folic placebo (sic) allocation.”
Walker 2012  (Continued)
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Comment: Outcome evaluators were blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote: "Of those who were recruited into the trial, the dropout rate was low,
with only 123 (13.5%) participants withdrawing from the time of randomisa-
tion to the 24-mo assessment”.
Comment: Reasons for withdrawal balanced across groups
Selective reporting (re-
porting bias)
High risk Comment: All cognitive results were reported, but not all were reported in suf-
ficient detail for inclusion. Results of this study were therefore missing from
some analyses.
Other bias Low risk Comment: no other important risks identified
Walker 2012  (Continued)
 
 
Methods 2-arm, parallel group, placebo controlled, double-blind RCT. Duration of treatment 6 months, duration
of follow-up 6 months
Participants Location: Germany, single centre
Recruitment: recruited by newspaper advertisement in Hannover region. Institute of Food Science,
University of Hanover
Number randomised: not reported. Baseline measures were taken from 241 women. Data are report-
ed for 220 who completed the study.
Participant (baseline) characteristics (provided for those who completed):
• Age, median (5th-95th percentile)* overall: 63 years (60-74)* vitamin: 63 years (60-74)* placebo: 64 years (60-75)• Gender: female 100%• Main diagnosis: healthy volunteers
Inclusion criteria: healthy females 60 years or older; no vitamin supplementation for two months be-
fore intervention; no medications that affect vitamin absorption on status at the time of enrolment
Exclusion criteria: not reported
Interventions Intervention (n=111):
Vitamin capsule (Nobilin Q10) contained 150 mg vitamin C (calcium ascorbate), 50 mg magnesium
(magnesium carbonate), 36 mg vitamin E (D- alfa-tocopherol acetate), 34 mg niacin (nicotinamide), 16
mg pantothenic acid, 9 mg ß-carotene, 3.4 mg pyridoxine (pyridoxine hydrochloride), 3.2 mg riboflavin,
2.4 mg thiamine (thiamine mononitrate), 400 µg folic acid (pteroyl glutamic acid), 200 µg biotin, 60 µg
selenium (selenium-enriched yeast), and 9 µg cobalamin (cyanocobalamin).
One capsule/day at breakfast for 6 months
Comparator group (n=109): placebo
One capsule/day at breakfast for 6 months
Use of additional interventions: 4.5% women received statin medication.
Outcomes Primary Outcomes:
Wolters 2005 
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Wechsler Adult Intelligence Scale-Revised (WAIS III)
Intelligence assessed by the Kurztest fuer Allgemeine Intelligenz (KAI)
Mild up to severe memory disorders assessed by a subtest of the Berliner Amnesie Test (BAT)
Secondary outcomes: levels of homocysteine and methylmalonic acid at baseline and end of treat-
ment
Eligible cognitive outcomes:
• episodic memory measured with Pattern recognition subtest of Berliner Amnesie Test (BAT) (higher
values indicate benefit)• speed of processing measured with WAIS-III revised symbol search test (higher values indicate benefit)
Function outcome extracted: none reported
Quality of life outcome extracted: none reported
Safety outcome extracted: none reported
*: outcome data included in statistical analyses
Notes Funding sources: Medicom Pharma. Vitamin capsules (Nobilin Q10R) and placebo capsules were do-
nated by Medicom Pharma AG, Springe (Germany).
Declarations of interest: no information provided
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Of these, 109 women had been randomly assigned to the placebo
group and 111 women to the vitamin group by a lottery."
Comment: unclear method of sequence generation
Allocation concealment
(selection bias)
Unclear risk Quote: "Of these, 109 women had been randomly assigned to the placebo
group and 111 women to the vitamin group by a lottery."
Comment: unclear method of allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: "Both capsules, the multivitamin and the placebo, were soP gelatine
capsules filled with soy oil. The oil in the placebo capsule was colored for iden-
tical appearance."
Comment: probably blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "The cognitive tests were performed on the day of blood sampling after
the women had had breakfast."
Comment: blinding of outcome assessment not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk 8.7% (21/241 assessed at baseline) dropped out, but it is unclear from which
group. Two participants were excluded by the experimenters for non-compli-
ance. The total number of patients randomised was unclear. Only completers'
data reported
Selective reporting (re-
porting bias)
Low risk All primary and secondary outcomes specified in the Methods were reported.
Wolters 2005  (Continued)
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Other bias Unclear risk There were baseline imbalances in educational level (higher in vitamin group)
and Symbol Search (better in vitamin group).
Wolters 2005  (Continued)
 
 
Methods 4-arm, double-blinded, multicentre parallel group RCT, with up to 8 years of treatment
Participants Location: 11 clinical centres in the US
Recruitment: recruited through 11 clinical centres in the US
Sample size: Quote "Of the 3640 AMD trial participants, 2166 (60%) completed the AREDS cognitive
battery near the end of the trial."
• Number randomised: 2737 in intervention, 903 in comparison (total 3640)• Number completed cognitive battery: 1632 in intervention, 534 in comparison (total 2166)
Group A (Antioxidants) baseline characteristics:
• Age (y), %:* 55-59: 4* 60-64: 16* 65-69: 34* 70-74: 29* 75-80: 16• Median age, y: 69• Gender, % female: 55
Group B (Zinc) baseline characteristics:
• Age (y), %:* 55-59: 2* 60-64: 18* 65-69: 29* 70-74: 34* 75-80: 18• Median age, y: 70• Gender, % female: 57
Group C (Antioxidants and Zinc) Baseline characteristics:
• Age (y), %:* 55-59: 3* 60-64: 17* 65-69: 33* 70-74: 30* 75-80: 17• Median age, y: 69• Gender, % female: 56
Group D (Placebo) Baseline characteristics:
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• Age (y), %:* 55-59: 3* 60-64: 16* 65-69: 32* 70-74: 31* 75-80: 18• Median age, y: 69• Gender, % female: 56
Inclusion criteria:
Aged 55 to 80 years old
Individuals who passed the screening evaluation and were interested in participating in AREDS were
provided with a one-month “run-in” supply of placebo to assess potential for tolerance of the inactive
ingredients and compliance with the treatment regimen. They were asked to take two tablets twice a
day for 1 month. Participants taking fewer than 75% of the prescribed tablets were ineligible for enrol-
ment. Participants who had good compliance with the run-in medication, who had adequate pupillary
dilation and no disqualifying lesions noted on photographs sent to the Reading Center for grading, and
who signed a second consent form were stratified into AMD categories at the time of randomisation.
Exclusion criteria:
Had to be free of any illness or condition that would make long-term follow-up or compliance with
study medications unlikely or difficult.
Interventions Intervention (n=1632): Two study medication tablets were to be taken orally each morning and 2 each
evening to meet the total daily dose requirement.
Group A (Antioxidants): 500 mg Vitamin C, 400 IU Vitamin E and 15 mg beta carotene daily
Group B (Zinc and Copper): 80 mg zinc oxide and 2 mg cupric oxide daily
Group C (Antioxidants and Zinc and Copper): 500 mg Vitamin C, 400 IU Vitamin E, 15 mg beta carotene,
80 mg zinc oxide, 2 mg cupric oxide daily
Comparator group (n=534): placebo taken orally that was identical in external appearance and similar
in internal appearance and taste
N.B. Data from groups A and B and the placebo group were included in this review.
Use of additional interventions (common to both treatment arms): no
Outcomes Outcomes of interest in the review:
The primary purpose of the study was to investigate the effects of the interventions on the progression
of age-related macular degeneration.
The AREDS cognitive function battery included six validated cognitive tests with eight components: 1)
The Modified Mini-Mental State Examination (3MS); 2) Animal Category; 3) Letter Fluency; 4) Logical
Memory Part I and 5) Logical Memory Part II, Wechsler Memory Scale Revised; 6) Immediate Recall and
7) Word List Mean, Bushke Selective Reminding Test; and 8) Digits Backwards.
Notes This was a cognitive substudy of AREDS, the Age-Related Eye Disease Study.
Funding sources: “Supported by contracts from the National Eye Institute and the National Institute
on Aging, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, with
additional support from Bausch & Lomb Inc, Rochester, NY”.
Declarations of interest: none declared. “The Writing Team for this report and the AREDS investigators
have no commercial or proprietary interest in the supplements used in this study”.
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Treatment adherence: At each visit, participants returned their used study medication bottles and any
unused tablets, and received new bottles of their study medication. “Estimated pill counts showed that
most patients took 75% or more of the assigned medications and adherence was balanced by treat-
ment”.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Eligibility verification and random treatment assignment were per-
formed by the Coordinating Center using the on-site computers, with proce-
dures to protect the integrity of randomization and to provide randomization
backup in case of hardware malfunction. Multiple levels of data encryption en-
sure the integrity of the treatment assignment files." “Each treatment assign-
ment database residing on the hard drives at each Clinical Center is encrypt-
ed and includes check numbers to insure tamper free operation and proper se-
quential treatment assignments. There were no cases of database corruption
during randomization.”
Comment: adequate method of random sequence generation
Allocation concealment
(selection bias)
Low risk Quote: “Eligibility verification and random treatment assignment were per-
formed by the Coordinating Center using the on-site computers, with proce-
dures to protect the integrity of randomization and to provide randomization
backup in case of hardware malfunction. Multiple levels of data encryption en-
sure the integrity of the treatment assignment files." “Each treatment assign-
ment database residing on the hard drives at each Clinical Center is encrypt-
ed and includes check numbers to insure tamper free operation and proper se-
quential treatment assignments. There were no cases of database corruption
during randomization.”
Comment: adequate allocation concealment
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Quote: “Four participants (0.1%) were reported to have been unmasked during
the trial."
“AREDS is a double-masked study. The AREDS participants, investigators and
Reading Center personnel are masked to study-wide outcome data and treat-
ment assignments.”
Comment: low risk for personnel and participants. Although 4 participants
were “unmasked”, this is likely to have been for safety reasons.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment: “AREDS is a double-masked study. The AREDS participants, investi-
gators and Reading Center personnel are masked to study-wide outcome data
and treatment assignments."
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote: “Another limitation is that not all participants in the trial had cognitive
testing."
“Of the 3,640 AMD trial participants, 2,166 (60%) completed the AREDS cogni-
tive battery near the end of the trial. Of the 1,474 participants without cogni-
tive testing, 330 died before the implementation of the cognitive study, and
1,144 refused or were otherwise unable to participate. Participants without
cognitive testing were more likely to be older, have more ocular abnormali-
ties, and be less educated compared with those participating in the ancillary
study.” No information was given about the treatment allocation of partici-
pants and non-participants in the cognitive sub-study.
Comment: high risk of differential non-participation
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Selective reporting (re-
porting bias)
Unclear risk Comment: This was an ancillary study and did not have a protocol of its own.
The AREDS study design did not mention any cognitive outcomes.
Other bias Low risk Comment: no other risks identified
Ya:e 2004  (Continued)
AD: Alzheimer's disease
AD8: Ascertain Dementia 8-Item Informant Questionnaire (AD8) Dementia Screening Interview
ADAS-cog: Alzheimer's Disease Assessment Scale - cognitive
ADL: Activities of Daily Living
AMD: Age-related Macular Degeneration
APOE ϵ4: Apolipoprotein-E gene, ϵ4 allele
AREDS: The Age-Related Eye Disease Study
BASF: BASF is a registered chemical company, BASF originally stood for Badische Anilin- und Soda-Fabrik.
BAT: Berliner Amnesie Test
BDI: Beck Depression Inventory
betaCarot: ß-carotene
B-PROOF: B-Vitamins for the Prevention of Osteoporotic Fractures study
BTACT: Brief Test of Adult Cognition by Telephone
CaD: Calcium and Vitamin D
CANTAB: Cambridge Automated Neuropsychological Test Battery
CDR: Clinical Dementia Rating scale
CERAD: Consortium to Establish a Registry for Alzheimer's Disease
CERAD e: expanded Consortium to Establish a Registry in Alzheimer's Disease
CERAD T: CERAD battery total score
CoA: coenzyme A reductase
CONSORT: Consolidated Standards of Reporting Trials
CVD: CardioVascular Disease
CVLT: California Verbal Learning Test
DCT: Digit Cancellation Test
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
EBMT: East Boston Memory Test
FA: Folic acid
F00: ICD-10 code for dementia in Alzheimer's disease
F01: ICD-10 code for vascular dementia
F03: ICD-10 code for unspecified dementia
F-TICSm: modified Telephone Interview for Cognitive Status
G30: ICD-10 code for Alzheimer's disease
GDS: Geriatric Depression Scale
HbA1c: Hemoglobin A1c
HCY: homocysteine
HMG-COA: 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase
holoTC: Holotranscobalamin
IADL: Instrumental Activities of Daily Living
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly
IQR: Interquartile range
ISRCTN: International Standard Randomised Controlled Trial Number
KAI: Kurztest fuer Allgemeine Intelligenz
K10: Kessler Distress 10–Scale
LDCT: Letter Digit Coding Test.
MCI: Mild cognitive impairment
MI: Memory Impairment
MIS: Memory Impairment Screen
MMA: Methylmalonic acid
MMSE: Mini-Mental State Examination
MoCA: Montreal Cognitive Assessment
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MRI: Magnetic resonance imaging
msec: millisecond
MTS: Matching To Sample visual search test
n: number
NYU: New York University
PHS: Physicians’ Health Study
RAVLT: Rey Auditory Verbal Learning Test
RBC: Red blood cell
RDA: recommended daily allowances
RI-48: rappel indicé–48 items (cued-recall test–48 items)
SD: standard deviation
SF-36: 36-item Short Form Survey
SU.FOL.OM3: SUpplementation with FOlate, vitamin B6 and B12 and/or OMega-3 fatty acids trial
RCT: randomised clinical trial
SWM: spatial working memory
TCogS: Telephone Cognitive Screen
TIA: Transient Ischaemic Attack
TICS: Telephone Interview for Cognitive Status
TICSm: Modified Telephone Interview for Cognitive Status
TMT: Trail Making Test
VISP: Vitamin Intervention for stroke prevention trial
vit: vitamin
Vit D: vitamin D supplementation
WACS: Women’s Antioxidant and Cardiovascular Study
WADLS: Western Australian Data Linkage System
WAFACS: Women’s Antioxidant and Folic Acid Cardiovascular Study
WAIS: Wechsler Adult Intelligence Scale
WHI: Women's Health Initiative
WHIMS: Women's Health Initiative Memory Study
WHISCA: Women's Health Initiative study of Cognitive Aging
wk: week
y: year
Zn: zinc
3MS: The Modified Mini-Mental State Examination
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abbasi 2013 No cognitive outcomes
ACTRN12607000321448 Ineligible population: participants had MCI
Alavi 2014 Ineligible population. Additional detail: included in related Cochrane review focussing on the MCI
study population
Almeida 2010 Subpopulation of included study focussing on depression outcome. Participants also included in
Hankey 2013
Anonymous 2003 Ineligible population
Arwert 2003 Ineligible intervention
Benton 1995 Ineligible population
Bryan 2002 Ineligible intervention: duration of intervention 5 weeks
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Study Reason for exclusion
Chan 2010 Ineligible experimental intervention: combined experimental intervention
Cheng 2016 Wrong design: non-randomised
Chew 2015 Wrong design: RCT with 2x2 factorial design (omega-3 fatty acids; lutein and zeaxanthin; the combi-
nation; double placebo) with a second randomisation to multivitamin supplements with or without
beta carotene and with or without high dose of zinc. The analyses of effects of beta carotene and
zinc were not eligible, as no tests for interaction were performed for omega-3, lutein and zeaxan-
thin.
Corless 1987 Wrong population
De Jager 2012 Ineligible population: participants had MCI
Dhesi 2004 Ineligible intervention: vitamin D delivered parenterally
Flicker 2011 Wrong population: all had vitamin D deficiency
Ford 2008 Ineligible outcomes
Harris 2015 Ineligible intervention: included plant extracts and probiotics as well as vitamins and minerals
Hvas 2004 Ineligible population: 56% cognitively impaired at baseline
Imaoka 2016 Ineligible population: participants cognitively impaired at baseline
Krikorian 2010 Ineligible population: participants had CDR (Clinical Dementia Rating scale) classification consis-
tent with MCI
Kwok 2017 Ineligible population: We were unable to obtain separate data for participants with mild cognitive
impairment (CDR 0.5) and normal cognition (CDR 0) at baseline.
Li 2015 Ineligible population. Baseline cognitive status unclear. Data presented pictorially only (bar
charts). Baseline mean MMSE < 23
Liu 2015 Study withdrawn prior to participant enrolment (ClinicalTrials.gov Identifier: NCT01317849)
Loriaux 1985 Ineligible experimental intervention
Macpherson 2012 Ineligible population: participants had subjective cognitive decline
Maniam 2004 Other reason. Additional details: potentially eligible RCT described only in an abstract published in
2004. No related full report has been identified and the likelihood such report will be published in
future was judged to be minimal.
McNeill 2007 No eligible outcomes
Miller 2016 No eligible outcomes
Murray-Kolb 2011 Ineligible population: age range 19-55 years
NCT00903695 Ineligible population: participants had MCI
NCT01095211 Ineligible population: duration of intervention 45 days
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Study Reason for exclusion
NCT01708005 Ineligible intervention: combined vitamins, endophospholipids, and omega-3 fatty acids
NCT02185222 Ineligible population: participants had memory complaint
NCT02467153 No eligible outcomes
Ng 2017 Ineligible intervention: combined protein, calorie, and vitamin supplements
Ong 2016 Ineligible intervention: no placebo control
Pase 2015 Ineligible intervention: combined experimental intervention
Pathansali 2006 Ineligible intervention: duration of intervention 4 weeks
Petersen 2005 Ineligible population. Additional detail: included in related Cochrane review focussing on popula-
tion with MCI
Pettersen 2017 Ineligible intervention: no placebo control
Quick 2013 Ineligible design
Rietsema 2014 Ineligible design
Schietzel 2016 Ineligible intervention: no placebo control
Smith 1999 Ineligible population: Excluded if MMSE < 18, but no information on mean MMSE; likely to have in-
cluded participants with dementia or MCI
Summers 2010 Ineligible experimental intervention: combined experimental intervention
Van Uffelen 2007 Ineligible population. Additional detail: included in related Cochrane review focussing on popula-
tion with MCI
Wouters-Wesseling 2005 Ineligible experimental intervention: combined experimental intervention
MCI: Mild cognitive impairment
CDR: Clinical Dementia Rating scale
MMSE: Mini Mental State Examination
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Cluster double-blind, placebo controlled trial with 18 month follow-up
Participants Location: metropolitan Santiago, Chile, 15 health centres, 20 participants selected from each
health centre
Setting of recruitment and treatment: GP practices
Number randomised: not known
Participant (baseline) characteristics: not known
Inclusion criteria: Potential study subjects will be identified from the registry of older people par-
ticipating in the PACAM in 15 health centres.
Sanchez 2011 
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1. men and women aged 70 to 79 years
2. participating in the National Health Service Nutrition Program for Older People (PACAM)
Exclusion criteria:
1. diabetes (fasting blood glucose greater than or equal to 126 mg/dL)
2. hypothyroidism (thyroid stimulating hormone (TSH) greater than 6 mlU/L)
3. serum creatinine greater than or equal to 30 mg/mL
4. serum vitamin B12 level less than 120 or greater than 700 pmol/L or vitamin B12 supplemented
5. cerebrovascular disease
6. previous gastrointestinal surgery
7. unexplained weight lost greater than or equal to 3 kg in the previous 3 months
8. low cognitive development (Mini-mental test less than 20, and Pfeffer test greater than 5)
Interventions Intervention:
1. 1 mg B12 pill taken daily and a routine PACAM food
2. placebo pill and the PACAM food fortified to provide 1 mg of B12 as consumed on a daily basis
Comparator group:
Routine PACAM food and a placebo pill
All subjects in the three study arms will receive both a pill and the food supplement in order to
maintain the double blind nature of the study.
A routine fortified food program provided monthly is delivered by the Ministry of Health under the
PACAM programme through the health centres. The nutritional products are 1 kg of Años Dorados
(a cereal-legume and vegetable powdered food) which provides 400 kcal/100 g and multiple mi-
cronutrients (including B12 1.4 µg/100 g) and 1 kg of Bebida Láctea, a micronutrient fortified milk-
based drink (including B12 2.8 µg/100 g ). The recommended serving size of these supplements
provides daily 1.4 µg or 58.3% of the daily B12 recommended intake (World Health Organization
(WHO) 2002) and 20% of daily energy needed by older people.
The pill will be identical in size, shape, colour, smell, and taste for both the intervention and the
placebo arms of the trial. The intervention pill and the fortified milk base drink will each contain 1
mg of B12.
Use of additional interventions (common to both treatment arms): not reported
Outcomes Primary Outcomes:
1. serum vitamin B12 status, assessed at initial visit and 3, 9, and 18 months
2. haematological and biochemical parameters, assessed at initial visit and 3, 9, and 18 months
3. peripheral nerve conduction, assessed at initial visit, 3, and 18 months
4. compound muscle action potential (CMAP) amplitude, distal motor latency, and F-wave latency
(a measure of conduction time from the distal stimulation site to the spinal cord), assessed at
initial visit, 3, and 18 months
5. Mini-mental score: Mini Mental State Examination (MMSE), assessed at initial visit and 18 months
Secondary Outcomes:
1. serum folate, homocysteine, methyl malonic acid, holotranscobalamin, assessed at initial visit
and 3, 9, and 18 months
2. neurological battery evaluation includes sensory pathways of conduction of afferent sensory
pathways of small diameter, quantitative thermal and somatosensory responses, specific neu-
rosensory pathways, and visual evoked potential. Assessed at initial visit, 3, and 18 months.
3. cognitive function: Test Wechsler, Consortium to Establish a Registry for Alzheimer's Disease (CER-
AD), Test Hamilton and Trail Making Test, assessed at initial visit and 18 months
Sanchez 2011  (Continued)
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Compliance with the nutrition intervention is defined for this study as collecting more than 1 kg per
month of the fortified food as documented by the health centres. Compliance for the pill interven-
tion will be monitored based on collection of the pills supplement from the health centre, 12 out of
18 months will be considered compliant.
A subsample of 120 subjects (8 per cluster, 40 per arm) will undergo neurophysiological tests.
Notes Funding sources: Chilean National Science and Technology Research Fund (FONDECYT 1070592)
(Fondo de Desarrollo Científico y Tecnológico (Chile) (ref: FONDECYT Nº 1070592)), Ministry of
Health (Chile).
Declarations of interest, quote: “The authors declare that they have no competing interests."
Reasons for classification as "study awaiting classification":
This study is marked as "completed" in ISRCTN registry (last edited 11-10-2011), but no results are
available. We made several attempts to contact authors of the protocol, but received no replies.
Sanchez 2011  (Continued)
CERAD: Consortium to Establish a Registry for Alzheimer's Disease
CMAP: compound muscle action potential
PACAM: National Health Service Nutrition Program for Older People
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   B vitamins versus control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive functioning 10   Std. Mean Difference (Random, 95% CI) Subtotals only
1.1 3-12 months of supplementation
(final measurement data)
3 2556 Std. Mean Difference (Random, 95% CI) 0.00 [-0.08, 0.08]
1.2 3-12 months of supplementation
(change from baseline data)
2 317 Std. Mean Difference (Random, 95% CI) -0.03 [-0.26, 0.19]
1.3 > 1-2 years of supplementation (fi-
nal measurement data)
5 6956 Std. Mean Difference (Random, 95% CI) -0.01 [-0.08, 0.06]
1.4 > 1-2 years of supplementation
(change from baseline data)
1 241 Std. Mean Difference (Random, 95% CI) 0.06 [-0.20, 0.31]
1.5 > 2-5 years of supplementation (fi-
nal measurement data)
4 3985 Std. Mean Difference (Random, 95% CI) -0.01 [-0.11, 0.09]
1.6 > 5-10 years of supplementation (fi-
nal measurement data)
3 10249 Std. Mean Difference (Random, 95% CI) -0.01 [-0.09, 0.07]
2 Episodic memory 10   Std. Mean Difference (Random, 95% CI) Subtotals only
2.1 3-12 months of supplementation
(final measurement data)
4 1442 Std. Mean Difference (Random, 95% CI) 0.02 [-0.08, 0.12]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 3-12 months of supplementation
(change from baseline data)
2 430 Std. Mean Difference (Random, 95% CI) 0.04 [-0.15, 0.23]
2.3 > 1-2 years of supplementation (fi-
nal measurement data)
4 5625 Std. Mean Difference (Random, 95% CI) 0.05 [-0.03, 0.13]
2.4 > 1-2 years of supplementation
(change from baseline data)
1 241 Std. Mean Difference (Random, 95% CI) 0.06 [-0.19, 0.32]
2.5 > 2-5 years of supplementation (fi-
nal measurement data)
3 3523 Std. Mean Difference (Random, 95% CI) -0.05 [-0.15, 0.05]
2.6 > 5-10 years of supplementation (fi-
nal measurement data)
1 1053 Std. Mean Difference (Random, 95% CI) -0.10 [-0.22, 0.02]
3 Executive function 7   Std. Mean Difference (Random, 95% CI) Subtotals only
3.1 3-12 months of supplementation
(final measurement data)
3 536 Std. Mean Difference (Random, 95% CI) 0.14 [-0.18, 0.46]
3.2 3-12 months of supplementation
(change from baseline data)
1 171 Std. Mean Difference (Random, 95% CI) 0.39 [0.07, 0.71]
3.3 > 1-2 years of supplementation (fi-
nal measurement data)
3 2976 Std. Mean Difference (Random, 95% CI) -0.01 [-0.15, 0.13]
3.4 > 2-5 years of supplementation (fi-
nal measurement data)
2 2648 Std. Mean Difference (Random, 95% CI) -0.06 [-0.13, 0.02]
3.5 > 5-10 years of supplementation (fi-
nal measurement data)
1 1049 Std. Mean Difference (Random, 95% CI) 0.02 [-0.10, 0.15]
4 Speed of processing 7   Std. Mean Difference (Random, 95% CI) Subtotals only
4.1 3-12 months of supplementation
(final measurement data)
2 289 Std. Mean Difference (Random, 95% CI) -0.04 [-0.28, 0.19]
4.2 3-12 months of supplementation
(change from baseline data)
3 487 Std. Mean Difference (Random, 95% CI) 0.12 [-0.34, 0.58]
4.3 > 1-2 years of supplementation (fi-
nal measurement data)
2 1030 Std. Mean Difference (Random, 95% CI) 0.03 [-0.09, 0.15]
4.4 > 1-2 years of supplementation
(change from baseline data)
1 241 Std. Mean Difference (Random, 95% CI) -0.04 [-0.29, 0.21]
4.5 > 2-5 years of supplementation (fi-
nal measurement data)
1 818 Std. Mean Difference (Random, 95% CI) -0.08 [-0.22, 0.06]
5 Incidence of MCI or dementia 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 > 2-5 years of supplementation 1 1803 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.69, 1.48]
6 All-cause mortality 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6.1 3-12 months of supplementation 1 201 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.33]
6.2 >1 to 2 years of supplementation 1 3680 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.66, 1.11]
6.3 >2-5 years of supplementation 1 1127 Risk Ratio (M-H, Random, 95% CI) 1.98 [1.22, 3.21]
6.4 >5-10 years of supplementation 1 12064 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.95, 1.12]
 
 
Analysis 1.1.   Comparison 1 B vitamins versus control, Outcome 1 Overall cognitive functioning.
Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.1.1 3-12 months of supplementation (final measurement data)  
Hankey 2013 691 712 -0 (0.053) 54.91% -0.04[-0.14,0.07]
McMahon 2006 127 126 -0 (0.126) 9.89% -0.05[-0.3,0.2]
Walker 2012 447 453 0.1 (0.067) 35.2% 0.08[-0.05,0.21]
Subtotal (95% CI)       100% 0[-0.08,0.08]
Heterogeneity: Tau2=0; Chi2=1.94, df=2(P=0.38); I2=0%  
Test for overall effect: Z=0.04(P=0.97)  
   
1.1.2 3-12 months of supplementation (change from baseline data)  
Ford 2010 127 128 0 (0.125) 82.54% 0[-0.25,0.25]
Stott 2005 42 20 -0.2 (0.272) 17.46% -0.19[-0.72,0.34]
Subtotal (95% CI)       100% -0.03[-0.26,0.19]
Heterogeneity: Tau2=0; Chi2=0.4, df=1(P=0.53); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
1.1.3 > 1-2 years of supplementation (final measurement data)  
Hankey 2013 617 621 -0 (0.057) 20.95% -0.01[-0.12,0.1]
Kang 2008 1002 1007 0 (0.045) 26.09% 0.01[-0.08,0.1]
McMahon 2006 126 127 0 (0.126) 6.98% 0.02[-0.22,0.27]
Van der Zwaluw 2014 1278 1278 0.1 (0.04) 28.47% 0.05[-0.03,0.13]
Walker 2012 447 453 -0.2 (0.067) 17.51% -0.16[-0.3,-0.03]
Subtotal (95% CI)       100% -0.01[-0.08,0.06]
Heterogeneity: Tau2=0; Chi2=7.88, df=4(P=0.1); I2=49.25%  
Test for overall effect: Z=0.33(P=0.74)  
   
1.1.4 > 1-2 years of supplementation (change from baseline data)  
Ford 2010 118 123 0.1 (0.129) 100% 0.06[-0.2,0.31]
Subtotal (95% CI)       100% 0.06[-0.2,0.31]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
   
1.1.5 > 2-5 years of supplementation (final measurement data)  
Andreeva 2011 446 425 0.1 (0.068) 24.98% 0.08[-0.05,0.22]
Durga 2007 405 413 -0.1 (0.07) 24.32% -0.15[-0.29,-0.01]
Hankey 2013 219 243 0.1 (0.093) 17.87% 0.08[-0.1,0.26]
Favours vitamin B + folic acid 0.50.25-0.5 -0.25 0 Favours placebo
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Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Kang 2008 911 923 -0 (0.047) 32.83% -0.03[-0.12,0.06]
Subtotal (95% CI)       100% -0.01[-0.11,0.09]
Heterogeneity: Tau2=0.01; Chi2=6.8, df=3(P=0.08); I2=55.88%  
Test for overall effect: Z=0.22(P=0.83)  
   
1.1.6 > 5-10 years of supplementation (final measurement data)  
Hankey 2013 155 150 0.1 (0.115) 10.48% 0.12[-0.1,0.34]
Kang 2008 521 532 -0.1 (0.062) 27.01% -0.09[-0.21,0.03]
SEARCH 2010 4427 4464 0 (0.021) 62.51% 0[-0.04,0.04]
Subtotal (95% CI)       100% -0.01[-0.09,0.07]
Heterogeneity: Tau2=0; Chi2=3.27, df=2(P=0.19); I2=38.85%  
Test for overall effect: Z=0.31(P=0.75)  
Favours vitamin B + folic acid 0.50.25-0.5 -0.25 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 B vitamins versus control, Outcome 2 Episodic memory.
Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.2.1 3-12 months of supplementation (final measurement data)  
Dangour 2015 91 93 0.1 (0.148) 12.81% 0.06[-0.23,0.35]
Eussen 2006 65 40 0 (0.201) 6.9% 0.02[-0.38,0.41]
McMahon 2006 127 126 0 (0.126) 17.62% 0.05[-0.2,0.29]
Walker 2012 447 453 0 (0.067) 62.67% 0.01[-0.12,0.14]
Subtotal (95% CI)       100% 0.02[-0.08,0.12]
Heterogeneity: Tau2=0; Chi2=0.16, df=3(P=0.98); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.2.2 3-12 months of supplementation (change from baseline data)  
Ford 2010 127 128 0.1 (0.125) 61.39% 0.06[-0.18,0.31]
Lewerin 2005 113 62 0 (0.158) 38.61% 0[-0.31,0.31]
Subtotal (95% CI)       100% 0.04[-0.15,0.23]
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%  
Test for overall effect: Z=0.4(P=0.69)  
   
1.2.3 > 1-2 years of supplementation (final measurement data)  
Kang 2008 1002 1007 0 (0.045) 33.39% 0[-0.09,0.09]
McMahon 2006 124 125 -0.1 (0.127) 8.46% -0.06[-0.31,0.19]
Van der Zwaluw 2014 1231 1236 0.1 (0.04) 36.15% 0.05[-0.03,0.13]
Walker 2012 447 453 0.2 (0.067) 22.01% 0.18[0.05,0.31]
Subtotal (95% CI)       100% 0.05[-0.03,0.13]
Heterogeneity: Tau2=0; Chi2=5.56, df=3(P=0.14); I2=46.04%  
Test for overall effect: Z=1.31(P=0.19)  
   
1.2.4 > 1-2 years of supplementation (change from baseline data)  
Ford 2010 118 123 0.1 (0.129) 100% 0.06[-0.19,0.32]
Subtotal (95% CI)       100% 0.06[-0.19,0.32]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
Favours vitamin B + folic acid 10.5-1 -0.5 0 Favours placebo
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Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
   
1.2.5 > 2-5 years of supplementation (final measurement data)  
Andreeva 2011 446 425 0.1 (0.068) 29.59% 0.05[-0.08,0.19]
Durga 2007 405 413 -0.1 (0.07) 28.54% -0.14[-0.27,0]
Kang 2008 911 923 -0.1 (0.047) 41.86% -0.07[-0.16,0.03]
Subtotal (95% CI)       100% -0.05[-0.15,0.05]
Heterogeneity: Tau2=0; Chi2=3.97, df=2(P=0.14); I2=49.63%  
Test for overall effect: Z=1.02(P=0.31)  
   
1.2.6 > 5-10 years of supplementation (final measurement data)  
Kang 2008 521 532 -0.1 (0.062) 100% -0.1[-0.22,0.02]
Subtotal (95% CI)       100% -0.1[-0.22,0.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.65(P=0.1)  
Test for subgroup differences: Chi2=6.02, df=1 (P=0.3), I2=16.94%  
Favours vitamin B + folic acid 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 B vitamins versus control, Outcome 3 Executive function.
Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.3.1 3-12 months of supplementation (final measurement data)  
Dangour 2015 91 93 -0.2 (0.148) 34.94% -0.17[-0.46,0.12]
Eussen 2006 61 38 0.3 (0.208) 27.19% 0.35[-0.06,0.76]
McMahon 2006 127 126 0.3 (0.126) 37.87% 0.27[0.02,0.52]
Subtotal (95% CI)       100% 0.14[-0.18,0.46]
Heterogeneity: Tau2=0.05; Chi2=6.4, df=2(P=0.04); I2=68.73%  
Test for overall effect: Z=0.84(P=0.4)  
   
1.3.2 3-12 months of supplementation (change from baseline data)  
Lewerin 2005 110 61 0.4 (0.161) 100% 0.39[0.07,0.71]
Subtotal (95% CI)       100% 0.39[0.07,0.71]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.42(P=0.02)  
   
1.3.3 > 1-2 years of supplementation (final measurement data)  
Kang 2008 1000 1007 -0.1 (0.045) 45.87% -0.07[-0.15,0.02]
McMahon 2006 124 125 0.2 (0.127) 19.73% 0.23[-0.02,0.48]
Van der Zwaluw 2014 352 368 -0.1 (0.075) 34.4% -0.07[-0.21,0.08]
Subtotal (95% CI)       100% -0.01[-0.15,0.13]
Heterogeneity: Tau2=0.01; Chi2=5.1, df=2(P=0.08); I2=60.77%  
Test for overall effect: Z=0.11(P=0.91)  
   
1.3.4 > 2-5 years of supplementation (final measurement data)  
Durga 2007 405 413 -0 (0.07) 30.95% -0.04[-0.18,0.1]
Kang 2008 909 921 -0.1 (0.047) 69.05% -0.07[-0.16,0.03]
Subtotal (95% CI)       100% -0.06[-0.13,0.02]
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Favours vitamin B + folic acid 10.5-1 -0.5 0 Favours placebo
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Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=1.48(P=0.14)  
   
1.3.5 > 5-10 years of supplementation (final measurement data)  
Kang 2008 519 530 0 (0.062) 100% 0.02[-0.1,0.15]
Subtotal (95% CI)       100% 0.02[-0.1,0.15]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Test for subgroup differences: Chi2=8.8, df=1 (P=0.07), I2=54.52%  
Favours vitamin B + folic acid 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.4.   Comparison 1 B vitamins versus control, Outcome 4 Speed of processing.
Study or subgroup B-Vitamins Control Std. Mean
Difference
Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.4.1 3-12 months of supplementation (final measurement data)  
Dangour 2015 91 93 0 (0.148) 65.02% 0[-0.29,0.29]
Eussen 2006 65 40 -0.1 (0.201) 34.98% -0.12[-0.52,0.27]
Subtotal (95% CI)       100% -0.04[-0.28,0.19]
Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.36(P=0.72)  
   
1.4.2 3-12 months of supplementation (change from baseline data)  
Ford 2010 127 128 -0.3 (0.126) 37.96% -0.28[-0.52,-0.03]
Lewerin 2005 113 62 0.3 (0.159) 35.63% 0.27[-0.04,0.58]
Stott 2005 37 20 0.5 (0.281) 26.41% 0.47[-0.08,1.03]
Subtotal (95% CI)       100% 0.12[-0.34,0.58]
Heterogeneity: Tau2=0.13; Chi2=10.49, df=2(P=0.01); I2=80.93%  
Test for overall effect: Z=0.5(P=0.62)  
   
1.4.3 > 1-2 years of supplementation (final measurement data)  
Ford 2010 150 149 -0 (0.116) 28.92% -0.04[-0.27,0.19]
Van der Zwaluw 2014 358 373 0.1 (0.074) 71.08% 0.06[-0.09,0.2]
Subtotal (95% CI)       100% 0.03[-0.09,0.15]
Heterogeneity: Tau2=0; Chi2=0.55, df=1(P=0.46); I2=0%  
Test for overall effect: Z=0.49(P=0.63)  
   
1.4.4 > 1-2 years of supplementation (change from baseline data)  
Ford 2010 118 123 -0 (0.129) 100% -0.04[-0.29,0.21]
Subtotal (95% CI)       100% -0.04[-0.29,0.21]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.3(P=0.76)  
   
1.4.5 > 2-5 years of supplementation (final measurement data)  
Durga 2007 405 413 -0.1 (0.07) 100% -0.08[-0.22,0.06]
Subtotal (95% CI)       100% -0.08[-0.22,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
Test for subgroup differences: Chi2=1.74, df=1 (P=0.78), I2=0%  
Favours vitamin B + folic acid 10.5-1 -0.5 0 Favours placebo
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Analysis 1.5.   Comparison 1 B vitamins versus control, Outcome 5 Incidence of MCI or dementia.
Study or subgroup B-Vitamins Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 > 2-5 years of supplementation  
Hankey 2013 50/908 49/895 100% 1.01[0.69,1.48]
Subtotal (95% CI) 908 895 100% 1.01[0.69,1.48]
Total events: 50 (B-Vitamins), 49 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.03(P=0.98)  
Favours B-Vitamins 1000.01 100.1 1 Favours control
 
 
Analysis 1.6.   Comparison 1 B vitamins versus control, Outcome 6 All-cause mortality.
Study or subgroup B-Vitamins Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.6.1 3-12 months of supplementation  
Dangour 2015 0/99 1/102 100% 0.34[0.01,8.33]
Subtotal (95% CI) 99 102 100% 0.34[0.01,8.33]
Total events: 0 (B-Vitamins), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
1.6.2 >1 to 2 years of supplementation  
Toole 2004 99/1827 117/1853 100% 0.86[0.66,1.11]
Subtotal (95% CI) 1827 1853 100% 0.86[0.66,1.11]
Total events: 99 (B-Vitamins), 117 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.15(P=0.25)  
   
1.6.3 >2-5 years of supplementation  
Andreeva 2011 44/542 24/585 100% 1.98[1.22,3.21]
Subtotal (95% CI) 542 585 100% 1.98[1.22,3.21]
Total events: 44 (B-Vitamins), 24 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=2.77(P=0.01)  
   
1.6.4 >5-10 years of supplementation  
SEARCH 2010 983/6033 951/6031 100% 1.03[0.95,1.12]
Subtotal (95% CI) 6033 6031 100% 1.03[0.95,1.12]
Total events: 983 (B-Vitamins), 951 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.79(P=0.43)  
Test for subgroup differences: Chi2=9.36, df=1 (P=0.02), I2=67.95%  
Favours Vitamin B 1000.01 100.1 1 Favours control
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Comparison 2.   Antioxidants versus control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive functioning 5   Mean Difference (Random, 95% CI) Subtotals only
1.1 3-12 months Vitamin E supple-
mentation
1   Mean Difference (Random, 95% CI) 1.4 [1.18, 1.62]
1.2 3-12 months Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) -0.14 [-0.37, 0.09]
1.3 > 2-5 years antioxidants (Vitamin
E + Vitamin C + Beta Carotene) sup-
plementation
1   Mean Difference (Random, 95% CI) 0.09 [-0.05, 0.23]
1.4 > 2-5 years Vitamin E supple-
mentation
1   Mean Difference (Random, 95% CI) 0.01 [-0.23, 0.25]
1.5 > 2-5 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) 0.16 [-0.08, 0.40]
1.6 > 2-5 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) -0.18 [-0.42, 0.06]
1.7 > 5-10 years antioxidants (Vita-
min E + Vitamin C + Beta carotene)
supplementation
1   Mean Difference (Random, 95% CI) 0.6 [-0.20, 1.40]
1.8 > 5-10 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) 0.46 [0.14, 0.78]
1.9 > 5-10 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) -0.13 [-0.46, 0.20]
1.10 > 10 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.18 [0.01, 0.35]
2 Episodic memory 4   Mean Difference (Random, 95% CI) Subtotals only
2.1 3-12 months Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.08]
2.2 > 2-5 years Vitamin E supple-
mentation
1   Mean Difference (Random, 95% CI) -0.02 [-0.07, 0.03]
2.3 > 2-5 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) -0.05 [-0.10, -0.00]
2.4 > 2-5 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.01 [-0.05, 0.07]
2.5 > 5-10 years antioxidants (Vita-
min E + Vitamin C + Beta Carotene)
supplementation
1   Mean Difference (Random, 95% CI) -0.3 [-1.30, 0.70]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.6 > 5-10 years Vitamin E supple-
mentation
2   Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.09]
2.7 > 5-10 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) -0.14 [-0.22, -0.06]
2.8 > 5-10 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.02 [-0.05, 0.09]
2.9 > 10 years Beta Carotene supple-
mentation
1   Mean Difference (Random, 95% CI) -0.06 [-0.11, -0.02]
3 Executive function 4   Mean Difference (Random, 95% CI) Subtotals only
3.1 3-12 months Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.07 [-0.48, 0.62]
3.2 > 2-5 years Vitamin E supple-
mentation
1   Mean Difference (Random, 95% CI) 0.42 [0.06, 0.78]
3.3 > 2-5 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) -0.03 [-0.39, 0.33]
3.4 > 2-5 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.22 [-0.14, 0.58]
3.5 > 5-10 years antioxidants (Vita-
min E + Vitamin C + Beta Carotene)
supplementation
1   Mean Difference (Random, 95% CI) -0.4 [-0.99, 0.19]
3.6 > 5-10 years Vitamin E supple-
mentation
2   Mean Difference (Random, 95% CI) 0.11 [-0.26, 0.48]
3.7 > 5-10 years Vitamin C supple-
mentation
1   Mean Difference (Random, 95% CI) -0.25 [-0.70, 0.20]
3.8 > 5-10 years Beta Carotene sup-
plementation
1   Mean Difference (Random, 95% CI) 0.01 [-0.44, 0.46]
3.9 > 10 years Beta Carotene supple-
mentation
1   Mean Difference (Random, 95% CI) 0.01 [-0.36, 0.38]
4 Incidence of dementia 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 > 2-5 years of supplementation 1 20536 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.61, 1.64]
5 All-cause mortality 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 > 2-5 years antioxidants (Vita-
min E + Vitamin C + + Beta Carotene)
supplementation
1 20536 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.97, 1.11]
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Analysis 2.1.   Comparison 2 Antioxidants versus control, Outcome 1 Overall cognitive functioning.
Study or subgroup Favours [ex-
perimental]
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.1.1 3-12 months Vitamin E supplementation  
Anand 2011 38 36 1.4 (0.114) 100% 1.4[1.18,1.62]
Subtotal (95% CI)       100% 1.4[1.18,1.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=12.29(P<0.0001)  
   
2.1.2 3-12 months Beta Carotene supplementation  
Grodstein 2007 936 968 -0.1 (0.119) 100% -0.14[-0.37,0.09]
Subtotal (95% CI)       100% -0.14[-0.37,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
   
2.1.3 > 2-5 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supple-
mentation
 
MRC/BHF 2002 10241 10228 0.1 (0.07) 100% 0.09[-0.05,0.23]
Subtotal (95% CI)       100% 0.09[-0.05,0.23]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.29(P=0.2)  
   
2.1.4 > 2-5 years Vitamin E supplementation  
Kang 2009 0 0 0 (0.123) 100% 0.01[-0.23,0.25]
Subtotal (95% CI)       100% 0.01[-0.23,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.08(P=0.93)  
   
2.1.5 > 2-5 years Vitamin C supplementation  
Kang 2009 0 0 0.2 (0.123) 100% 0.16[-0.08,0.4]
Subtotal (95% CI)       100% 0.16[-0.08,0.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
   
2.1.6 > 2-5 years Beta Carotene supplementation  
Kang 2009 0 0 -0.2 (0.123) 100% -0.18[-0.42,0.06]
Subtotal (95% CI)       100% -0.18[-0.42,0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.47(P=0.14)  
   
2.1.7 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta carotene) supple-
mentation
 
YaIe 2004 566 534 0.6 (0.41) 100% 0.6[-0.2,1.4]
Subtotal (95% CI)       100% 0.6[-0.2,1.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.46(P=0.14)  
   
2.1.8 > 5-10 years Vitamin C supplementation  
Kang 2009 0 0 0.5 (0.163) 100% 0.46[0.14,0.78]
Subtotal (95% CI)       100% 0.46[0.14,0.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.82(P=0)  
   
Favours placebo 21-2 -1 0 Favours antioxidants
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Study or subgroup Favours [ex-
perimental]
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.1.9 > 5-10 years Beta Carotene supplementation  
Kang 2009 0 0 -0.1 (0.168) 100% -0.13[-0.46,0.2]
Subtotal (95% CI)       100% -0.13[-0.46,0.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.77(P=0.44)  
   
2.1.10 > 10 years Beta Carotene supplementation  
Grodstein 2007 2031 2021 0.2 (0.087) 100% 0.18[0.01,0.35]
Subtotal (95% CI)       100% 0.18[0.01,0.35]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.07(P=0.04)  
Favours placebo 21-2 -1 0 Favours antioxidants
 
 
Analysis 2.2.   Comparison 2 Antioxidants versus control, Outcome 2 Episodic memory.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.2.1 3-12 months Beta Carotene supplementation  
Grodstein 2007 936 968 0 (0.033) 100% 0.02[-0.05,0.08]
Subtotal (95% CI)       100% 0.02[-0.05,0.08]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.65)  
   
2.2.2 > 2-5 years Vitamin E supplementation  
Kang 2009 0 0 -0 (0.026) 100% -0.02[-0.07,0.03]
Subtotal (95% CI)       100% -0.02[-0.07,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.78(P=0.43)  
   
2.2.3 > 2-5 years Vitamin C supplementation  
Kang 2009 0 0 -0 (0.026) 100% -0.05[-0.1,-0]
Subtotal (95% CI)       100% -0.05[-0.1,-0]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.96(P=0.05)  
   
2.2.4 > 2-5 years Beta Carotene supplementation  
Kang 2009 0 0 0 (0.031) 100% 0.01[-0.05,0.07]
Subtotal (95% CI)       100% 0.01[-0.05,0.07]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
   
2.2.5 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supple-
mentation
 
YaIe 2004 566 534 -0.3 (0.51) 100% -0.3[-1.3,0.7]
Subtotal (95% CI)       100% -0.3[-1.3,0.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.59(P=0.56)  
   
Favours antioxidants 10.5-1 -0.5 0 Favours placebo
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
122
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.2.6 > 5-10 years Vitamin E supplementation  
Kang 2006 2596 2630 -0 (0.02) 58.76% -0.01[-0.05,0.03]
Kang 2009 0 0 0.1 (0.036) 41.24% 0.06[-0.01,0.13]
Subtotal (95% CI)       100% 0.02[-0.05,0.09]
Heterogeneity: Tau2=0; Chi2=2.9, df=1(P=0.09); I2=65.5%  
Test for overall effect: Z=0.55(P=0.58)  
   
2.2.7 > 5-10 years Vitamin C supplementation  
Kang 2009 0 0 -0.1 (0.041) 100% -0.14[-0.22,-0.06]
Subtotal (95% CI)       100% -0.14[-0.22,-0.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.43(P=0)  
   
2.2.8 > 5-10 years Beta Carotene supplementation  
Kang 2009 0 0 0 (0.036) 100% 0.02[-0.05,0.09]
Subtotal (95% CI)       100% 0.02[-0.05,0.09]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.56(P=0.58)  
   
2.2.9 > 10 years Beta Carotene supplementation  
Grodstein 2007 2031 2021 -0.1 (0.024) 100% -0.06[-0.11,-0.02]
Subtotal (95% CI)       100% -0.06[-0.11,-0.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=17.68, df=1 (P=0.02), I2=54.76%  
Favours antioxidants 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 2.3.   Comparison 2 Antioxidants versus control, Outcome 3 Executive function.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
2.3.1 3-12 months Beta Carotene supplementation  
Grodstein 2007 936 968 0.1 (0.282) 100% 0.07[-0.48,0.62]
Subtotal (95% CI)       100% 0.07[-0.48,0.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.25(P=0.8)  
   
2.3.2 > 2-5 years Vitamin E supplementation  
Kang 2009 0 0 0.4 (0.184) 100% 0.42[0.06,0.78]
Subtotal (95% CI)       100% 0.42[0.06,0.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.29(P=0.02)  
   
2.3.3 > 2-5 years Vitamin C supplementation  
Kang 2009 0 0 -0 (0.184) 100% -0.03[-0.39,0.33]
Subtotal (95% CI)       100% -0.03[-0.39,0.33]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.87)  
Favours antioxidants 21-2 -1 0 Favours placebo
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Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
   
2.3.4 > 2-5 years Beta Carotene supplementation  
Kang 2009 0 0 0.2 (0.184) 100% 0.22[-0.14,0.58]
Subtotal (95% CI)       100% 0.22[-0.14,0.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.2(P=0.23)  
   
2.3.5 > 5-10 years antioxidants (Vitamin E + Vitamin C + Beta Carotene) supple-
mentation
 
YaIe 2004 566 534 -0.4 (0.299) 100% -0.4[-0.99,0.19]
Subtotal (95% CI)       100% -0.4[-0.99,0.19]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.34(P=0.18)  
   
2.3.6 > 5-10 years Vitamin E supplementation  
Kang 2006 2595 2630 -0 (0.138) 61.09% -0.04[-0.31,0.23]
Kang 2009 0 0 0.4 (0.23) 38.91% 0.35[-0.1,0.8]
Subtotal (95% CI)       100% 0.11[-0.26,0.48]
Heterogeneity: Tau2=0.04; Chi2=2.12, df=1(P=0.15); I2=52.86%  
Test for overall effect: Z=0.59(P=0.56)  
   
2.3.7 > 5-10 years Vitamin C supplementation  
Kang 2009 0 0 -0.2 (0.23) 100% -0.25[-0.7,0.2]
Subtotal (95% CI)       100% -0.25[-0.7,0.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.09(P=0.28)  
   
2.3.8 > 5-10 years Beta Carotene supplementation  
Kang 2009 0 0 0 (0.23) 100% 0.01[-0.44,0.46]
Subtotal (95% CI)       100% 0.01[-0.44,0.46]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
   
2.3.9 > 10 years Beta Carotene supplementation  
Grodstein 2007 2031 2021 0 (0.188) 100% 0.01[-0.36,0.38]
Subtotal (95% CI)       100% 0.01[-0.36,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
Test for subgroup differences: Chi2=9.22, df=1 (P=0.32), I2=13.28%  
Favours antioxidants 21-2 -1 0 Favours placebo
 
 
Analysis 2.4.   Comparison 2 Antioxidants versus control, Outcome 4 Incidence of dementia.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 > 2-5 years of supplementation  
MRC/BHF 2002 31/10269 31/10267 100% 1[0.61,1.64]
Subtotal (95% CI) 10269 10267 100% 1[0.61,1.64]
Total events: 31 (Experimental), 31 (Control)  
Favours antioxidants 1000.01 100.1 1 Favours control
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Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0(P=1)  
Favours antioxidants 1000.01 100.1 1 Favours control
 
 
Analysis 2.5.   Comparison 2 Antioxidants versus control, Outcome 5 All-cause mortality.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.5.1 > 2-5 years antioxidants (Vitamin E + Vitamin C + + Beta Carotene)
supplementation
 
MRC/BHF 2002 1446/10269 1389/10267 100% 1.04[0.97,1.11]
Subtotal (95% CI) 10269 10267 100% 1.04[0.97,1.11]
Total events: 1446 (Experimental), 1389 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.15(P=0.25)  
Favours antioxidants 20.5 1.50.7 1 Favours control
 
 
Comparison 3.   Vitamin D3 versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive functioning 1   Mean Difference (Random,
95% CI)
Subtotals only
1.1 3-12 months of supplementation 1 4122 Mean Difference (Random,
95% CI)
0.0 [-0.24, 0.24]
1.2 > 1-2 years of supplementation 1 3910 Mean Difference (Random,
95% CI)
0.0 [-0.25, 0.25]
1.3 > 2-5 years of supplementation 1 3515 Mean Difference (Random,
95% CI)
-0.2 [-0.53, 0.13]
1.4 > 5-10 years of supplementation 1 918 Mean Difference (Random,
95% CI)
-0.1 [-0.81, 0.61]
2 Episodic memory 1   Mean Difference (Random,
95% CI)
Subtotals only
2.1 > 5-10 years of supplementation 1 1420 Mean Difference (Random,
95% CI)
0.05 [-0.03, 0.13]
3 Executive function 1   Mean Difference (Random,
95% CI)
Subtotals only
3.1 > 5-10 years of supplementation 1 1420 Mean Difference (Random,
95% CI)
0.0 [-0.08, 0.08]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 Speed of processing 1   Mean Difference (Random,
95% CI)
Subtotals only
4.1 > 5-10 years of supplementation 1 1420 Mean Difference (Random,
95% CI)
0.03 [-0.05, 0.11]
5 Incident MCI 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
5.1 > 5-10 years of supplementation 1 4143 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.72, 1.23]
6 Incident all-cause dementia 1   Risk Ratio (M-H, Random, 95%
CI)
Subtotals only
6.1 > 5-10 years supplementation 1 4143 Risk Ratio (M-H, Random, 95%
CI)
1.09 [0.70, 1.71]
 
 
Analysis 3.1.   Comparison 3 Vitamin D3 versus placebo, Outcome 1 Overall cognitive functioning.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
3.1.1 3-12 months of supplementation  
Rossom 2012 2028 2094 0 (0.122) 100% 0[-0.24,0.24]
Subtotal (95% CI)       100% 0[-0.24,0.24]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.1.2 > 1-2 years of supplementation  
Rossom 2012 1918 1992 0 (0.128) 100% 0[-0.25,0.25]
Subtotal (95% CI)       100% 0[-0.25,0.25]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
3.1.3 > 2-5 years of supplementation  
Rossom 2012 1718 1797 -0.2 (0.167) 100% -0.2[-0.53,0.13]
Subtotal (95% CI)       100% -0.2[-0.53,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.19(P=0.23)  
   
3.1.4 > 5-10 years of supplementation  
Rossom 2012 450 468 -0.1 (0.365) 100% -0.1[-0.81,0.61]
Subtotal (95% CI)       100% -0.1[-0.81,0.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.78)  
Test for subgroup differences: Chi2=1.14, df=1 (P=0.77), I2=0%  
Favours placebo 42-4 -2 0 Favours intervention
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Analysis 3.2.   Comparison 3 Vitamin D3 versus placebo, Outcome 2 Episodic memory.
Study or subgroup Favours
vitamin D3
+ calcium
Placebo Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
3.2.1 > 5-10 years of supplementation  
Rossom 2012 690 730 0.1 (0.04) 100% 0.05[-0.03,0.13]
Subtotal (95% CI)       100% 0.05[-0.03,0.13]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.25(P=0.21)  
Favours vitamin D3 + calcium 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 3.3.   Comparison 3 Vitamin D3 versus placebo, Outcome 3 Executive function.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
3.3.1 > 5-10 years of supplementation  
Rossom 2012 690 730 0 (0.04) 100% 0[-0.08,0.08]
Subtotal (95% CI)       100% 0[-0.08,0.08]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours vit D3 + calcium 10050-100 -50 0 Favours placebo
 
 
Analysis 3.4.   Comparison 3 Vitamin D3 versus placebo, Outcome 4 Speed of processing.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
3.4.1 > 5-10 years of supplementation  
Rossom 2012 690 730 0 (0.04) 100% 0.03[-0.05,0.11]
Subtotal (95% CI)       100% 0.03[-0.05,0.11]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
Favours vit D3 + calcium 0.40.2-0.4 -0.2 0 Favours placebo
 
 
Analysis 3.5.   Comparison 3 Vitamin D3 versus placebo, Outcome 5 Incident MCI.
Study or subgroup Vitamin D3
+ calcium
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.5.1 > 5-10 years of supplementation  
Rossom 2012 98/2034 108/2109 100% 0.94[0.72,1.23]
Subtotal (95% CI) 2034 2109 100% 0.94[0.72,1.23]
Total events: 98 (Vitamin D3 + calcium), 108 (Placebo)  
Heterogeneity: Not applicable  
Favours vitamin D3 + calcium 50.2 20.5 1 Favours placebo
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Study or subgroup Vitamin D3
+ calcium
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.45(P=0.65)  
Favours vitamin D3 + calcium 50.2 20.5 1 Favours placebo
 
 
Analysis 3.6.   Comparison 3 Vitamin D3 versus placebo, Outcome 6 Incident all-cause dementia.
Study or subgroup Vitamin D3
+ calcium
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.6.1 > 5-10 years supplementation  
Rossom 2012 39/2034 37/2109 100% 1.09[0.7,1.71]
Subtotal (95% CI) 2034 2109 100% 1.09[0.7,1.71]
Total events: 39 (Vitamin D3 + calcium), 37 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.39(P=0.7)  
Favours vitamin D3 + calcium 50.2 20.5 1 Favours placebo
 
 
Comparison 4.   Zinc + copper versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive functioning 1   Mean Difference (Random, 95%
CI)
Subtotals only
1.1 > 5-10 years of supplementation 1 1072 Mean Difference (Random, 95%
CI)
0.6 [-0.19, 1.39]
2 Episodic memory 1   Mean Difference (Random, 95%
CI)
Subtotals only
2.1 > 5-10 years of supplementation 1 1072 Mean Difference (Random, 95%
CI)
-0.7 [-1.74, 0.34]
3 Executive function 1   Mean Difference (Random, 95%
CI)
Subtotals only
3.1 > 5-10 years of supplementation 1 1072 Mean Difference (Random, 95%
CI)
-0.3 [-0.89, 0.29]
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Analysis 4.1.   Comparison 4 Zinc + copper versus placebo, Outcome 1 Overall cognitive functioning.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.1.1 > 5-10 years of supplementation  
YaIe 2004 538 534 0.6 (0.404) 100% 0.6[-0.19,1.39]
Subtotal (95% CI)       100% 0.6[-0.19,1.39]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.49(P=0.14)  
Favours placebo 52.5-5 -2.5 0 Favours intervention
 
 
Analysis 4.2.   Comparison 4 Zinc + copper versus placebo, Outcome 2 Episodic memory.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.2.1 > 5-10 years of supplementation  
YaIe 2004 538 534 -0.7 (0.528) 100% -0.7[-1.74,0.34]
Subtotal (95% CI)       100% -0.7[-1.74,0.34]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.32(P=0.19)  
Favours zinc + copper 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 4.3.   Comparison 4 Zinc + copper versus placebo, Outcome 3 Executive function.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
4.3.1 > 5-10 years of supplementation  
YaIe 2004 538 534 -0.3 (0.299) 100% -0.3[-0.89,0.29]
Subtotal (95% CI)       100% -0.3[-0.89,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Favours zinc+ copper 52.5-5 -2.5 0 Favours placebo
 
 
Comparison 5.   Complex multivitamin versus control
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Overall cognitive functioning 1   Mean Difference (Random,
95% CI)
Subtotals only
1.1 > 2-5 years of supplementation 1 5947 Mean Difference (Random,
95% CI)
0.04 [-0.09, 0.17]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.2 > 5-10 years of supplementation 1 2324 Mean Difference (Random,
95% CI)
0.12 [-0.14, 0.38]
2 Episodic memory 2   Mean Difference (Random,
95% CI)
Subtotals only
2.1 3-12 months of supplementation 1 124 Mean Difference (Random,
95% CI)
33.17 [-28.12, 94.46]
2.2 > 2-5 years of supplementation 1 5942 Mean Difference (Random,
95% CI)
-0.01 [-0.05, 0.03]
2.3 > 5-10 years of supplementation 1 2324 Mean Difference (Random,
95% CI)
-0.01 [-0.07, 0.05]
3 Executive function 1   Mean Difference (Random,
95% CI)
Subtotals only
3.1 > 2-5 years of supplementation 1 5942 Mean Difference (Random,
95% CI)
-0.02 [-0.33, 0.29]
3.2 > 5-10 years of supplementation 1 2324 Mean Difference (Random,
95% CI)
-0.22 [-0.65, 0.21]
4 Speed of processing 1   Mean Difference (Random,
95% CI)
Subtotals only
4.1 3-12 months of supplementation 1 127 Mean Difference (Random,
95% CI)
-14.71 [-57.22, 27.80]
 
 
Analysis 5.1.   Comparison 5 Complex multivitamin versus control, Outcome 1 Overall cognitive functioning.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
5.1.1 > 2-5 years of supplementation  
Grodstein 2013 2980 2967 0 (0.066) 100% 0.04[-0.09,0.17]
Subtotal (95% CI)       100% 0.04[-0.09,0.17]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.6(P=0.55)  
   
5.1.2 > 5-10 years of supplementation  
Grodstein 2013 1165 1159 0.1 (0.133) 100% 0.12[-0.14,0.38]
Subtotal (95% CI)       100% 0.12[-0.14,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
Test for subgroup differences: Chi2=0.29, df=1 (P=0.59), I2=0%  
Favours placebo 0.50.25-0.5 -0.25 0 Favours intervention
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Analysis 5.2.   Comparison 5 Complex multivitamin versus control, Outcome 2 Episodic memory.
Study or subgroup Favours
multivi-
tamins
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
5.2.1 3-12 months of supplementation  
Cockle 2000 65 59 33.2 (31.27) 100% 33.17[-28.12,94.46]
Subtotal (95% CI)       100% 33.17[-28.12,94.46]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
   
5.2.2 > 2-5 years of supplementation  
Grodstein 2013 2978 2964 -0 (0.02) 100% -0.01[-0.05,0.03]
Subtotal (95% CI)       100% -0.01[-0.05,0.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.49(P=0.62)  
   
5.2.3 > 5-10 years of supplementation  
Grodstein 2013 1165 1159 -0 (0.031) 100% -0.01[-0.07,0.05]
Subtotal (95% CI)       100% -0.01[-0.07,0.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=1.13, df=1 (P=0.57), I2=0%  
Favours multivitamins 0.20.1-0.2 -0.1 0 Favours control
 
 
Analysis 5.3.   Comparison 5 Complex multivitamin versus control, Outcome 3 Executive function.
Study or subgroup Multivi-
tamin
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
5.3.1 > 2-5 years of supplementation  
Grodstein 2013 2978 2964 -0 (0.158) 100% -0.02[-0.33,0.29]
Subtotal (95% CI)       100% -0.02[-0.33,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.9)  
   
5.3.2 > 5-10 years of supplementation  
Grodstein 2013 1165 1159 -0.2 (0.219) 100% -0.22[-0.65,0.21]
Subtotal (95% CI)       100% -0.22[-0.65,0.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Test for subgroup differences: Chi2=0.55, df=1 (P=0.46), I2=0%  
Favours multivitamin 10.5-1 -0.5 0 Favours control
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Analysis 5.4.   Comparison 5 Complex multivitamin versus control, Outcome 4 Speed of processing.
Study or subgroup Experi-
mental
Control Mean Dif-
ference
Mean Difference Weight Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
5.4.1 3-12 months of supplementation  
Cockle 2000 66 61 -14.7
(21.688)
100% -14.71[-57.22,27.8]
Subtotal (95% CI)       100% -14.71[-57.22,27.8]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.68(P=0.5)  
Favours complex multivit 10050-100 -50 0 Favours placebo
 
 
A P P E N D I C E S
Appendix 1. Biological plausibility of vitamins and minerals
 
Supplement* Route Biological plausibility
Vitamins    
Vitamin A antioxidant;
anti-inflammato-
ry;
an-
ti-cholinesterase;
beta-amyloid inhi-
bition
Carboxylic form of Vitamin A known as all-trans retinoic acid has been shown to have
memory restorative function and it may be attributed to its anti-cholinesterase, anti-ox-
idative and anti-inflammatory potential (Sodhi 2013). Vitamin A and ß-carotene may also
inhibit the formation, extension and destabilising effects of beta-amyloid fibrins. Plasma
or cerebrospinal fluid concentrations of vitamin A and beta-carotene have been reported
to be lower in AD patients, and increased Vit A/beta carotene concentrations have been
clinically shown to slow the progression of dementia (Ono 2012).
Vitamin D neuronal activity Vitamin D receptor (VDR) and 1, alpha-hydroxylase, the terminal calcitriol-activating en-
zyme, are distributed throughout both the foetal and adult brain. This is thought to play
a role in brain development and critical brain functions (McCann 2008). Significant corre-
lation between serum 25(OH)D levels and cognitive scores were reported in DeLuca 1975
and Przybelski 2007.
Vitamin E antioxidant;
beta-amyloid inhi-
bition
Vitamin E consists of a group of tocopherols and tocotrienols. Apart from lipid antioxi-
dant activity, other functions include membrane stabilisation by forming complexes with
the products of lipid hydrolysis (Wang 2000). It has been shown that the antioxidant and
free radical scavenging activity of Vitamin E inhibits amyloid beta protein induced neu-
ronal cell death and may have implication in prevention and treatment of Alzheimer’s de-
mentia (Behl 1992).
Vitamin K neuronal activity Vitamin K participates in the synthesis of sphingolipids. Sphingolipids participate in im-
portant cellular events such as proliferation, differentiation, senescence, and cell-cell in-
teractions. Sphingolipid metabolism has been linked to age-related cognitive decline and
neurodegenerative diseases such as Alzheimer's disease (Ferland 2012). A cross-sectional
study found correlations between higher serum phylloquinone concentration and better
cognitive scores in tests evaluating episodic verbal memory among healthy older adults
(Ferland 2013).
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Thiamine
(Vitamin B1)
neuronal activity Thiamine is required as a cofactor in the cellular production of energy and enhances nor-
mal neuronal activities (Osiezagha 2013). Rats with an episode of induced thiamine defi-
ciency had cognitive, learning, and memory impairments (Langlais 1995).
Riboflavin
(Vitamin B2)
neuronal activity Riboflavin (7,8-dimethyl-10-ribityl-isoalloxazine) is water-soluble. Symptoms of neurode-
generation and peripheral neuropathy in riboflavin deficiency have been documented in
animal studies, but not observed in humans. Subclinical riboflavin deficiency may con-
tribute to increased concentrations of plasma homocysteine and may be associated with
increased risk of cardiovascular disease and impaired handling of iron (Powers 2003).
Niacin
(Vitamin B3)
vascular:
anti-inflammatory
Niacin is a water-soluble precursor cofactor essential for the formation of dozens of en-
zymes. Niacin decreases atherosclerosis development mainly by reducing LDL choles-
terol. It also has modest HDL-cholesterol-raising and anti-inflammatory effects (Kühnast
2013).
Niacin deficiency causes pellagra. Its neuropsychiatric symptoms are similar to those in
Alzheimer's disease or vascular dementia (Amanullah 2010).
Vitamin B6
(Pyridoxine, pyri-
doxal, pyridoxam-
ine, Pyridoxal 5'
phosphate (PLP)
and pyridoxam-
ine 5' phosphate
(PMP), Pyridox-
ine 5'-phosphate
(PNP))
homocysteine;
neuronal activity
Vitamin B6 is a group of water-soluble compounds (vitamers). Pyridoxal 5' phosphate
(PLP) and pyridoxamine 5' phosphate (PMP) are the active coenzyme forms of vitamin B6
(ODS 2014).
Vitamin B6 has many important brain functions such as biosynthesis of neurotransmitters
(GABA, dopamine, noradrenaline, serotonin), receptor binding, macronutrient metabo-
lism, and gene expression. In a study looking at low plasma B6 levels predicting cognitive
decline and depression in at-risk individuals, low PLP status was seen as a risk factor for
cognitive decline and depression in at-risk populations (Scott 2013).
Folic Acid
(Vitamin B9)
antioxidant;
homocysteine;
neuronal activity
Folate is a cofactor and promotes the remethylation of homocysteine -- an amino acid
that can induce DNA strand breakage, oxidative stress, and apoptosis. Folate is required
for normal development of the nervous system, playing important roles regulating neuro-
genesis and programmed cell death. Folate deficiency and its resultant increase in homo-
cysteine levels has been linked to several neurodegenerative conditions, including stroke,
Alzheimer's disease, and Parkinson's disease (Mattson 2003).
Vitamin B12
(cobalamins:
cyanocobalamin,
hydroxocobal-
amin, methyl-
cobalamin, hy-
droxocobalamin)
homocysteine;
neuronal activity
Vitamin B12 acts as a coenzyme in metabolism of amino acids and fatty acids required
for the synthesis of nucleic acids, erythrocytes, and in the maintenance of myelin (Pawlak
2014). Lower vitamin B12 status has been associated with increased rates of cognitive de-
cline and dementia (Clarke 2007b; O'Leary 2012).
Pantothenic Acid
(Vitamin B5)
energy; metabo-
lism
Pantothenic acid (PA) is a component of coenzyme A, an essential cofactor in fatty acid
oxidation, lipid elongation, and fatty acid synthesis (Kelly 2011). This may have an indi-
rect effect in cognition.
Biotin
(Vitamin H)
energy; metabo-
lism
Biotin is also known as Vitamin H and is part of the B complex group of vitamins. They act
as cofactors in carboxylase enzymes, fatty acid, and amino acid metabolism. This may
have an indirect effect in cognition.
Vitamin C antioxidant Vitamin C has antioxidant functions and is required for the synthesis of noradrenaline
from dopamine. It has been reported that Vitamin C levels have been lower than controls
in patients with senile dementia of Alzheimer’s type (Jeandel 1989). In a longitudinal and
cross-sectional study it was found that higher vitamin C levels were associated with bet-
ter memory performance (Perrig 1997).
  (Continued)
Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
133
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Minerals    
Calcium neuronal activity Calcium ions regulate a number of physiological processes including neuronal gene ex-
pression and the neuronal secretion of neurotransmitters (Delage 2014; Dolphin 2012).
Supplementation with calcium together with vitamin D was found to have no significant
association with incident cognitive impairment (Rossom 2012).
Ozawa 2012 concluded that, in the general Japanese population, higher self-reported di-
etary intakes of potassium, calcium, and magnesium reduced the risk of all-cause demen-
tia, especially Vascular Dementia (VaD). The proposed mechanism was through the re-
duction of of vascular risk factors.
Chromium energy produc-
tion; metabolism.
Chromium is needed for energy production and has been found to promote the effect of
insulin involved in metabolism and storage of protein, carbohydrates and lipids within
the CNS (Anderson 1997; Institute of Medicine 2011; Ozawa 2012). Chromium is involved
in metabolism of nucleic acid, which is needed to build DNA, the genetic material in cells;
and promotes synthesis of cholesterol and fatty acids needed for brain function. It may
lower LDL cholesterol and triglyceride levels, raise HDL cholesterol levels and reduce high
blood pressure (Preuss 1997), hence may affect vascular risk factors.
Insulin resistance is implicated in the pathophysiological changes associated with
Alzheimer's disease, and pharmaceutical treatments that overcome insulin resistance
improve memory function in subjects with mild cognitive impairment (MCI) and early
Alzheimer's disease. Chromium (Cr) supplementation improves glucose disposal in pa-
tients with insulin resistance and diabetes. A double-blind RCT suggested that supple-
mentation with Chromium picolinate can enhance cognitive inhibitory control and cere-
bral function in older adults at risk for neurodegeneration (Krikorian 2010). An addition-
al study reported a positive correlation between cognitive function and serum chromium
levels (Smorgon 2004).
Copper antioxidant Copper is a component of an antioxidant enzyme called superoxide dismutase that pro-
tects cells from damage by harmful free radicals. Copper is necessary for a healthy nerve
system and taste sensitivity (Institute of Medicine 2011).
Copper may promote non-amyloidogenic processing of amyloid precursor protein (APP)
and thereby lower the Aβ production in cell culture systems, and it increases lifetime
and decreases soluble amyloid production in APP transgenic mice (Borchardt 1999). In
Alzheimer patients, a decline of Aβ levels in CSF is reported in adults in the treatment
group (Kaden 2011).
Iodine neuronal develop-
ment and struc-
ture.
Iodine is needed for the synthesis of thyroid hormones which, in turn, are needed for the
myelination of the central nervous system. Iodine is necessary for the normal develop-
ment of the brain. A deficiency of this mineral during critical periods of development in
gestation can lead to intellectual disability and neurodevelopmental problems (Bath
2013a). Positive association was found between maternal iodine status and child IQ at
age 8 years and reading ability at age 9 years (Bath 2013b).
Iron neuronal activity Iron is needed for development of oligodendrocytes and numerous enzymes that synthe-
sise neurotransmitters such as noradrenaline, serotonin, and dopamine. It is important
for production of the haemoglobin in red blood cells (Delage 2014; Institute of Medicine
2011). Regression analysis showed that non-anaemic iron-deficient adolescent girls who
received iron performed better on a test of verbal learning and memory than girls in the
control group (Bruner 1996)
Magnesium energy, metabo-
lism
Magnesium is involved in hundreds of enzyme reactions, including protein synthesis. It
plays a role in energy production; can improve insulin sensitivity in diabetics; helps regu-
late blood sugar level; and regulates neuro-muscular transmission.
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Higher self-reported dietary intakes of potassium, calcium, and magnesium have been re-
ported to reduce the risk of all-cause dementia, especially VaD, in the general Japanese
population (Ozawa 2012).
Manganese metabolism Manganese is needed to synthesise fatty acids and cholesterol, and metabolise carbohy-
drates and proteins. It is important for energy production. It promotes utilisation of other
key nutrients like vitamin B1 (thiamine), biotin, choline, ascorbic acid, and vitamin E (De-
lage 2014).
Manganese is needed for glucose metabolism, which helps regulate blood glucose. It is
needed to make manganese superoxide dismutase (MnSOD), one of the key antioxidants
that protects cells from free radical damage, and so helps maintains healthy nerves. It
works synergistically with the B-complex vitamins to generate an overall feeling of well-
being (Institute of Medicine 2011).
Molybdenum metabolism Molybdenum promotes normal cell function; and functions as a cofactor for three essen-
tial enzymes that play a vital role in carbohydrate metabolism, utilisation of iron, sulphite
detoxification, and uric acid formation (Delage 2014; Institute of Medicine 2011).
Phosphorus metabolism, neu-
ronal structure
and function.
Phosphorus is needed for metabolism of carbohydrates and fats to produce energy and
is involved in the production of ATP required for growth and repair of cells and tissues; it
is needed to make cell membranes. It helps the body utilise the B-complex vitamins that
support proper muscle and nerve function (Delage 2014; Institute of Medicine 2011).
Potassium nerve transmis-
sion.
Potassium is involved in regulating nerve transmissions and muscle contractions. It helps
the body handle sodium and so reduces the risk of high blood pressure (Berr 2012). It has
been found to lower the risk of stroke and ischaemic heart disease. Potassium is needed
for synthesis of protein from amino acids (Delage 2014; Institute of Medicine 2011).
Higher self-reported dietary intakes of potassium, calcium, and magnesium reduce the
risk of all-cause dementia, especially VaD, in the general Japanese population (Ozawa
2012).
Selenium antioxidant. Selenium is an important antioxidant especially in combination with vitamin E, in the
central nervous system and other body tissues (Delage 2014; Mehdi 2013; Rahman 2007).
Low selenium levels were found to be associated with poorer cognitive function (Berr
2012; Smorgon 2004). Supplementation with selenium has been associated with im-
proved overall health, reducing oxidative stress and reducing the risk of dementia (Mehdi
2013).
Sodium neuronal activity Sodium is essential for regulating muscle contractions, nerve transmissions essential for
normal CNS physiological mechanisms and homeostasis (Delage 2014; Institute of Medi-
cine 2011).
Zinc antioxidant
neuronal activity
Zinc is a constituent of the antioxidant enzyme superoxide dismutase that helps reduce
the harm from free radicals. Zinc regulates cell division and synthesis of genetic cell DNA.
It is essential for reproduction, repair, and normal growth within the CNS (Delage 2014).
Zinc is found in high levels in the brain where it performs catalytic, structural and regu-
latory roles in cellular metabolism. Zinc is bound to proteins but free zinc is present in
synaptic vesicles and performs a role in neurotransmission mediated by glutamate and
gamma-aminobutyric acid (GABA). Short-term deficits of zinc have been shown to impair
certain measures of mental and neurological function while long-term deficits of zinc, es-
pecially during gestation, result in malformation or deficits in attention, learning, memo-
ry and neuropsychological behaviour (Institute of Medicine 2011).
Zinc was found to be capable of reducing post-ischaemic injury to a variety of tissues and
organs through a mechanism that might involve the antagonism of copper reactivity. Al-
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though the evidence for the antioxidant properties of zinc is compelling, the mechanisms
are still unclear (Powell 2000).
* Only orally-administered supplements taken at any dose for at least 12 weeks are considered. Supplements that combine vitamins
or minerals are eligible as well.
Footnotes
Aβ: Amyloid β Protein
AD: Alzheimers' Disease
APP: amyloid precursor protein
ATP: Adenosine triphosphate 
CNS: central nervous system
Cr: Chromium 
CSF: CerebroSpinal Fluid
DNA: DeoxyriboNucleic Acid
GABA: Gamma-AminoButyric Acid
HDL: high-density lipoproteins
IQ: Intelligence quotient
LDL: Low-density lipoprotein
MCI: Mild Cognitive Impairment
MnSOD: manganese superoxide dismutase
PLP: Pyridoxal 5' phosphate
PMP: pyridoxamine 5' phosphate
PNP: Pyridoxine 5'-phosphate
VaD: Vascular Dementia
VDR: Vitamin D receptor
25(OH)D: serum hydroxyvitamin D
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Appendix 2. Sources searched and search strategies
 
Source Search strategy Hits retrieved
ALOIS (www.medi-
cine.ox.ac.uk/alois)
(Date of most re-
cent search: 25
January 2018)
Basic search: VIT
[Studies within ALOIS are coded VIT if the intervention is a vitamin or mineral]
Dec 2014: 254
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 3
Jan 2018: 1
MEDLINE In-
process and oth-
er non-indexed
citations and
MEDLINE 1950-
present (Ovid SP)
(Date of most re-
cent search: 25
January 2018)
1. exp *Vitamins/
2. exp *Minerals/
3. exp *Dietary Supplements/
4. Calcium Carbonate/
5. vitamin*.ti,ab.
6. cholecalciferol.ti,ab.
7. ergocalciferol.ti,ab.
8. toxiferol.ti,ab.
9. retinol.ti,ab.
10. "retinoic acid".ti,ab.
11. Vitamin A/
Dec 2014: 1320
Jul 2015: 53
Mar 2016: 111
Aug 2016: 103
Mar 2017: 166
Jan 2018: 120
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12. Vitamin B 12/
13. Vitamin D/
14. Vitamin E/
15. "beta-carotene".ti,ab.
16. "alpha-carotene".ti,ab.
17. "gamma-carotene".ti,ab.
18. "beta-cryptoanthin".ti,ab.
19. thiamine.ti,ab.
20. riboflavin.ti,ab.
21. niacin.ti,ab.
22. nicotinamide.ti,ab.
23. pantothenic.ti,ab.
24. pyridoxine.ti,ab.
25. pyridoxal.ti,ab.
26. pyridoxamine.ti,ab.
27. biotin.ti,ab.
28. "folic acid".ti,ab.
29. Folic Acid/
30. cyanocobalamin.ti,ab.
31. methylcobalamin.ti,ab.
32. "l-ascorbic acid".ti,ab.
33. "ascorbic acid".ti,ab.
34. ascorbate.ti,ab.
35. Ascorbic Acid/
36. phylloquinone.ti,ab.
37. phytomeadione.ti,ab.
38. phytonadine.ti,ab.
39. mineral*.ti,ab.
40. multivitamin*.ti,ab.
41. "diet* supplement*".ti,ab.
42. calcium.ti,ab.
43. Calcium/
44. iron.ti,ab.
45. zinc.ti,ab.
46. sodium.ti,ab.
47. potassium.ti,ab.
48. phosphorus.ti,ab.
49. magnesium.ti,ab.
50. chloride.ti,ab.
51. sulphur.ti,ab.
52. mangansese.ti,ab.
53. cobalt.ti,ab.
54. selenium.ti,ab.
55. copper.ti,ab.
56. iodine.ti,ab.
57. fluoride.ti,ab.
58. or/1-57
59. *Aging/
60. Aged/
61. "Aged, 80 and over"/
62. Middle Aged/
63. Age Factors/
64. "mild cognitive impairment".ti,ab.
65. Mild Cognitive Impairment/
66. MCI.ti,ab.
67. AAMI.ti,ab.
68. ACMI.ti,ab.
69. ARCD.ti,ab.
70. CIND.ti,ab.
71. (nMCI or aMCI or mMCI or MCIa).ti,ab.
72. "old* adults".ti,ab.
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73. elderly.ti,ab.
74. "old* age*".ti,ab.
75. "middle age*".ti,ab.
76. seniors.ti,ab.
77. "senior citizens".ti,ab.
78. "community dwelling".ti,ab.
79. pensioners.ti,ab.
80. "aged sample".ti,ab.
81. "aged population".ti,ab.
82. or/59-81
83. 58 and 82
84. *Cognition/
85. *Cognition Disorders/
86. Memory/
87. Memory Disorders/
88. (cognit* adj3 (func* or declin* or reduc* or impair* or improve* or deficit* or progress*
or perform* or abilit*)).ti,ab.
89. "mental perform*".ti,ab.
90. memory.ti,ab.
91. "executive function*".ti,ab.
92. Executive Function/
93. Attention/
94. (speed adj2 processing).ti,ab.
95. "episodic memory".ti,ab.
96. Memory, Episodic/
97. or/84-96
98. 83 and 97
99. randomized controlled trial.pt.
100. controlled clinical trial.pt.
101. randomized.ab.
102. placebo.ab.
103. drug therapy.fs.
104. randomly.ab.
105. trial.ab.
106. groups.ab.
107. or/99-106
108. exp Animals/ not humans.sh.
109. 107 not 108
110. 98 and 109 [all results]
111. *Vitamins/
112. *Cognition/
113. "Aged, 80 and over"/ or Aged/ or Middle Aged/
114. Mild Cognitive Impairment/
115. "mild cognitive impairment".ti,ab.
116. 113 or 114 or 115
117. 111 and 112 and 116
118. 99 or 100
119. 117 and 118 [results sent directly to author team]
120. 110 not 119 [results minus those sent directly to author team. These results will be
screened by the 'crowd']
Embase
1974-24 January
2018 (Ovid SP)
(Date of most re-
cent search: 25
January 2018)
1. exp *vitamin/
2. exp *mineral/
3. exp diet supplementation/
4. calcium/
5. vitamin*.ti,ab.
6. mineral*.ti,ab.
Dec 2014: 1275
Jul 2015: 114
Mar 2016: 184
Aug 2016: 94
Mar 2017: 257
Jan 2018: 250
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7. cholecalciferol.ti,ab.
8. ergocalciferol.ti,ab.
9. toxiferol.ti,ab.
10. retinol.ti,ab.
11. retinal.ti,ab.
12. "retinoic acid".ti,ab.
13. vitamin D/
14. vitamin B complex/ or vitamin B group/
15. vitamin D/
16. vitamin K epoxide reductase/ or vitamin K group/
17. colecalciferol/ or calcitriol/ or calcitriol derivative/
18. ascorbic acid/
19. vitamin supplementation/
20. "beta-carotene".ti,ab.
21. beta carotene/
22. "alpha-carotene".ti,ab.
23. alpha carotene/
24. "gamma-carotene".ti,ab.
25. gamma carotene/
26. "beta-cryptoanthin".ti,ab.
27. thiamine.ti,ab.
28. thiamine/
29. riboflavin.ti,ab.
30. riboflavin/
31. niacin.ti,ab.
32. nicotinic acid/
33. nicotinamide.ti,ab.
34. pantothenic.ti,ab.
35. pyridoxamine.ti,ab.
36. pantothenic acid/
37. pyridoxamine/
38. biotin.ti,ab.
39. biotin/
40. "folic acid".ti,ab.
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41. folic acid/
42. cyanocobalamin.ti,ab.
43. cyanocobalamin/
44. methylcobalamin.ti,ab.
45. "l-ascorbic acid".ti,ab.
46. "ascorbic acid".ti,ab.
47. phylloquinone.ti,ab.
48. phytonadine.ti,ab.
49. phytomeadione.ti,ab.
50. multivitamin*.ti,ab.
51. "vitamin* supple*".ti,ab.
52. "diet* supplement*".ti,ab.
53. calcium.ti,ab.
54. iron.ti,ab.
55. iron/
56. zinc.ti,ab.
57. zinc/
58. sodium.ti,ab.
59. sodium/
60. potassium.ti,ab.
61. citrate potassium/ or potassium/ or clavulanate potassium/ or diclofenac potassium/
62. phosphorus.ti,ab.
63. phosphorus/
64. magnesium.ti,ab.
65. magnesium/
66. chloride.ti,ab.
67. chloride/
68. sulphur.ti,ab.
69. mangansese.ti,ab.
70. cobalt.ti,ab.
71. cobalt/
72. selenium.ti,ab.
73. selenium/
74. copper.ti,ab.
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75. copper/
76. iodine.ti,ab.
77. fluoride.ti,ab.
78. fluoride/
79. or/1-78
80. aging/
81. aged/
82. middle aged/
83. mild cognitive impairment/
84. "mild cognitive impairment".ti,ab.
85. MCI.ti,ab.
86. AAMI.ti,ab.
87. ACMI.ti,ab.
88. ARCD.ti,ab.
89. CIND.ti,ab.
90. (nMCI or aMCI or mMCI or MCIa).ti,ab.
91. "middle age*".ti,ab.
92. "old* age*".ti,ab.
93. "old* adults".ti,ab.
94. "community dwelling".ti,ab.
95. "senior citizens".ti,ab.
96. seniors.ti,ab.
97. pensioners.ti,ab.
98. "aged sample".ti,ab.
99. "aged population".ti,ab.
100. or/80-99
101. exp cognition/
102. cognition disorders/
103. episodic memory/ or memory/
104. memory disorder/
105. dementia/
106. Alzheimer disease/
107. dement*.ti,ab.
108. alzheimer*.ti,ab.
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109. cognition.ti,ab.
110. cognitive.ti,ab.
111. or/101-110
112. 79 and 100 and 111
113. randomized controlled trial/
114. controlled clinical trial/
115. placebo.ab.
116. (random* adj2 divide*).ti,ab.
117. (random* adj2 allocate*).ti,ab.
118. trial.ab.
119. "double-blind*".ti,ab.
120. "single blind*".ti,ab.
121. or/113-120
122. 112 and 121
123. *Cognition/
124. exp *vitamin/ or exp *vitamin supplementation/
125. exp *mineral/ or exp *mineral supplementation/
126. (vitamin* or mineral*).ti.
127. 124 or 125 or 126
128. exp *aging/
129. (elderly or "middle age*" or "old* adults" or MCI or "mild cognitive impairment").ti.
130. exp *middle aged/
131. 128 or 129 or 130
132. 123 and 127 and 131
133. 113 or 114
134. 132 and 133
135. 122 not 134
PsycINFO
1806-January
week 2 2018 (Ovid
SP)
(Date of most re-
cent search: 25
January 2018)
1. exp Aging/
2. exp Cognitive Impairment/
3. "cognit* impair*".ti,ab.
4. MCI.ti,ab.
5. AAMI.ti,ab.
6. ACMI.ti,ab.
7. ARCD.ti,ab.
Dec 2014: 202
Jul 2015: 15
Mar 2016: 10
Aug 2016: 0
Mar 2017: 14
Jan 2018: 9
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8. CIND.ti,ab.
9. (nMCI or aMCI or mMCI or MCIa).ti,ab.
10. "old* age*".ti,ab.
11. elderly.ti,ab.
12. "middle age*".ti,ab.
13. "old* adults".ti,ab.
14. seniors.ti,ab.
15. "senior citizens".ti,ab.
16. "community dwelling".ti,ab.
17. pensioners.ti,ab.
18. or/1-17
19. exp Cognition/
20. exp Dementia/
21. 19 or 20
22. randomi?ed.ti.
23. (randomly adj2 allocat*).ab.
24. (randomly adj2 divide*).ab.
25. RCT.ti,ab.
26. "double-blind*".ti,ab.
27. "single blind*".ti,ab.
28. "randomi?ed trial".ab.
29. "randomi?ed control* trial".ab.
30. "random allocation".ab.
31. "controlled clinical trial".ti,ab.
32. or/22-31
33. exp Vitamins/
34. exp Dietary Supplements/
35. vitamin*.ti,ab.
36. mineral*.ti,ab.
37. calcium.ti,ab.
38. Calcium/
39. exp Ascorbic Acid/
40. exp Folic Acid/
41. "folic acid".ti,ab.
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42. cholecalciferol.ti,ab.
43. ergocalciferol.ti,ab.
44. toxiferol.ti,ab.
45. retinol.ti,ab.
46. retinal.ti,ab.
47. "retinoic acid".ti,ab.
48. "beta-carotene".ti,ab.
49. "alpha-carotene".ti,ab.
50. "gamma-carotene".ti,ab.
51. "beta-cryptoanthin".ti,ab.
52. thiamine.ti,ab.
53. riboflavin.ti,ab.
54. niacin.ti,ab.
55. nicotinamide.ti,ab.
56. pantothenic.ti,ab.
57. pyridoxine.ti,ab.
58. pyridoxal.ti,ab.
59. pyridoxamine.ti,ab.
60. biotin.ti,ab.
61. "folic acid".ti,ab.
62. cyanocobalamin.ti,ab.
63. methylcobalamin.ti,ab.
64. "l-ascorbic acid".ti,ab.
65. "ascorbic acid".ti,ab.
66. ascorbate.ti,ab.
67. phylloquinone.ti,ab.
68. phytomeadione.ti,ab.
69. phytonadine.ti,ab.
70. multivitamin*.ti,ab.
71. "diet* supplement*".ti,ab.
72. iron.ti,ab.
73. zinc.ti,ab.
74. sodium.ti,ab.
75. potassium.ti,ab.
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76. phosphorus.ti,ab.
77. magnesium.ti,ab.
78. chloride.ti,ab.
79. sulphur.ti,ab.
80. mangansese.ti,ab.
81. cobalt.ti,ab.
82. selenium.ti,ab.
83. copper.ti,ab.
84. iodine.ti,ab.
85. fluoride.ti,ab.
86. 18 or 21
87. or/33-85
88. 86 and 87
89. 32 and 88
90. exp *Vitamins/
91. (vitamin* or mineral*).ti.
92. 90 or 91
93. exp *Cognition/
94. (cognition or cognitive).ti.
95. 93 or 94
96. (elderly or "middle age*" or "old* adults" or MCI or "mild cognitive impairment").ti.
97. 92 and 95 and 96
98. (randomised or randomised or RCT or trial).ti.
99. 97 and 98
100. 89 not 99
CINAHL (EBSCO-
host)
(Date of most re-
cent search: 25
January 2018)
S1 (MM “Vitamins+")
S2 (MM “Minerals+")
S3 (MH "Dietary Supplements") OR (MH "Dietary Supplementation") OR (MH "Dietary Car-
bohydrates") OR (MH "Dietary Fiber") OR (MH "Sodium, Dietary") OR (MH "Dietary Fats")
OR (MH "Dietary Proteins") OR (MH "Dietary Sucrose”)
S4 TX vitamin*
S5 TX mineral*
S6 TX “diet* supple*”
S7 (MH "Fatty Acids") OR (MH "Fatty Acids, Omega-6") OR (MH "Fatty Acids, Unsaturat-
ed") OR (MH "Trans Fatty Acids") OR (MH "Fatty Acids, Monounsaturated") OR (MH "Fatty
Acids, Saturated") OR (MH "Fatty Acids, Essential”)
Dec 2014: 493
Jul 2015: 7
Mar 2016: 35
Aug 2016: 15
Mar 2017: 24
Jan 2018: 23
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S8 TX “fatty acid*”
S9 (MH "Vitamin A”)
S10 (MH "Vitamin B12") OR (MH "Vitamin B Complex") OR (MH "Thiamine") OR (MH "Ri-
boflavin") OR (MH "Pyridoxine") OR (MH “Carnitine")
S11 (MH "Folic Acid”)
S12 (MH "Ascorbic Acid”)
S13 (MH "Vitamin D") OR (MH "Cholecalciferol") OR (MH "Ergocalciferols") OR (MH “Cal-
citriol")
S14 (MH "Vitamin E") OR (MH "Pantothenic Acid”)
S15 (MH "Vitamin K") OR (MH “Osteocalcin")
S16 TX “beta-carotene"
S17 TX “alpha-carotene"
S18 TX thiamine
S19 TX riboflavin
S20 TX niacin
S21 TX pantothenic
S22 TX nicotinamide
S23 TX pyridoxine
S24 TX pyridoxal
S25 TX biotin
S26 (MH “Calcium")
S27 TX calcium
S28 TX iron
S29 (MH “iron”)
S30 (MH “Zinc”)
S31 TX zinc
S32 (MH “Sodium”)
S33 TX sodium
S34 (MH “Potassium")
S35 TX potassium
S36 (MH “Phosphorus")
S37 TX phosphorus
S38 (MH “Magnesium")
S39 TX magnesium
S40 (MH "Sodium Chloride, Dietary”)
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S41 TX chloride
S42 TX sulphur
S43 TX cobalt
S44 TX selenium
S45 TX copper
S46 TX iodine
S47 TX flouride
S48 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR
S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36
OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47
S49 (MH “Aging")
S50 (MH "Aged") OR (MH "Aged, 80 and Over”)
S51 (MH "Middle Age”)
S52 TX "Mild Cognitive Impairment”
S53 TX MCI OR AAMI OR ACMI OR ARCD OR CIND
S54 TX nMCI OR aMCI OR mMCI OR MCIa
S55 TX elderly
S56 TX "old* adults”
S57 TX "old* age*”
S58 TX pensioners
S59 TX "community dwelling”
S60 TX seniors
S61 TX "senior citizen*”
S62 TX "age* sample”
S63 TX "age* population”
S64 S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR S58 OR S59 OR
S60 OR S61 OR S62 OR S63
S65 S48 AND S64
S66 (MH "Cognition") OR (MH "Cognition Disorders") OR (MH "Delirium, Dementia,
Amnestic, Cognitive Disorders”)
S67 TX cognition
S68 TX memory
S69 (MH "Memory") OR (MH "Memory Disorders") OR (MH "Memory, Short Term”)
S70 TX "executive function”
S71 TX "cognitive* declin*”
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S72 TX "cognitive* improv*”
S73 TX "cognitive deficit*”
S74 TX "mental perform*”
S75 TX dementia
S76 TX alzheimer*
S77 (MH “Dementia+")
S78 S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR
S77
S79 S65 AND S78
S80 (MH "Randomized Controlled Trials”)
S81 AB randomly
S82 AB placebo
S83 AB groups
S84 AB RCT
S85 TX "double blind*”
S86 TX "single blind*”
S87 TX "controlled clinical trial”
S88 TI randomised
S89 TI randomized
S90 S80 OR S81 OR S82 OR S83 OR S84 OR S85 OR S86 OR S87 OR S88
S91 S79 AND S90
ISI Web of Science
[includes: Web
of Science (1945-
present); BIOSIS
Previews (1926-
present); MEDLINE
(1950-present);
Journal Citation
Reports]; BIOSIS
Previews
(Date of most re-
cent search: 25
January 2018)
("mild cognitive impairment" OR elderly OR "age* subjects" OR "old* adult*" OR "middle
age*" OR MCI) AND TOPIC: ("randomly allocated" OR "random allocation" OR randomised
OR randomized OR RCT OR "controlled trial" OR "double blind" OR "single blind") AND
TOPIC: (vitamin* OR mineral* OR "diet* suppl*" OR "ascorbic acid" OR "folic acid" OR
iron OR calcium OR sodium OR zinc OR potassium OR magnesium OR cobalt OR copper
OR iodine) AND TOPIC: (cognition OR dementia OR memory OR "executive function" OR
alzheimer*)
Timespan: All years.
Search language=Auto
Dec 2014: 932
Jul 2015: 34
Mar 2016: 100
Aug 2016: 43
Mar 2017: 67
Jan 2018: 55
LILACS (BIREME)
(Date of most re-
cent search: 25
January 2018)
cognition OR "mild cognitive impairment" OR elderly OR "aged subjects" OR "older
adults" OR "middle aged" [Words] and randomly OR randomised OR randomized OR RCT
OR "controlled trial" [Words] and vitamin OR vitamins OR mineral OR minerals OR "fatty
acid" OR "folic acid" [Words]
Dec 2014: 28
Jul 2015: 0
Mar 2016: 0
Aug 2016: 1
Mar 2017: 0
  (Continued)
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Jan 2018: 0
CENTRAL (via
CRSO)
(Date of most re-
cent search: 25
January 2018)
#1 MeSH descriptor: [Aged, 80 and over] explode all trees
#2 MeSH descriptor: [Aged] explode all trees
#3 MeSH descriptor: [Middle Aged] explode all trees
#4 MeSH descriptor: [Mild Cognitive Impairment] explode all trees
#5 "cognit* impair*" or MCI
#6 elderly
#7 "old* adults"
#8 "old* age*"
#9 "old* sample"
#10 senior citizens
#11 pensioners
#12 seniors
#13 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Cognition] explode all trees
#15 MeSH descriptor: [Dementia] explode all trees
#16 cognit*
#17 memory
#18 "executive function*"
#19 processing
#20 "mental perform*"
#21 dement*
#22 alzheimer*
#23 #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 MeSH descriptor: [Vitamins] explode all trees
#25 MeSH descriptor: [Minerals] explode all trees
#26 vitamin*
#27 mineral*
#28 "ascorbic acid"
#29 "folic acid"
#30 MeSH descriptor: [Fatty Acids] explode all trees
#31 zinc or iron or calcium or sodium or potassium or magnesium or cobalt or copper or
selenium or iodine or flouride or chloride
#32 "beta-carotene"
Dec 2014: 395
Jul 2015: 10
Mar 2016: 50
Aug 2016: 48
Mar 2017: 90
Jan 2018: 54
  (Continued)
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#33 "alpha-carotene"
#34 thiamine
#35 riboflavin
#36 niacin
#37 biotin
#38 pantothenic
#39 nicotinamide
#40 pyridoxal
#41 "diet* suppl*"
#42 #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38
or #39 or #40 or #41
#43 #13 and #23 and #42
Clinicaltrials.gov
(www.clinicaltrial-
s.gov)
(Date of most re-
cent search: 25
January 2018)
In Intervention studies: [intervention] vitamin* OR mineral* OR "diet* suppl*" OR "ascor-
bic acid" OR "folic acid" OR iron OR calcium OR sodium OR zinc OR potassium OR mag-
nesium OR cobalt OR copper OR iodine AND [condition]: cognition OR "mild cognitive im-
pairment" OR elderly OR "aged subjects" OR "older adults" OR "middle aged"
Trial Status: all
Dec 2014: 147
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 6
Jan 2018: 8
ICTRP Search
Portal (http://
apps.who.int/tri-
alsearch) (in-
cludes: Australian
New Zealand Clini-
cal Trials Registry;
ClinicalTrilas.gov;
ISRCTN; Chinese
Clinical Trial Reg-
istry; Clinical Tri-
als Registry – In-
dia; Clinical Re-
search Informa-
tion Service – Re-
public of Korea;
German Clinical
Trials Register;
Iranian Registry
of Clinical Trials;
Japan Primary
Registries Net-
work; Pan African
Clinical Trial Reg-
istry; Sri Lanka
Clinical Trials Reg-
istry; The Nether-
lands National Tri-
al Register)
In Intervention studies: [intervention] vitamin* OR mineral* OR "diet* suppl*" OR "ascor-
bic acid" OR "folic acid" OR iron OR calcium OR sodium OR zinc OR potassium OR mag-
nesium OR cobalt OR copper OR iodine AND [condition]: cognition OR "mild cognitive im-
pairment" OR elderly OR "aged subjects" OR "older adults" OR "middle aged"
Trial Status: all
Dec 2014: 25
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 4
Jan 2018: 2
  (Continued)
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(Date of most re-
cent search: 25
January 2018)
TOTAL before de-duplication Dec 2014: 5071
Jul 2015: 233
Mar 2016: 496
Aug 2016: 304
Mar 2017: 631
Jan 2018: 522
TOTAL: 7257
TOTAL after de-duplication Dec 2014: 3451
Jul 2015: 200
Mar 2016: 399
Aug 2016: 208
Mar 2017: 522
Jan 2018: 431
TOTAL: 5211
TOTAL after first assessment by the Crowd and CDCIG information specialists Dec 2014: 448
Jul 2015: 81
Mar 2016: 70
Aug 2016: 45
Mar 2017: 43
Jan 2018: 38
TOTAL: 725
  (Continued)
 
Appendix 3. Definitions of design, patient and intervention characteristics as applied in the stratified analyses
exploring between trial variations in intervention e:ect
 
Item Definition
Bias-related characteristics*
Concealment of allocation
(avoiding selection bias)
The guidance from the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011)
will be used to judge bias related to sequence generation and concealment of allocation using the
two Cochrane 'Risk of bias' items. From these, the statistician will derive a single variable to be
used in the stratified analysis: allocation concealment will be judged at low risk of bias if the inves-
tigators responsible for patient selection were unable to suspect before allocation which treatment
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was next. Concealment will downgraded to high risk of bias if there is evidence of inadequate se-
quence generation.
Blinding of patients and per-
sonnel (avoiding performance
bias)
Low risk of bias will be judged if:
- a credible sham procedure was used; or if a placebo supplement or pill was used that was re-
ported to be identical in appearance to the experimental intervention and the specific outcome or
group of outcomes is/are likely to be influenced by lack of blinding
- blinding is absent or suboptimal and the specific outcome, such as mortality, is not likely to be in-
fluenced by lack of blinding
Blinding of outcome assess-
ment (avoiding detection bias)
For self-reported/partner-reported outcomes:
Low risk of bias will be judged if:
- self-reported outcomes were assessed AND blinding of patients was considered adequate AND
there was no information to suggest that there was an investigator involved during the process of
outcome assessment; OR if blinding of investigators performing the outcome assessment was re-
ported AND an attempt to blind patients was reported
For other outcomes:
Outcome assessment was considered to be blinded if the outcome assessment was reported to be
blinded.
Statistical analyses (avoiding
attrition bias)
For continuous outcomes
Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the difference in percentage of partic-
ipants not analysed was 5% or lower across trial arms
- for trials using imputations to handle missing data: the percentage of participants with missing
data did not exceed 20% AND the difference in percentage of participants with imputed data was
10% or lower across trial arms AND applied imputation methods were judged to be appropriate
For binary outcomes of rare events
Low risk of bias will be judged if:
- the event rate is low (e.g. incidence of dementia) AND at least 95% of the patients randomised
were analysed AND there is no evidence of differential reasons for missing data that may alter the
estimate AND the rate of missing data does not exceed the expected event rates
For binary outcomes of non-rare events
Low risk of bias will be judged if:
- at least 90% of the patients randomised were analysed AND the difference in percentage of partic-
ipants not analysed was 5% or lower across trial arms AND there is no evidence of differential rea-
sons for missing data that may alter the estimate AND the rate of missing data does not exceed the
expected event rates
Trial Size A large trial will be defined by a sample size calculation for the primary outcome.
Follow-up duration For the cognitive outcomes, we will group studies according to these follow-up cut-oIs to de-
scribe immediate results (up to 12 weeks), short-term (up to 1 year), medium-term (1 to 2 years)
and longer-term results (more than 2 years). For the secondary outcome all-cause dementia, only
outcome data at 1 year of follow-up or longer will be considered and therefore the grouping will in-
clude short-term (1 year), medium-term (up to 2 years) and longer-term results (more than 2 years).
Treatment-related characteristics
Treatment duration The minimum treatment duration of 3 months is considered short-term, 3 to 12 months as medi-
um-term, and 12 months for long-term.
Dose of treatment Treatment will be analysed as high dose versus low dose according to previously reported cut-oIs.
Mechanisms of action of the
supplements**
Supplements postulated to share a main mechanism of action in preventing development of de-
mentia, including:
• Antioxidant properties - affecting superoxide dismutase (vitamin A, C, D, E, selenium)• Regulation/lowering levels of homocysteine: vitamins B12, folate and B6
  (Continued)
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Participant-related characteristics
Cognition-related criteria No risk of deficiency versus at risk of deficiency for the type of vitamin and minerals investigated
(e.g. presence of malabsorptive diseases, malnutrition, comorbidities or concomitant medications,
and ethnicity (Vitamin D))
  (Continued)
 
* The descriptions depicted in this Table are in addition to the guidance provided by Cochrane (Higgins 2011).
** Knowledge of possible mechanisms of actions is evolving, and we will consider other possible subgroups for data analysis as new
information arises during the development of the review.
Appendix 4. Composition of Centrum Silver ® used in Grodstein 2013
 
Vitamin A (IU) 5000*
Vitamin C (mg) 60
Vitamin D (IU) 400
Vitamin E (IU) 45
Vitamin K (µg) 10
Thiamin (mg) 1.5
Riboflavin (mg) 1.7
Niacin (mg) 20
Vitamin B6 (mg) 3
Folic Acid (µg) 400
Vitamin B12 (µg) 25
Biotin (µg) 30
Pantothenic Acid (mg) 10
Calcium (mg) 200
Iron (mg) 4
Phosphorus (mg) 48
Iodine (µg) 150
Magnesium (mg) 100
Zinc (mg) 15
Selenium (µg) 20
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Copper (mg) 2
Manganese (mg) 3.5
Chromium (µg) 130
Molybdenum (µg) 160
Chloride (mg) 72.6
Potassium (mg) 80
Boron (µg) 150
Nickel (µg) 5
Vanadium (µg) 10
Silicon (mg) 2
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
There are a number of significant diIerences between this review and its protocol.
Published protocols anticipated the production of two reviews with distinct populations: cognitively healthy people in midlife (40 years to
65 years; Denton 2015) and in late life (> 65 years). However, it became apparent that many studies straddled this arbitrary age boundary
so that it was not possible logically to assign them to one review rather than the other. Therefore, it was decided to produce a single review
covering participants in mid- and late-life.
The protocols specified that participants should have been cognitively assessed at baseline. Again, this criterion would have led to
exclusion of a large amount of potentially informative data and was dropped in favour of a more pragmatic approach. If a study stated
that participants were cognitively healthy or if they were a large population sample with no cognitive inclusion criteria, then they were
assumed to be eligible.
The protocol specified only three time points for grouping outcomes: 12 weeks to 1 year, 1 to 2 years and > 2 years. However, we considered
that the very wide variation in durations of follow-up justified further subdivisions at 5 and 10 years. Particularly in the middle-aged and
'young' elderly, trial durations as short as 2 years are unlikely to be able to detect eIects on the trajectory of age-related cognitive decline.
Appendix 3 described a stringent method for assessing blinding. In practice, we adopted a more flexible approach and for multicentre
studies with generally rigorous methods, we accepted trial authors' statements about blinding of participants and investigators in the
absence of further detail.
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Dietary Supplements;  Antioxidants  [administration & dosage];  Ascorbic Acid  [administration & dosage];  Calcium  [administration
& dosage];  Cholecalciferol  [administration & dosage];  Cognition  [*drug eIects]  [physiology];  Cognitive Dysfunction  [*prevention
& control];  Copper  [administration & dosage];  Dementia  [prevention & control];  Folic Acid  [administration & dosage];  Minerals
 [*administration & dosage];  Randomized Controlled Trials as Topic;  Selenium  [administration & dosage];  Vitamin A  [administration
& dosage];  Vitamin B 12  [administration & dosage];  Vitamin B 6  [administration & dosage];  Vitamin E  [administration & dosage]; 
Vitamins  [*administration & dosage];  Zinc  [administration & dosage];  beta Carotene  [administration & dosage]
MeSH check words
Adult; Aged; Humans; Middle Aged
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